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ABSTRACT
Stem cells are unspecialised cells found in the body which possess the ability to self 
renew and can be induced to proliferate and differentiate into more specialised cells. 
MSCs are adult stem cells that are capable of leaving the bone marrow and travelling in 
the bloodstream to a different site, where they may perform repair or regeneration 
processes of various mesenchymal tissues such as cartilage, bone and fat. Due to these 
properties of MSCs, it proves to be a useful source for the repair and regeneration of 
cartilage.
The aims of this study were to: 1) characterise primary bovine MSCs by assessing the 
gene expression of hyaline cartilage-specific genes (SOX-9, Aggrecan and Collagen type 
II) and non-specific genes (Collagen type I and type X); 2) investigate the effects of 
culture medium supplemented with FGF-2 or with the addition of an extra growth factor, 
TGF-p2, on bovine MSCs in a two dimensional culture system; 3) characterise the 
phenotypes of MSCs tissue grafts produced using MSCs pre-cultured in culture medium 
supplemented with FGF-2 or with the addition of TGF-132 in a three dimension culture 
system (Transwell) seeded at high (6xl06 cells) and low (0.5x106 cells) cell density.
Our study showed that different bone chamber size and thickness influenced the amount 
of marrow and cells harvested without interfering with the fibroblastic-shaped cell 
morphology and their adherence ability. The presence of stem/progenitor cell features is 
present in undifferentiated P0 BMSCs and PI and P2 BMSCs cultured in FGF-2 or with 
the addition of TGF-p2. Gene expression analyses on undifferentiated P0 BMSCs and PI 
and P2 BMSCs cultured in FGF-2 or with the addition of TGF-p2 suggested that the 
MSCs contain both fibroblastic and chondrogenic features. This implies that the MSCs 
are not fully committed towards a chondrogenic lineage. We have demonstrated that it is 
possible to generate a tissue graft using passaged BMSCs in a Transwell culture system 
but seeding density is important. The ideal seeding cell density is 0.5x106 cells/well using 
P2 and P3 BMSCs pre-cultured in either FGF-2 or with the addition of TGF-P2. The 
tissue graft produced has a high expression level of aggrecan, collagens type I and II, 
which suggested that it has a fibro-cartilage phenotype.
XVI
CHAPTER 1: General Introduction
1.1 Stem cells
Stem cells are unspecialised cells found in the body which possess the ability to self renew and 
can be induced to proliferate and differentiate into more specialised cells (Barry and Murphy 
2004; Adam et al., 2005). Due to these properties, they can serve as reserve cells for damaged or 
compromised adult tissues requiring more extensive repair, regeneration or expansion. Stem cells 
can be derived from embryos and adults, which are referred to as embryonic and adult stem cells. 
They can also be categorised into three types, totipotent, pluripotent and multipotent. Totipotent 
means their potential is total with the capacity to give rise to any cell type and placenta and 
foetal membranes within the body, these are also referred to as the germ cells. Pluripotent 
(embryonic stem cells) can differentiate into virtually any cell type in the body. Multipotent cells 
(tissue specific adult stem cells) can give rise to only a limited number of cell types and these are 
generally known as adult stem cells (Collas & Hakelien 2003). The different types of stem cells 
are summarised in Figure 1.1.
Embryonic stem cells (ESCs) are totipotent cells that are derived from four or five days embryo, 
known as the blastocyst. They are developed from eggs that are fertilised in vitro. The blastocyst 
is composed of three structures; trophoblast (outer layer of the blastocyst), blastocoel (cavity of 
blastocyst) and inner cell mass (cells at the end of the blastocoel). Adult stem cells (ASCs) are 
multipotent, undifferentiated cells which may be found in mature tissues. The exact origin of 
ASCs is currently unknown. They appear to remain as quiescent cells in a specific area of each 
tissue until they appear to be activated by tissue injury or disease (Lorenzini et al., 2007; Kim & 
Szele 2008).
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Figure 1.1: Flow diagram to illustrate the origin of the different categories of stem cells, 
totipotent, pluripotent and multipotent (www.stemcellresearch.org/images/prenti 1 .jpg).
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The presence of stem cells in the bone marrow was first suggested by the observations of the 
German pathologist Cohnheim, 130 years ago (J Cohnheim 1867) through the study of wound 
repair. Later, more definitive evidence for the existence of stem cells in the bone marrow was 
obtained by Alexander Friedenstein (Friedenstein et al., 1966; 1968), who characterised the 
multipotentiality of stem cells some thirty years ago (Owen 1988; Owen and Friedenstein 1988). 
These marrow stromal stem cells are able to give rise to cells of the fibroblastic, reticular, 
adipogenic, osteogenic and possibly other lineages, such ability is termed mesengenesis (Caplan 
1994).
M esenchym al stem cell
Proliferation Bone m arrow  and/or periosteum
C om m itm ent
Lineage progression
Myoblast CHtaobla&t Chondrocyte Strom® PraaOpocyte Tenoblast 
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Figure 1.2: A schematic diagram to illustrate the transition changes of MSCs through a series of 
steps namely proliferation, commitment, differentiation and maturation, resulting in the 
formation of specific tissues such as bone, cartilage and muscle (Adapted from Risbud and 
Sittenger, 2002).
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In addition to stem cells, other committed cells are also capable of undergoing 
transdifferentiation a process, in which cells from one lineage dedifferentiate into an 
intermediate cell type before redifferentiating into cells of an alternative lineage (Collas & 
Hakelien 2003). Due to their fascinating properties, there has been much interest in the use of 
stem cells for therapeutic use, for conditions such as paralysis, stroke, heart attack, 
musculoskeletal tissue injuries and neurodegenerative disease, and for diseases such as 
osteogenesis imperfecta and arthritis. However, further knowledge on stem cells is needed in 
order to improve the use of stem cells for clinical therapy.
Stem cell
Mature cell
Differentiation
Progenitor cell TRANSDIFFERENTIATION
Mature cell
Figure 1.3: Flow diagram to show the process of transdifferentiation (Adapted from Collas & 
Hakelien 2003).
1.1.1 Differentiation o f Embryonic stem cells (ESCs) to chondrocytes
The primary purpose of ESCs is to segregate and form unique morphologies and functional units 
that are integrated into the whole physiology of the organism (Dennis & Caplan 1993; 
Macdonald 2002). ESCs are able to differentiate into three layers, endoderm which later forms 
the interior gut lining; mesoderm, forming the muscle, bone, blood, cartilage; and ectoderm 
producing the epidermal tissues and the nervous system, which eventually specialise into any 
bodily tissue (Collas & Hakelien 2003; Lee & Hui 2006).
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Figure 1.4: Formation of the three fetal layers during embryogenesis from ESCs and the 
transitions of such layers into specific tissues and organs of the human body (Adapted from 
www.stemcure.com).
In vitro cell culture of ESCs under certain conditions may allow the ESCs to remain 
undifferentiated (unspecialised). However, during the culture period, if the cells are clumped 
together and form embryoid bodies, this will enable the cells to differentiate spontaneously 
resulting in the formation of specific cell types such as muscle cells and nerve cells. Therefore, 
when using ESCs, it is important to control their differentiation behaviour by optimising the
composition of the culture medium. Multiple studies have shown the effect of limb bud 
progenitor on ESCs (Sui et al, 2003), or murine ESCs exposed to dexamethasone (Tanaka et al., 
2004) and cultured on three dimensional hydrogels in the presence of glucosamine (Hwang et 
al., 2006 a and b) contributed to the chondrogenesis of ESCs. In addition, other studies have also 
suggested the ability of ESCs to differentiate into other cell types such as those from the 
chondro-, osteo- and adipo- lineages (zur Niedeu et al.,. 2005). ESCs derived from early mouse 
embryo are able to form epidermis containing a dermal layer, similar to native skin when 
exposed to matrix from normal human fibroblast and bone morphogenic protein-4 (BMP-4) 
(Aberdam 2004). In vitro studies by Hegert and colleagues have demonstrated that ESCs are able 
to differentiate towards the chondrogenic and osteogenic lineages (Hegert et al., 2002; Lengner 
et al., 2004). Furthermore, high and low oxygen tensions have been shown to stimulate the 
differentiation of ESCs into cardiomyocytes (Kurosawa et al., 2006). These studies together have 
demonstrated the possible multi-potential ability of ESCs.
Although ESCs are pluripotent and can be grown easily in culture, they are more difficult to 
obtain than adult stem cells (ASCs). Also existing legal and ethical issues surrounding the use of 
ESCs still exist. In contrast, ASCs enable the development on cell-based regenerative therapies 
using a patient’s own cells, which can be expanded in vitro and re-introduced into the patient 
with minimal rejection risk. For this reason, ASCs demonstrated to be a better candidate for the 
regeneration and repair of damaged tissues (Caplan 2009).
1.1.2 Adult stem cells (ASCs)
Adult stem cells do not function in the embryonic microenvironment and do not respond to 
embryonic signalling molecules that specify tissue morphologies or those that induce an 
embryonic function (Caplan & Dennis 2006). They are undifferentiated cells that are responsible 
for the regenerative capacities of tissue going through numerous cycles of cell division while 
maintaining their undifferentiated state.
A common rich source of adult stem cells is found in the bone marrow; but these can also be 
found in other specific areas such as blood, skin, liver, bone, fat and intestine, where they may 
remain as quiescent (non-dividing) cells for many years (Ryans et al., 2006). Adult stem cells 
from all of these tissues can differentiate into specialised lineage cells (see Figure 1.5) and for 
these reasons, such adult stem cells are referred to as multipotent. Adult stem cells are the 
preferred cell type for transplantation and tissue repairs because they have fewer ethical issues 
than ESCs. Also adult stem cells are hypoimmunogenic due to the lack of major 
histocompatibility complex II (MHC-II) and co-stimulatory molecule expression and are less 
likely to form teratomas (Ryans et al., 2006).
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Figure 1.5: Diagram showing distinct niches that exist within the bone marrow 
(www.stemcell.nih.gov).
There are two main types of adult stem cells, haematopoietic stem cells (HSCs) and bone 
marrow mesenchymal stem cells (b-MSCs). HSCs from bone marrow can generate various blood
cells including red blood cells, platelets, and macrophages as shown in Figure 1.5., also they are 
being used currently for treating diseases such as leukaemia and multiple myeloma (Lee & Hui 
2006). In contrast, b-MSCs are non-haematopoietic cells or stromal cells found in the bone 
marrow stroma. They provide a physical support for maturing precursors of blood cells and serve 
as a repository of a blood range of cell-derived cues and signals. This subsequently drives the 
commitment, differentiation and maturation of HSCs. MSCs are able to multi-differentiate into a 
wide range of musculoskeletal tissues such as bone, cartilage, muscle and fat. Since b-MSCs are 
capable of forming musculoskeletal tissues, they are a potential cell source for the repair and 
regeneration of cartilage for treating osteochondral defects and degenerative joint diseases, for 
example arthritis.
1.1.2.1 Mesenchymal Stem Cells (MSCs)
MSCs are capable of leaving the bone marrow and travelling in the bloodstream to a different 
site, where they may perform repair or regeneration processes of various mesenchymal tissues 
such as cartilage, bone and fat (Risbud & Sittenger 2002; Bosnakovski et al., 2005). MSCs are 
common precursors to differentiated cell lineages found in bone and bone marrow, including 
adipocytes, chondrocytes, osteoblasts and hematopoiesis-supporting stroma (Phinney 2002) 
hence a heterogenous cell population. Unfortunately, to date there are no definitive markers and 
no accurate measures of the capacity for self-renewal of MSCs, which makes the characterisation 
of adult stem cells a challenging task for researchers.
Over time, the nomenclature of MSCs has evolved from fibroblast colony-forming cells, colony- 
forming unit fibroblasts, to mesenchymal progenitor cells or marrow stromal cells. Currently, 
they are referred to as mesenchymal stem cells, and were first identified some 40 years ago by 
Alexander Friedentsein as able to differentiate into cells of the connective tissue lineages (Owen 
1988; Owen & Friedenstein 1988). Early studies by Friedenstein and colleagues suggested the 
presence of osteogenic precursors within the bone marrow (Petrakova et al, 1963; Friedenstein
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et al, 1961 and 1966). Subsequently their work has shown that marrow cells are capable of 
making new bone tissue at early passages, but lose such ability by the fifth passage, suggesting 
that prolonged passaging may cause the precursor cells to lose their multi-differentiation 
potential (Friedenstein et al., 1968; Friedenstein & Kuralesova 1971). By 1970, Friedenstein had 
developed a simple isolation method and primary culture of stem cells from marrow which 
highlighted several findings:
1. rare population of b-MSCs in bone marrow,
2. MSCs do not enter S-phase until up to 60 hours after initial plating
3. MSCs have a high replicative capacity in vitro
4. MSCs are clonogenic and form colonies of irregular shape and density
The conditions in which MSCs are cultured are also important since this contributes to the 
variations in size, morphology, proliferation potential, alkaline phosphatase levels and 
osteogenic capacities in vivo (Friedenstein et al., 1982). Subsequent groups identified the multi­
lineage potentials of MSCs (Beresford et al., 1992; Umezawa et al., 1992; Dorheim et al., 1993; 
Dennis et al., 1999) and demonstrated that marrow stromal cell cultures are an admixture of 
cells, including reticular cells, adipocytes, osteogenic cells, smooth muscle cells, endothelial 
cells and macrophages, with varying developmental potentials and that culture conditions used to 
expand the cells in vitro do not support long-term maintenance of the phenotype of MSCs (see 
Figure 1.6). Several studies using different animal models in ovine, murine and rat have shown 
that bone marrow derived MSCs obtained from adult or foetal animal model have potential for 
cartilage repair (Seedhom et al, 2007; Bernardo et al., 2007).
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1.2 Characteristics of b-MSCs
To date, the identification of MSCs has been based on their morphology, special adherent 
properties, great proliferative ability and their ability to multi-differentiate into other tissue types 
such as muscle, adipose and pericytes (Tuan et al, 2003). Considerable efforts have been made 
in defining the true characterisation of b-MSCs, based on morphology, phenotype, gene 
expression or a combination of the three (Friedenstein 1961; Castro-Malaspina et al, 1980; Tuan 
et al., 2003; Baksh et al., 2004). The proliferation of MSCs can be manipulated by many factors 
such as cytokines, growth factors, oxygen tension and culture system used. The different cell 
morphologies observed when using different preparation procedures and culture periods also 
show alterations to molecular expression patterns and expression of lineage specific antigens 
(Perkins & Fleishman 1990). Phinney and colleagues used serial analysis of gene expression 
(SAGE) to identify transcripts found in human stromal cells (Tremain et al, 2001), and indicated 
the presence of different mesenchymal cell lineages. Furthermore, Haynesworth et al., 1996 and 
Lee et al, 2001 reported that cytokine receptors were not expressed by one population of cells 
(in vitro studies), supporting the presence of mixed cell populations in marrow.
When culturing b-MSCs in vitro, it has been shown that in older individuals, the population of 
MSCs harvested decreases in comparison to that from younger individuals (Caplan 1994). 
Furthermore, during cell expansion in vitro, it has also been shown that increased passaging 
results in senescence of MSCs (inability for MSCs to divide), consequently affecting the 
differentiation potential of MSCs (Digirolamo et al, 1999).
The proliferation of MSCs can be influenced by the addition of fibroblast growth factor (FGF) to 
the basal medium and by the initial seeding cell density (Solchaga et al, 2005; Johnstone et al, 
1998; Satomura et al, 1998; Digirolamo et al, 1999). Together these factors contribute to the 
cell expansion profile and appear to govern the proliferation activity of MSCs in culture (Colter 
et al, 2000). It is interesting to note that the addition of FGF-2 to the culture medium changes 
the cell morphology of MSCs from flatter, polygonal and spread out MSCs (referred to as type II
MSCs population) to smaller, spindle-like fibroblastic MSCs, (referred to as type I MSC 
population). In addition, type I MSCs has been suggested to have a faster growth kinetic and 
maybe derived from type II MSCs in human (Solchaga et al., 2005; Johnstone et al., 1998; 
Digirolamo et al, 1999).
From the above, it is obvious that many factors affect the features and the behaviour of MSCs. 
Therefore further standardisation and improved characterisation methods are essential to further 
our knowledge on the behaviour of MSCs when they are subjected to different 
microenvironments. In the following section, we will discuss some methods that are commonly 
used for characterising MSCs.
1.2.1 Cell surface markers and molecules associated with MSCs
Different techniques were previously used to separate MSCs and HSCs. These include low 
forward angle scatter which separates the cells based on the cell size; low side angle scatter, 
separation method by cell granularity and by protein contents in cells (Hung et al, 2002). To 
date, the common methods used to differentiate MSCs from HSCs involve cell surface markers 
to stain the cells, followed by separation using fluorescence activated cell sorting (FACS).
Continuous progress has been made towards characterising the cell surface antigenic profile of 
bone marrow-derived MSC population using various techniques including FACS and magnetic 
bead sorting techniques (Alsalameh et al., 2004; Fickert et al., 2004). An extensive number of 
antibodies have been raised to identify cell surface antigens, some of which exist on MSCs. To 
date the antigenic phenotype of b-MSCs has not been shown to be unique and they share features 
of cells found in mesenchymal, epithelial, endothelial and muscle tissues. However, it has been 
widely agreed that b-MSCs do not express CD45, CD34 and CD 14, the typical markers for the 
characterisation of hematopoietic stem cells (Baddoo et al., 2003). In contrast, markers such as 
CD29, CD44, CD71, CD90, CD 106, CD 120 and CD 124 were found to be expressed strongly by
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b-MSCs (Pittenger et al, 1999). In addition to the above markers, the expression of other less 
MSCs -  specific markers (including cytokines and growth factors together with their receptors), 
plus adhesion and extracellular matrix molecules such as collagens, proteoglycans and 
fibronectin have also shown to be expressed by MSCs (see Table 1.2) (Miguell et al., 2001). 
Monoclonal antibodies raised against SH2, an epitope present on CD 105 (or endoglin, which is 
part of the transforming growth factor beta receptor) (Haynesworth et al, 1992; Barry et al, 
1999) and SH3 and SH4, epitopes present on CD 73 (activated leukocyte cell adhesion molecule, 
ALCAM) (Haynesworth et al, 1992; Barry et al, 2001a) have been used to characterise MSCs. 
It is interesting to note that SH2, SH3 and SH4 antibodies do not react with haematopoietic cells 
or osteocytes.
STRO-1 is a monoclonal antibody that reacts with non-haematopoietic, multipotent progenitor 
bone marrow stromal cells (Zannettino et al, 2007; Song et al, 2005, Dennis et al, 2002; 
Gronthos et al, 1994; Simmons & Torok-Storb 1991). Following cell isolation, monoclonal 
antibody raised against STRO-1 antigen is used to investigate the multi-lineage potential of 
MSCs (Simmons & Torok-Storb 1991; Gronthos et al, 1994). Monoclonal antibody raised 
against the low-affinity nerve growth factor receptor was also used to characterise the multi­
lineage potential of MSCs after isolation (Quirici et al, 2002). SB-10 antibody reacts with an 
antigen on undifferentiated MSCs, which disappears once the cells embark along the osteogenic 
pathway and begin to express cell surface alkaline phosphatase (Stewart et al, 2003; Bruder et 
al, 1998; Bruder et al, 1997). SB-10 antigen has been identified as CD 166 (activated leukocyte­
cell adhesion molecule). However, all these antigens do not provide the specificity needed for in 
vivo evaluation since they are also expressed on other cell types.
Analysis of cell surface molecules indicates that MSCs express a large spectrum of cell adhesion 
molecules, such as integrins, which have potential importance in cell binding and homing 
interactions (Docheva et al, 2007). MSCs have a high expression of integrins alpha (a) -1, -5 
and beta (p) 1 (Ip et al, 2007; Lee et al, 2004) and a low expression of integrins a -4, -L and p -
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2. Expression of specific integrins by MSCs may contribute to the homing mechanisms for the 
sites of injury, binding to specific matrix molecules (Chang et al., 2007) and improving their 
differentiation potential towards specific lineages (Varas et al., 2007). Table 1.2 is a generalised 
table to summarise the types of markers, molecules and receptors that are currently found to exist 
on MSCs.
It is important to note that the expression of cell surface molecules may vary due to different 
culture length of time, culture conditions and sample preparations. Therefore it is important to 
maintain a standardised protocol when culturing MSCs in vitro in order to minimise the variation 
between batches of cell culture (Devine 2002; Jackson et al., 2002). Currently, the commonly 
used in vitro conditions for chondrogenic differentiation of MSCs are high glucose, serum-free 
culture medium with the supplementation of Dexamethasone and selected pro-chondrocyte 
factors such as TGF-J33, FGF-2 and BMPs (Johnstone et al., 1998; Mackay et al., 1998; Yoo et 
al., 1998; Pittenger et al., 1999; Barry et al., 2001b). In order to create a more standardised 
isolation protocol and a better optimised cell culture conditions for the in vitro study of MSCs, it 
is essential for us to gain a better understanding on the molecular signalling pathways for 
chondrogenesis. This will therefore enable us to improve the development on the conditions 
required for directing MSCs towards a chondrogenic lineage.
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Markers Designation
Specific antigens
( m o le c u le s  t h a t  a r e  o n  c e l l  s u r fa c e  t h a t  
s t im u la t e  a n  im m u n e  r e s p o n s e )
SH-2, SH-3, SH-4 
STRO-1 
A-smooth muscle actin 
MAB 1740
Cytokines and growth factors
( P r o te in s  t h a t  a c t  a s  s i g n a l l i n g  c o m p o u n d s  
t h a t  s t im u la te  c e l l u l a r  p r o l i f e r a t i o n  a n d  
d i f f e r e n t ia t i o n )
Interleukins: la , 6, 7, 8, 11, 12, 14,15 
LIF, SCF, Flt-3 ligand 
GM-CSF, G-CSF, M-CSF
Cytokines and growth factor 
receptors
IL-1R, 3R, 4R, 6R, 7R 
LIFR, SCFR,
IFNyR,
TNFIR, TNFIIR, TGFpIR, TGFpiIR 
bFGFR, PDGFR, EGFR
Adhesion molecules
( c e l l  s u r f a c e  p r o t e in s  t h a t  a r e  i n v o lv e d  in  
b in d in g  w i t h  o t h e r  c e l l s  o r  E C M )
Integrins: avp3, avp5 
Integrin chains: a  -2, -3, -4, -5, av, p3, p4 
ICAM-1, ICAM-2 
VCAM-1 
LFA-3, L-selectin, CD44
Extracellular matrix Collagen type I, III, IV, V, VI 
Fibronectin, Laminin, Hyaluronan, Proteoglycans
Table 1.2 Specific antigens, cytokines receptor, adhesion molecules and production of cytokines 
and matrix molecules on bone marrow - derived mesenchymal progenitors (Haynesworth et al, 
1992; Caplan & Bruder 2001; Miguell et al, 2001; Dennis et al, 2002).
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1.3 The mesengenic process of chondrogenesis during embryonic 
development
During embryonic development, the initial differentiation of MSCs into each of the different 
lineages is controlled by unique ‘bioactive’ factors termed osteogenic (O-MSF), chondrogenic 
(C-MSF), myogenic (M-MSF) mesenchymal stimulating factor (Caplan 1994; Majumdar et al., 
1998). The cells undergo the processes of proliferation, differentiation and maturation where 
they eventually commit to and differentiate into specific lineage. During these stages, the cells 
undergo distinct changes in which they synthesize different ECM proteins at different stages. 
Figure 1.7 is a schematic diagram that outlines chondro- and osteo- genesis of b-MSCs and 
illustrates how b-MSCs proliferate, commit and differentiate into cartilage and bone respectively. 
The chondrogenesis of MSCs can be described in three different stages, 1) mesenchymal cell 
proliferation and condensation, 2) chondroprogenitor proliferation and differentiation and 3) 
chondrogenesis and terminal differentiation.
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Figure 1.7: A diagram to illustrate the sequence of events that occur during chondrogenesis. The 
spatial growth patterns and differentiation factors (above the forward arrows) and the 
transcription factors (below the forward arrows) are shown. The extracellular matrix proteins that 
distinguish the different stages of chondrogenesis are also indicated (indicated by the reverse 
arrows) (Adapted from Goldring et al., 2006).
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1.3.1 Mesenchymal cell proliferation and condensation
Mesenchymal stem cell proliferation and condensation are the first events to occur during 
chondrogenesis. During this process, many transcriptional factors are involved, which activate or 
inhibit certain molecules, consequently producing a selection of distinct ECM proteins. The 
production of these various ECM proteins allows us to identify stages of chondrogenesis.
A range of factors are thought to contribute to the early stages of chondrogenesis as shown in 
Figure 1.7. TGF-p is one of the earliest signals detected in chondrocyte condensation, which 
stimulates the production of fibronectin that later binds to syndecan, subsequently down- 
regulating the expression of cell adhesion molecules such as N-cadherin and N-CAM (Goldring 
et al., 2006; Sandell 1999). The expression of these ECM proteins is dependent upon BMP 
signalling (e.g. BMP-2, -4 and -6) via BMP receptors (Yoon & Lyons 2004). Members of the 
Wnt and FGF signalling families have been shown to interact to maintain expression of certain 
molecules such as FGF-10 and induce a positive feedback loop through Wnt 8 and 10, (Omitz 
2005). Other factors play a role in this stage of chondrogenesis, including Hox 11 and 13, which 
regulate cell proliferation, and Hox A and D, which support the expression of FGF-8 and Sonic 
Hedgehog genes (Shh) (Goldring et al., 2006). Prior to condensation, prechondrogenic MSCs 
produce hyaluronan and collagens type I and IIA, which contributes to matrix assembly 
(Knudson 2003).
1.3.2 Chondroprogenitor proliferation and differentiation
During chondroprogenitor proliferation and differentiation, expression of many ECM molecules 
is turned on including collagen type IX, collagen type II, aggrecan, and link protein. Collagens 
type IIB, IX and XII appear to be distinct ECM proteins of chondroprogenitor cells. The 
expression of such ECM proteins is induced by the co-expression of Sox-5 and Sox-6 (de 
Crombrugghe et al., 2001). Sox-9 and members of the FGF family are continuously expressed,
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suggesting that they may be important for maintaining signalling pathways involved in cellular 
proliferation and differentiation. In contrast, Wnt signals are down regulated during this stage, 
suggesting that they are involved in earlier events of chondrogenesis. During chondroprogenitor 
proliferation and differentiation, cell-cell and cell-matrix interactions and the association with 
cell adhesion molecules contributes to the formation of gap junctions and changes that occur in 
cytoskeletal structures (Shum & Nuckolls 2002; Goldring et al., 2006).
1.3.3 Chondrogenesis and terminal differentiation
During chondrogenesis, BMPs are involved in stimulating the differentiation of 
chondroprogenitor cells and regulate later stages of chondrocyte maturation and terminal 
* differentiation to a hypertrophic phenotype. During chondrogenesis, the activation of 
transcription factors such as Runx, Stat and Fra2/JunD and PTHrP contributes to the production 
of and decline of ECM proteins such as collagen X and collagens IIB, IX and XII. At this stage, 
the hedgehog family instead of being regulated by Wnt, is now modulated by patched (Ptc), (a 
Shh receptor), this clearly shows that throughout chondrogenesis of MSCs, a constant change of 
transcription factors is occurring in order to result in production of the appropriate ECM proteins 
at each stage. Beyond this stage, the matured matrix will begin to calcify through the influence 
of other factors such as osterix and VEGF, which eventually cause the cells to further 
differentiate towards the bone lineage (Reddi 1998; Chung 2004).
Previous in vitro studies carried out using human MSCs have demonstrated some of the culture 
conditions necessary for the chondrogenesis of MSCs. Commonly, MSCs are cultured in serum- 
free medium with the presence of nutrient supplements and the pro-chondrogenic factors such as 
dexamethasone and TGF-Ps (Yoo et al., 1998; Johnstone et al., 1998; Murdoch et al., 2007). 
These published work suggested that in order to convert MSCs derived from various locations 
successfully into chondrocytes, it is necessary to create a microenvironment in vitro which is
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similar to that during embryonic development. In the following section, the differentiation of 
MSCs into chondrogenic lineage will be discussed in detail.
1.4 Differentiation of MSCs to a chondrogenic lineage
In order to use stem cells successfully in regenerative medicine for the repair of cartilage, it is 
important to have a well-defined and efficient protocol, which helps to direct stem cells into this 
specific chosen lineage. This therefore will prevent stem cells differentiating spontaneously into 
any lineage other than the chondrogenic lineage. In addition, the defined media may help to 
improve the integration and engraftment within the recipient tissues. The conditions currently 
known to be required for the differentiation of MSCs towards a different chosen lineage are 
shown in Figure 1.8. Since this project relates to the differentiation of b-MSCs into chondrogenic 
lineage, therefore much of the culture conditions described will focus or relate to chondrogenesis 
ofb-MSCs.
1.4,1 Use of cytokines and growth factors for chondrogenic differentiation of 
MSCs
Cytokines and growth factors are signalling proteins that regulate cellular events through binding 
to target cell surface receptors, consequently promoting cell proliferation, differentiation and 
maturation. At present, some cytokines have been identified as enhancers, which increase 
proliferation and differentiation potentials ofb-MSCs on certain differentiation lineages (Banfi et 
al., 2002; Bianchi et al., 2003). In terms of chondrogenesis, numerous cytokines and growth 
factors have been implicated, such as transforming growth factors- beta (TGF-P) and its various 
isoforms, fibroblast growth factor-2 (FGF-2), Insulin-like growth factor-1 (IGF-1), bone 
morphogenic proteins (BMPs), and interleukin-1 beta (IL-ip) (Heng et al., 2004; Solchaga et al,
2005), many of which display a high degree of functional overlap.
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Figure 1.8: Conditions and factors necessary for differentiating MSCs towards specific lineages 
(Adapted from Tuan et al., 2003).
During embryonic development, different factors are involved in order to induce chondrogenesis 
and osteogenesis (Shea et al, 2003). Therefore it is important to understand the influence of 
different factors supplemented to the culture medium used for culturing MSCs in vitro for their 
differentiation towards a chondrogenic lineage. Common factors used for the chondrogenesis of 
MSCs and their effects during in vitro studies from previous publications will be discussed in the 
following sections.
1.4.1.1 Transforming growth factors -  beta (TGF-P)
TGF- p are multifunctional peptides, which consist of three subtypes in human, TGF p-1, P-2 
and p-3. These are responsible for tissue regeneration, cell differentiation, embryonic
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development and the regulation of the immune system. TGF- P triggers cellular responses 
through receptor mechanisms which later stimulate a series of signalling events within the cells, 
as shown in Figure 1.9, allowing them to act as a negative autocrine growth factor.
TGF-P has been known to be one of the most potent inducers of chondrogenic differentiation in 
MSCs from bone marrow and other tissue sources (Tuan et al, 2003). Previous studies using 
BMP and/or IGF-1 were supplemented together with TGF-p3 in either a cyclic or combined 
pattern to the culture medium. The combined use of these factors demonstrated a more effective 
response on the induction of chondrogenesis of MSCs, suggesting that the combined use of BMP 
and/or IGF-1 factors may influence the effect of TGF-P3 on the chondrogenic differentiation of 
b-MSCs (Indrawattana et al., 2004; Kim et al, 2005). Other study has used different 
concentrations of TGF-p and has shown to have an effect upon the expression levels of certain 
extracellular matrix molecules (Bosnakovski et al, 2004). These studies suggested that the effect 
of TGF-P on chondrogenesis ofb-MSCs may be increased by including more than one growth 
factor in the culture medium. Interestingly, Jin and co-workers showed that TGF- P3 appeared to 
have a different affect on chick leg bud mesenchymal cells where TGF- p3 seemed to inhibit 
chondrogenesis (Jin et al, 2007). However, in their previous publication they have suggested 
that TGF- P3 stimulates chondrogenesis of chick wing bud mesenchymal cells (Jin et al, 2006). 
These together indicate that cytokine TGF- p3 has different effects depending on the origin of 
the mesenchymal cells.
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Figure 1.9: Key events within the transforming growth factor signalling pathway (Adapted from 
Expert Reviews in Molecular Medicine by Cambridge University Press 2003).
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Different isoforms of TGF-p all have the ability to induce chondrogenic differentiation of MSCs, 
however, a study by Barry and colleagues has shown that TGF p-2 and p-3 appeared to be more 
effective than TGF- pi (Barry 2003). In the presence of TGF- p3, MSCs synthesise extracellular 
matrix molecules such as aggrecan, link protein, cartilage oligomeric matrix protein (COMP), 
decorin, type II collagen and chondroadherin, which are distinguishable proteins found at the 
early stages of chondrogenesis. The synthesis of these proteins indicates that such MSCs are 
differentiating towards the chondrogenic lineage (Barry et al, 2001; Barry 2003). Previous study 
by Melhom and colleagues demonstrated that TGF-p 1 has an influence on the procollagen type 
IIA transcript, which is associated with the development and early stage of pathology of cartilage 
in b-MSCs, but not in adipose-derived adult stem cells. However, TGF-P 1 also induces the 
production of procollagen type IIB in b-MSCs only which is mainly found in mature 
chondrocyte cartilage (Mehlhom et al, 2006). The above studies suggested that the effect of 
different isoforms of TGF p on the chondrogenesis of MSCs may vary between species and the 
culture conditions that different research groups have used. Therefore further studies are 
necessary in order to have a better understanding on the effect of different isoforms of TGF-p 
towards the differentiation of MSCs to a chondrogenic lineage.
The effects of the TGF-P superfamily on chondrogenic differentiation are transduced through 
two major intracellular signalling pathways, SMAD family of signalling molecules and mitogen- 
activated protein kinase (MAPK) signalling, both of which are activated by TGF-P receptor 
complex, as shown in Figure 1.9 (Massague & Wotton 2000; Stanton et al, 2003). On the other 
hand, other previous studies have also suggested that spontaneous chondrogenesis of bovine b- 
MSCs occurred without the addition of any external bioactive stimulators such as TGF- p family 
(Bosnakovski et al, 2004). Therefore controversies exist on the necessity of such external pro- 
chondrogenic stimulator for triggering chondrogenesis ofb-MSCs.
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1.4.1.2 Bone Morphogenetic Proteins (BMPs)
BMPs are members of the TFG- p superfamily, which are synthesized as larger precursors with a 
hydrophobic signal sequence. They act on chemotaxis, mitosis and differentiation of progenitor 
stem cells. There are nearly 20 BMPs in the human genome which are crucial for biological 
function (Reddi 1998). In vivo, they have been identified to induce ectopic endochondral 
ossification (Urist 1965) and have been shown to be involved in stimulating the determination 
and differentiation of chondroprogenitor cells regulating the later stages of chondrogenic 
maturation and terminal differentiation of chondrocytes into a hypertrophic phenotype (Goldring 
et al., 2006).
In vitro studies have demonstrated the ability of such protein to trigger chondrogenesis of b- 
MSCs through the activation of various signalling pathways such as TGF-P activated kinase 
(TAK1), SMAD and Ras/ERKl/2 or to cause an induction of certain transcription factors such as 
Jun B, D, ID and DLX family members (see Figure 1.10), which subsequently influence the 
downstream events that may regulate chondrogenesis (Yoon & Lyons 2004; Goldring et al.,
2006). BMPs exist in many isoforms and in particular, BMP-2 has been shown to be the most 
effective isoform which is able to give rise to a large amount of cartilage rich proteoglycans than 
other isoforms such as BMP-4 and -6 (Sekiya et al., 2005). In addition, it is one of the commonly 
investigated isoforms since many studies have demonstrated its capability to trigger 
chondrogenesis through gene expression analysis.
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Figure 1.10: Signalling events for Bone Morphogenetic Protein. BMPs bind to BMP receptors 
present on the cell membrane. Signal transduction through BMP receptors result in the activation 
of Smad-1 via phosphorylation. Activated Smad-1 can either interact with Smad-4, which 
enables gene expression to occur, or Smad-6, which inactivate Smad-1 (Adapted from 
http://www.sigmaaldrich.com/img/assets/6460/bone morph.gif).
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BMP-2 has been shown to increase the production of SOX-9, type II collagen and aggrecan. This 
finding illustrated that BMP-2 contributes towards directing b-MSCs to a chondrogenic lineage. 
In addition, it has also been identified to regulate chondrogenesis of synovium-derived 
mesenchymal progenitor cells in a dose-dependent manner, suggesting that BMP-2 can be 
induced to express chondrocyte-specific genes (Park et al, 2005). In vivo, BMP-2 is thought to 
regulate the initiation of chondrogenic differentiation through manipulating the transcriptional 
regulation of chondrocyte-specfic transcription factors such as Bapxl, SOX-9 and Indian 
Hedgehog (IHh) (Lengner et al, 2004). Previous studies have also illustrated that when BMP-2 
was cultured with the presence of TGF-P isoforms in a serum-free environment, they appeared to 
improve the expression levels of SOX-9, aggrecan and type I and II collagens than those cultured 
independently in either of the factors (Kim et al., 2005; Park et al, 2005). All these studies have 
proved that BMP-2 is another important external protein that contributes towards chondrogenesis 
ofb-MSCs.
1.4.1.3 Fibroblast growth factors (FGFs)
FGFs are heparin-binding proteins that belong to the family of growth factors that are involved 
in wound healing and embryonic development. They are capable of interacting with cell-surface 
associated heparan sulphate proteoglycans (PGs) which are essential for FGF-signal transduction 
(Olsen et al, 2003). In humans, there are 20 members within the FGF family, all of which are 
structurally related signalling molecules. FGF-2 (also known as basic FGF) has high and low 
molecular weight isoforms, which either induce and exert nuclear activities through an autocrine 
mechanism, or is cytoplasmic and functions in an autocrine manner, respectively. The main 
function of FGF-2 is to promote endothelial cell proliferation and physical organisation of 
endothelial cells into tube-like structures, hence promoting angiogenesis. It also associates with 
many developmental processes such as mesoderm induction, antero-posterior patterning and 
neural induction (Botter & Niehrs, 2005). In addition, it contributes to the normal development
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of both vertebrates and invertebrates, any irregularities in their function may lead to a range of 
developmental defects such as congenital diseases (Coumoul & Deng, 2003).
The addition of FGF-2 appeared to select the population of MSCs that is more likely to 
differentiate chondrogenically Bianchi et al, 2003. The expansion of human b-MSCs in the 
presence of FGF-2 will enhance their chondrogenic potential via specific regulatory molecules 
and signalling pathways (Solchaga et al., 2005). Stevens and colleagues have demonstrated that 
the combined use of TGF-p with FGF-2 is able to differentiate perichondrium chondrogenically 
(Stevens et al, 2004), generating neo-cartilage with a hyaline-like nature. The addition of the 
FGF-2 during the early stages of in vitro culture of periosteum in the presence of TGF-p 
significantly enhanced the cellular levels and chondrogenesis in later stages by selecting the 
number of committed cells that are programmed for chondrogenesis (Solchaga et al, 2005).
1.4.1.4 Other components
In addition to TGF-p, BMPs and FGFs, other types of chemicals and biochemicals may also 
contribute to the promotion of MSCs towards a chondrogenic lineage (Heng et al, 2004), 
described in the following sections
1.4.1.4.1 Non-proteinaceous chemicals
Dexamethasone, for example, is not a specific factor that stimulates chondrogenesis of MSCs,
however, previous study by Johnstone has demonstrated that its addition to murine embryonic
cell culture induced chondrogenesis and that it supports cell viability, and delays collagen type X
appearance (Johnstone et al, 1998). Ascorbic acid has been suggested to promote terminal
differentiation of chondrocyte by increasing the production of vitamin D receptors (Farquharson
et al, 1998) which contributes to growth plate development and endochondral ossification.
Vitamin D receptor also promotes osteoclastogenesis and regulates the production of FGF in
osteoblast (Masuyam et al, 2006). Altaf et al, have suggested that the addition of ascorbate to
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the culture medium may enhance chondrogenesis of certain cell line (Altaf et al, 2006). In 
addition, ascorbate was also found to increase the cell numbers, protein levels and collagen 
content (Solursh & Jensen, 1982). The effects of these factors on chondrogenesis are induced 
through various signalling pathways such as SMAD (Massague & Wotton 2000) and MAP 
kinase (Stanton et al, 2003) intracellular signalling pathways.
Glucosamine (GlcN) is a natural amino monosaccharide that is a constituent of 
glycosaminoglycans (GAG) found in hyaline cartilage. Recently it has been shown to influence 
the chondrogenesis of human MSCs (Derfoul et al, 2007). Derfoul and colleagues have 
demonstrated that GlcN has a chondroprotective property on cartilage, but influences 
chondrogenesis in human MSCs. When GlcN was applied to human derived MSCs, expression 
of cartilage extracellular matrix components such as collagen type II and aggrecan was observed, 
therefore favouring chondrogenesis. Interestingly, GlcN treatment appeared to block IL-lp 
mediated regulations and inhibits the expression of MMP-13, which is involved in cartilage 
degradation (Derfoul et al, 2007).
Another component that was found to have a direct effect on the chondrogenesis of b-MSCs is 
serum, which has shown to influence cell proliferation. Zuk and colleagues have shown that 1 % 
serum in the media is enough to induce chondrogenic differentiation, indicating that different 
serum concentrations influence the lineage-specificity ofb-MSCs (Zuk et al, 2001) suggesting 
that serum does not solely affect the quality of cells but also the rate at which the cells grow. 
Other studies have also illustrated that the removal of serum reduces the rate of cell proliferation 
(Lennon et al, 1995), but was still possible to culture MSCs in a serum-free environment 
(Schmitt et al, 2003).
1.4.1.4.2 Biophysical parameters
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As well as the supplements added to the culture medium that affects the behaviour and the 
lineage determination of MSCs, the environment to which they are exposed during culture also 
affects their differentiation outcome. Khan and colleagues have demonstrated the effect of 
oxygen tension on the chondrogenesis of human MSCs (Khan et al, 2007). Elderly human 
MSCs derived from intrapatellar fat pad were cultured at 20% (normoxic) and 5% (hypoxic) 
oxygen. The different oxygen tension was shown to influence the overall ECM production, and 
the rate of cell proliferation (Khan et al., 2007). In addition, the type of culture method used also 
needs to be considered since it may affect the cell-cell interaction, which promotes intercellular 
coupling consequently affecting the downstream events. At present, pellet and micromass culture 
systems have been the common systems used to study the molecular and cellular events that 
occur during chondrogenesis of MSCs in vitro. These culture systems restrict the cells to a 
confined space, enabling intimate contact between cells allowing cell-cell interactions 
(Bosnakovski et al., 2004; Lengner et al, 2004), which may help to induce chondrogenesis. The 
use of scaffolds to culture MSCs in animal models has also illustrated the potential of 
chondrogenesis of MSCs (Cai et al, 2007). Recently, the use of Genzyme transwell model has 
proven the possibility of forming a tissue graft using human derived MSCs (Murdoch et al,
2007).
As described above, numerous factors contribute towards directing MSCs into the chondrogenic 
lineage, Figure 1.11 summarises the factors that researchers have considered when attempting to 
differentiate MSCs into a variety of cell types for future stem cell therapies.
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Figure 1.11: A diagram that summarises the factors that may contribute to chondrogenic 
differentiation of mesenchymal stem cells in vitro. Modified from (Heng et al., 2004)
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The influence of these parameters on the chondrogenesis of MSCs are commonly characterised 
by the expression of some chondrogeinc markers such as SOX-9, Collagen type II and Aggrecan. 
Other markers that were previously used are Notch receptors and their ligands such as Delta and 
Jagged (Oldershaw & Hardingham 2009).
1.4.1.4.2 SOX-9
SOX-9 is expressed in all chondroprogenitors during embryogenesis and its expression is 
directly controlled by BMP signalling. The Syr-type, high mobility group (HMG)-box containing 
transcription factor SOX-9, is a regulator of chondrocyte lineage (see Figure 1.12) through 
binding to the minor groove of the essential DNA sequence motifs in chondrocyte-specific 
enhancer elements of the type II and type IX collagen genes and the cartilage-derived retinoic- 
acid-sensitive protein (de Crombrugghe et al., 2001; Lefebvre & de Crombrugghe 1998). Sox-9 
is also capable of forming complexes with SOX -5 and -6 and may interact with other 
chondrocyte-associated transcription factors. Unlike SOX-9, SOX -5 and -6 do not contain a 
transcription domain. However they appear to cooperate with SOX-9 in DNA transfection 
experiments to activate a cartilage-specific enhancer of collagen type II and aggrecan genes (de 
Crombrugghe et al., 2001). BMP has also been found to induce the expression of SOX-9 and 
Msx2, (a homeodomain transcription factor), which leads to the formation of ectopic cartilage 
(Shum 2002). A recent study has suggested that the overexpression of SOX-9 enhances 
chondrogenesis, by subsequently increasing other signalling pathways such as IHh/PTHrP and 
Wnt. These factors together contribute to the increased chondrogenic differentiation of MSCs 
(Tsuchiya 2003).
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Figure 1.12: A flow chart to illustrate the possible contributions and effects of SOX-9 during 
cartilage development (adapted from de Crombrugghe et al., 2001)
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1.5 Notch signalling
When cells are cultured using a three dimensional system, this increases the cell-cell contacts 
resembling the conditions involved in the mesenchymal condensation process during 
development. This environment enables Notch signalling to occur.
Notch signalling exists in most multicellular organisms and has four different notch receptors, 
namely Notch -1,-2, -3 and -4. The Notch receptor is found on the cell membrane and binds to 
ligand proteins (Lai 2004). Ligand proteins are members of the Delta/Serrate/LAG-2 (DSL) 
family that bind to the extracellular domain of Notch receptor, inducing proteolytic cleavage, 
subsequently releasing the intracellular domain, which enters the cell nucleus allowing gene 
expression to occur (Figure 1.13). In mammals, there are multiple Delta-like and Jagged ligands 
in addition to a variety of other ligands such as F3/contactin. Notch and its ligands are both 
transmembrane proteins, so the cells expressing the ligands typically need to be adjacent to the 
Notch expressing cell for signalling to occur as shown in Figure 1.13. The Notch signalling 
pathway is important for cell-cell communication, which involves gene regulation mechanisms 
that control multiple cell differentiation processes during embryonic development and 
throughout adult life.
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Figure 1.13: A schematic diagram to show the interaction between the Notch extracellular 
domain with a Delta ligand. The Tumour Necrosis Factor Alpha Converting Enzyme (TACE) 
cleaves the Notch protein just outside the membrane. The extracellular portion of the Notch 
protein is released and continues to interact with its ligand. The ligand/Notch complex is then 
endocytosed by the ligand-expressing cell. The enzyme gamma secretase (y-scretase) cleaves the 
remaining intracellular portion of the Notch protein and this will migrate to the nucleus where it 
can regulate gene expression by activating the transcription factor CSL (Adapted from Bray 
2006).
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Previous studies carried out using murine and chick limb development have shown the activation 
of the Notch signalling pathway during the early stage of chondrogenesis (Crowe et al, 1999; 
Watanabe et al, 2003). Other studies using immunohistochemical method has suggested the 
presence of notch receptors in bovine and murine articular cartilage (Hayes et al, 2003; 
Dowthwaite et al., 2004). In particular, Notch-1 was found to be located within the surface zone 
of articular cartilage in bovine and murine specimens (Hayes et al., 2003), where a niche of 
chondroprogenitor cells was identified (Dowthwaite et al., 2004). These chondroprogenitor cells 
are able to differentiate into connective tissues cell lineage (Dowthwaite et al, 2004). These cells 
have high affinity for fibronectin, high colony forming efficiency and express Notch-1. 
Dowthwaite and colleagues have demonstrated that the inhibition of Notch signalling affects the 
. colony formation of such chondroprogenitor cells (Dowthwaite et al, 2004). These together 
indicated the possible contribution of Notch signalling towards cartilage development and on the 
proliferation and differentiation of progenitor cells. Previous studies by Oldershaw and 
colleagues have suggested a general down regulation of Notch receptors on human MSCs 
cultured using a three dimensional cell aggregate system (Hardingham et al, 2006). Further 
work from this group has demonstrated that Jagged-1 mediated Notch signalling contributes 
towards the initiation of chondrogenesis in human MSCs. However, such signalling must be 
inhibited in order to enable chondrogenesis to proceed (Oldershaw et al, 2008). Another study 
carried out during murine skeletal development indicated that Notch-1 is strongly localised 
within the condensing mesenchyme during the early stages of chondrogenesis (Watanabe et al, 
2003).
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1.6 Application of MSCs for the repair and regeneration of articular 
cartilage
When cartilage reaches maturity, the metabolism of chondrocytes drops dramatically. For 
cartilage tissue to perform its physiological function of dispersing compressive load during joint 
articulation, a balance between synthesis and degradation is vital. However, factors such as age, 
genetics, obesity, trauma, overload and instability may contribute to the biochemical changes 
within the matrix that cause the imbalance between the synthesis and degradation of the cartilage 
ECM, leading to the onset of degenerative joint diseases such as arthritis.
Arthritis is the most common joint disease affecting people aged over 65, therefore it is a major 
cause of pain and disability in the elderly. In the UK alone, approximately eight million people 
suffer from arthritis. It is a form of articular cartilage disease, which involves the loss of cartilage 
proteoglycan and catabolism of collagen. Together these cause erosion of the surface of the joint. 
In the early stages of the disease, aggrecan metabolites are released from the cartilage matrix and 
are detected in the synovial fluid (Lohmander 1991). Aggrecan catabolism is carried out by 
aggrecanases (Hardingham 1995), and is followed by breakdown of collagen type II (Hollander 
et al., 1994) in the later stages of arthritis. Collagen breakdown results in irreversible damage to 
the cartilage. The two most common forms of arthritis are osteoarthritis (OA), usually caused by 
injury or trauma, and rheumatoid arthritis (RA) that is due to an influx of inflammatory cells 
(Feldmann et al, 1996), releasing inflammatory cytokines and inducing the synthesis of matrix 
proteases that degrade the cartilage matrix molecules (Chu et al., 1992).
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1,6.1 Regeneration and repair of articular cartilage
Articular cartilage generally does not heal, or heals partially under certain biological conditions. 
Lesions usually lead to disability and symptoms such as joint pain. Treatments for lesions in the 
articular cartilage surface have historically included a variety of clinical procedures ranging from 
very conservative therapies to invasive surgery and including debridement, abrasion, 
perichondral grafting and mosaicplasty. These techniques reduce the necessity for open joint 
procedures, which can be risky particularly when performed on elderly patients. For patients 
with end stage OA or RA, total joint replacement may be the only option to relieve pain and 
prevent further damage to the subchondral bone. In some severe cases, replacement of an OA 
affected joint and replacement with an artificial joint to help mobility may be the only option 
(Hunziker 2001). However, there are disadvantages to using the above repair methods including 
expense, skeletal mal-alignment or changes in transarthrodial loading pattern, which may 
exacerbate the osteoarthritic condition, leading to the eventual amputation of the affected joint 
(Hunziker 2000 & 2001).
A recent approach to cartilage repair has involved the use of tissue engineering techniques. 
These have been used for a wide range of clinical applications for structural (such as cosmetic 
reconstruction), functional (such as musculoskeletal tissues) replacements, and for wound 
healing (such as autologous skin grafts in bum patients, chronic wound and comeal 
replacement). Tissue engineering involves the ex vivo production of replacement organs and 
tissues using i) cell lines, ii) natural products and / or iii) synthetic biomaterials as scaffolds to 
assist the repair, regeneration, remodelling and eventual structural and/or functional replacement 
of injured, diseased and pathological tissues. Cell precursors can be obtained from autologous 
and/or heterologous cells as well as from stem cells. Such stem cells can either be multipotent or 
pluripotent and are capable of forming a variety of mature cell types, derived from healthy or 
pathological tissue (Hunziker 2000 & 2001).
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An example of cell-based technique is a method known as autologous chondrocyte 
transplantation (ACT), which was first described by Matts Brittberg and Lars Peterson in the 
early 1990’s. This went on to be commercialised by Genzyme (Brittberg 1999; Brittberg et al,
1994). ACT involves transplanting the autologous cultured chondrocytes harvested from a low 
load bearing region of the cartilage via an arthroscopic procedure, into a debrided articular 
cartilage defect void, which helps to repair any symptomatic cartilage defects of the femoral 
condyle caused by acute or repetitive trauma Figure 1.14 (Kim et al, 2003). However, the 
removal of autologous cartilage sample from a healthy region may subsequently lead to the 
initiation of another site of pathology. Therefore it is important to seek an alternative tissue 
engineering method
1) Biopsy 5) Implantation2) Cell culture 3) Debridement 4) Periosteal flap
Figure 1.14: Autologous Chondrocyte Transplantation (ACT). Healthy chondrocytes are 
harvested from a low weight bearing region of the cartilage and undergo cell culture. 
Debridement is applied to the damaged region of the cartilage and a periosteal flap is sutured 
over the defect void. Cultured chondrocytes are then implanted into the debrided cartilage area 
(Adapted from www.genzymebiosurgery.com)
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1.6,2 Stem cells and tissue engineering
Stem cells are interesting and attractive candidates for tissue engineering on various 
mesenchymal tissues including cartilage because they are hypoimmunogenic and can evade 
allorejection, in addition to their self-renewal and broad multi-lineage differentiation potentials. 
Due to their unique properties and developmental plasticity, a great interest has emerged in using 
b-MSCs to repair damaged tissues and for tissue engineering of different organs including heart, 
cartilage and bone in order to replace a faulty organ (Tsonis 2002; Ryans et al., 2006). However, 
it is important to note that the overall performance of b-MSCs can have a dramatic impact on the 
overall health status of individuals. The number of b-MSCs controls the ability to remodel, repair 
and upon demand, rejuvenate various tissues naturally. The reducing number of b-MSCs with 
- age or infirmity (Caplan 1994) may explain why older people generally become more susceptible 
to degenerative diseases such as OA.
Despite all the specific features of MSCs, when removed from their physiological environment 
and placed in an ex vivo culture environment, they progressively become senescent with 
increasing passage number, and subsequently lose their proliferation and differentiation 
potentials (Mackay et al., 1998; Banfi et al, 2002), hindering the development of MSC-based 
therapies (Conget & Minguell 1999; Digirolamo et al., 1999). Hence the correct culture medium, 
the appropriate factors or stimulants and the timing at which these factors are added need to be 
identified in order to create an optimum culture environment for b-MSCs. In order to generate a 
tissue using MSCs that resembles articular cartilage, it is important to understand its morphology 
in further detail.
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1.7 Morphology of Articular Cartilage
Articular cartilage is a hyaline cartilage only 2 - 5  millimeters thick that covers the subchondral 
bone in all diarthrodial joints. It is a highly complicated tissue that is hypocellular, avascular and 
aneural (Buckwalter & Mankin 1998; Poole et al, 2001), which provides a low friction 
articulation surface by absorbing and distributing mechanical load (Akeson et al., 2002). 
Following endochondral ossification, cartilage relies heavily on diffusion of nutrients and the 
exchange of metabolites from the articular surface, resulting in its low reparative potential 
(Archer et al, 2003; Archer & Francis-West 2003; Ulrich-Vinther et al, 2003).
1.7.1 Extracellular Matrix (ECM)
The ECM of articular cartilage is primarily composed of collagens, proteoglycans and water. The 
combination of specific collagen fibril orientation, distribution and ‘location’ of different types 
of proteoglycans and water, allows the ECM of cartilage to disperse any applied forces on the 
articular joint and provides a smooth, frictionless surface enabling joint movement. It is 
interesting to note that whilst matrix glycoproteins and plasma proteins are produced by 
chondrocytes during the various stages of differentiation, they are at a lower level of expression 
in terminally differentiated chondrocytes (Sandell 1999).
1.7.2.1 Collasens:
Collagen is a rod-shaped protein found to be most abundant in the ECM of all mammals and 
plays an important role in development and tissue homeostasis (Kielty et al, 2002; Boot- 
Handford 2003). It contributes to the structure of all connective tissues by forming fibrous 
elements and also provides stability to other tissues and hence helps to maintain their structural 
integrity (Gelse 2003; Gustafsson 2003). Collagen contains at least 20 amino acid residues in the 
sequence of Glycine-X-Y where X and Y is proline or 4-hydroxyproline residues, occasionally, 
3-hydroxyproline, rarely found elsewhere in the body (Kadler 1996). In each chain, this
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sequence forms a left-handed helix and the chains wind around each other in a right- handed 
super triple helix. Twenty-eight members within the collagen family have now been identified 
and can be divided into separate classes according to their structures and functions as shown in 
Table 1.3 (Myllyhaijn & Kivirikko 2001; Fitzgerald & Bateman 2001; Young et al., 2000; Sato 
et al., 2002; Eyre 2004; Veit et al., 2006). Mutations of collagen genes have been linked to the 
onset of pathological diseases such as osteogenesis imperfecta and chondrodysplasia (Gustafsson 
2003).
Collagens in Articular Cartilage
In articular cartilage, collagen is the major proteinacous component, occupying approximately 
two-thirds of the tissues dry weight. Generally, collagens are composed of protein monomers 
which are stacked in a quarter-staggered array. Each of the monomers is made up of three 
polypeptide chains arranged in a triple helix. In embryonic and young adolescent animals, the 
fibril diameter is 17 -  20 nm. In contrast, in older animals wider fibrils are found with many 20 
nm fibrils protruding, suggesting an increase in fibril diameter with ageing (Bruckner & van der 
Rest 1994). Collagen types II, IX and XI are the key ‘cartilage-specific’ molecules which 
contribute to the mature matrix. In addition to these, types III, VI, X and XII are also present 
(Wotton & Duance 1994; Bruckner & van der Rest 1994; Gelse et al., 2003).
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Classes Comments Types Tissue Distribution
Fibril-
Forming
collagen
These contain a large triple 
helical domain with around 330 
Gly-X-Y repeats per chain; 
synthesised as large precursors; 
assemble into cross striated 
fibrils, with each molecule 
being displaced XA o f its length 
along the axis o f the fibril 
relative to its nearest neighbour 
(Burgeson, 1988)
/ Skin, bone, tendon, ligament, 
cornea, intervertebral disc and 
cartilage
II Vitreous, cartilage, intervertebral 
disc, body nucleus pulposus
III Skin, blood vessels, cartilage, 
reticular fibres o f most tissues (e.g. 
lung, liver, spleen), intervertebral 
disc
V Skin, bone, tendon, intervertebral 
disc, cartilage,
XI Skin, bone, tendon, intervertebral 
disc, cartilage
XXIV Developing cornea, bone
XXVII Chondrocytes,developing stomach, 
lung, gonad, skin, tooth
Network
Forming
Collagen
Self assemble into networks 
with longer non-collagenous 
domains; tetramers formation; 
supercoiled structure (Hulmes, 
2002)
IV Basement membranes, stromal 
region o f the cornea
VIII Descement’s membrane, endothelial 
cells
X Calcifying cartilage 
(regulate EO o f AC, Shen 2005)
Fibril 
associated 
collagens 
with an 
interrupted 
triple helix 
(FACITS)
No fibrils formed but attached 
to the surface o f pre-existing 
fibrils o f the fibril forming 
collagens (Shaw and Olsen, 
1991).
IX Cartilage and intervertebral disc
XII Skin, cartilage, intervertebral disc
XIV Skin, cartilage, intervertebral disc
XV Basement membranes, cartilage
XVI Skin, lung, arterial smooth muscle
XVII Most tissues, high levels in liver
XIX Most tissues, basement membranes
XX Comeal epithelium, tendon
XXI Blood vessels, smooth muscle
XXII Hair follicle
XXVI Testis, ovary
Other small 
groups
Beaded filaments VI Most tissues including cartilage
Anchoring fibrils for basement 
membranes
VII Anchor stroma to basement 
membranes in skin and cornea
Transmembrane
XXIII Prostate carcinoma
XIII Most tissues including skin
43
XVII Skin, muscle
Von 
Willebrand 
factor A 
(VWA) 
domain- 
containing 
proteins
Facilitate protein-protein 
interactions by presenting in the 
integrin and receptors 
responsible for the interaction 
with fibrillar collagens. It is 
also found in collagen types VI 
and VII. Several FACIT 
collagens also consist o f VWA 
domains. (Veit et al., 2006)
XXVIII Skin, calvaria, doral root ganglia, 
peripheral nerves, Schwann cells in 
the peripheral nervous system
Table 1.1: Different classes of collagens, the functions and features, the name and location in 
which the collagens are distributed. (Modified from Dr Alison Rees thesis, 2004)
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Collagen type II
The key collagen found in cartilage is collagen type II, which comprises 90% of the bulk 
collagen network in the matrix of articular cartilage (Wotton et al, 1999). Collagen type II 
belongs to the fibril forming collagen family and is made up of three identical alpha-1 (a-1) 
polypeptide chains that form a triple helix from which very short amino terminal and carboxyl- 
terminal telopeptide domains extend at each end. Collagen type II fibrils cross-link with collagen 
types XI and IX to form heterotypic fibrils. Type II collagen fibrils are organised as quarter- 
staggered polymers, as shown in Figure 1.15. In mature cartilage, collagen type II forms fibrillar 
networks with finer fibrils located at the surface layer whilst the thicker fibrils lie in the deep 
zone. (Aydelotte & Kuetter 1988 a and b).
Collagen Type IX
Collagen type IX belongs to the FACIT class of collagens. It is present in fibrils and represents ~ 
2% of the total collagen in articular cartilage. It is composed of a heterotrimer with its three 
alpha chains (a-1 [IX], a-2[IX] and a-3 [IX]) being products of different genes (Eyre & Wu
1995). Type IX collagen adds tensile strength to the tissue by cross-linking the type II collagen 
fibrils and acting to resist shear between fibrils (Akeson 2002). In addition, it facilitates fibril 
interactions with proteoglycan macromolecules. The globular domain, NC4 that projects out of 
the fibril, may be involved in molecular linkages with the inter-fibrillar matrix (Cremer et al., 
1998).
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Figure 1.15: shows the interactions between collagen types II, IX and XI in articular cartilage 
and how the collagens interact with other ECM molecules in the matrix. (Adapted from Reginato 
& Olsen 2002)
Collagen Type XI
This member of the fibril forming collagen family contributes ~ 3% of the total collagen in 
articular cartilage tissue. It is made up of three distinct a-chains (a-1 [XI], a-2[XI] and a-3[XI]) 
which co-assemble with collagen types IX and II (see Figure 1.15). Collagen type XI is present 
on the surface of, and within the heterotypic collagen fibrils.
Together, types II, XI and IX collagens form a cross-linked heteropolymer network during 
cartilage development (Eyre 1992; Eyre 2002a). Mutation of the genes encoding these collagens 
will affect the formation of a normal fibril which may lead to the onset of chondrodysplasia and 
destruction of joint cartilage (Eyre 1992; Cremer 1998).
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Other collagens in Articular Cartilage
It is also established that some other collagens, apart from collagen types II, IX and XI, are 
found in articular cartilage, these include collagen types I, III, V, VI XII and XIV, and changes 
in the expression levels of these occur with age and osteoarthritis (Nemeth-Csoka 1984; Poole et 
al, 1992; Kielty etal., 1993).
Collagen type I  is the most abundant collagen in mammals found in most tissues 
including skin, bone and tendon, but it is only present in minor amounts in articular cartilage. 
Type I collagen fibrils are 20 -  100 nm in diameter and may aggregate to form larger collagen 
fibrils. It consists of two a-1 (I) and one a-2 (I) chains. It belongs to the fibril forming class of 
collagens, and is mainly found in the superficial zone of articular cartilage in parallel 
arrangement (Duance 1983). Collagen type I akin to type II, is able to form heterofibrils. It 
associates with collagen types V and / or III (Kielty et al, 1993).
Collagen type III is the second most abundant collagen in mammals and possesses elastic 
properties due to disulphide bonds and no lysyl oxidase dependent crosslinks in the carboxyl 
terminal. It consists of a homotrimer of three a -1  (III) chains and resembles other fibrillar 
collagens in its structure (Cheung et al, 1983). This collagen copolymerises and links to 
collagen type II in adult human articular cartilage in significant amounts. These events lead to 
speculation that collagen type III may be produced by chondrocytes, in addition to collagen type 
II, in response to matrix damage similar to the wound healing role of collagen type III in type I 
collagen-based tissues (Eyre et al, 2006).
Collagen type V belongs to the fibril forming collagen family and possesses high 
homology to collagen type XI (Gelse et al, 2003).
Collagen type VI is a heteromeric and globular collagen. It forms a loose pericellular 
fibrillar meshwork in lacunae around the cells, known as the chondron that helps to anchor the 
cell membrane, maintain the integrity of the cell and protects against mechanical forces (Poole et
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al, 1992; Poole et al, 2002; Soder 2002). It has been found to be upregulated in osteroarthritic 
cartilage (Bruckner & van der Rest 1994; Chang & Poole 1996).
Collagen type X  is a member of the network forming collagen family, which is found 
predominantly in the hypertrophic region of the growth plate during endochondral ossification 
(Nerlich et al., 1992; Kielty et al, 1985; Mayne & Brewton 1993; Bruckner & van der Rest, 
1994; Mayne 1997). In disease states such as osteoarthritis (OA), chondrocytes appeared to 
synthesise an enhanced amount of collagen type X (Girkontaite et al, 1996).
Collagen types XII, XIV and XV are members of the FACIT family identified in bovine 
articular cartilage (Watt et al, 1992; Gelse et al, 2003).
The function and contribution of collagens to the extracellular matrix is based on various factors 
including size, composition and interactions, which together create a functional matrix.
1.7.3.1 Proteoglycans:
Another important component of the matrix is proteoglycans (PGs), which occupy most of the 
non-collagenous area of the matrix and make up 22 -  38% of the dry weight of articular 
cartilage. They are complex macromolecules with high molecular weight polyanionic elements 
(Knudson 2001). A proteoglycan monomer consists of a central protein core with one or more 
negatively charged carbohydrate side-chain substituents, known as glycosaminoglycans (GAG) 
(Figure 1.16); common GAG include chondroitin sulphate (CS), keratan sulphate (KS) and 
dermatan sulphate (DS). Such GAG chains are variable in length and are made of repeating 
disaccharide subunits. The polyanionic nature of GAG contributes to the hydrophilic properties 
of PGs, enabling water retention within the ECM, creating the swelling pressure and turgidity 
necessary for the function of normal articular cartilage.
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PG have no unifying features and they display great diversity of forms with regard to their size 
and the composition of their GAG side chains (Roughley PJ 1994). In addition, the biochemical 
composition of proteoglycan subunits has been shown to change with age (Roughley & White 
1980). Abnormalities of PGs have shown to contribute to pathologies such as chondrodysplasia 
(Schwartz & Domowicz 2002). The different PGs found in articular cartilage is summarised in 
Table 1.2.
Name of PGs Classes Features Reference
Aggrecan Hyalectin
-Bind to hyaluronan & other matrix 
glycoproteins
-KS & CS attachment between G2 and 
G3 domains
-Loss o f OA during joint degeneration
(Hardingham et al., 
1994; Watanabe et 
al, 1998; Kiani et al., 
2002)
Decorin Class I SLRPs 
(Small Leucine 
Rich 
Proteoglycans)
-Bind to TGF-beta, sequestering its 
mitogenic activity
-A decorating PG that associate with 
collagen fibrils, regulating collagen 
fibrillogenesis
-Most abundant out o f  all SLRPs 
-Detection is increased with age
(Roughley and Lee 
1994)
Biglycan
-Binds to TGF-beta
-Found in pericellular region o f  
proliferating cells
Fibromodulin
Class II SLRPs 
(Small Leucine 
Rich 
Proteoglycans)
-Regulate collagen fibril diameter by 
decorating collagen surface 
-Detection is increased with age
Lumican
-In young cartilage, it exists as KS-PG 
-Treatment with IL-1, chondrocytes 
synthesise lumican devoid o f GAG 
substitutions (Benjamin and 
Ralphs 2004)Keratocan
- Regulate collagen fibrillogenesis in 
tendon
Proline arginine- 
rich and leucine 
rich repeat
-Has four potential N-linked 
glycosylation sites
-Functions as a cartilage matrix 
protein with the capacity for matrix
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protein
(PRELP)
organisation
Epiphycan
(PG-Lb) Class III 
SLRPs
-Express during the development o f  
growth plate
-Excluded from presumptive articular 
cartilage and the hypertrophic zone
(Johnston 1997)
Mimecan
-Control cell growth, modulate by 
growth factors & cytokines
(Funderburgh et al, 
1997)
Perlecan
Large heparan 
sulphate 
proteoglycan
-Consists o f  five distinct domains 
-Enriched in the pericellular matrix 
Accumulates during cartilage 
development
(Hassell et al., 2003)
Superficial zone 
protein (SZP) or 
Proteogycan-4 
(PRG-4)
Novel
proteoglycan
Synthesised by superficial zone 
chondrocytes o f  articular cartilage 
-Proposed that it contribute to cell 
proliferation, cytoprotection, 
lubrication, self-aggregation & matrix 
binding
(Flannery et al., 
1999)
Syndecan
Cell surface 
transmembrane 
heparan 
sulphate 
proteoglycans
-Transmembrane heparan sulphate 
PGs
-Interact with FGF through HS-chains 
-Different members o f syndecans exist 
& are detected during various stages 
o f chondrogenesis
(Bemfield et al, 
1992)
Glypican
-Glypican-1 is expressed in cartilage 
-Possess an extracellular region with a 
GAG attachment site
(Tumova et al, 2000)
Table 1.2: A table that shows the types of proteoglycans found in articular cartilage
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Glvcosaminoglvcans (GAG)
GAG are long linear polysaccharide chains, which vary in length and are made up of repeating 
disaccharide units. These repeating disaccharides are composed of a hexosamine and either 
uronic acid or galactose sugar. Such repeats also contain ester-sulphate on several of the sugar 
hydroxyls which contribute to the polyanionic properties of the GAG and ultimately the 
physiological functions of cartilage. The commonly recognised GAG include; chondroitin 
sulphate (CS), keratan sulphate (KS), dermatan sulphate (DS), heparan sulphate (HS), heparin 
(Hep) and hyaluronic acid (HA) (Paulsson & Heinegard 1984). The enrichment of GAG within 
cartilage creates an anion-rich environment, which allows water to be drawn in from the 
surrounding area, therefore enabling hydration of the ECM, subsequently allowing load to be 
dispersed throughout the cartilage. The GAG chains and their complex sulphation motifs also 
bind specific growth factors and thereby play important roles in cytokine or growth factor 
presentation in ECM and to cells.
Aggrecan
Aggrecan is the predominant proteoglycan present in articular cartilage (Kiani 2002). It belongs 
to the high molecular weight aggregating group of PG and is largely expressed in cartilage 
(Hardingham 1995). It is a member of the hyalectin family of proteoglycans, which has the 
ability to bind hyaluronan at the amino-terminus end whilst the carboxyl-end binds to other 
matrix glycoproteins via the G3 C-type lectin domain (Halberg et al, 1988; Watanable et al., 
1998; Zhang et al., 1998). Due to its structure, it provides the tissues’ ability to resist 
compressive loads.
The core protein of 250 -  300 kDa contains three globular domains known as Gl, G2 and G3 
(Hardingham 1992; Roughley 2006). Between Gl and G2 is the interglobular domain (IGD) and 
glycosaminoglycans attachment region is located between G2 and G3. GAG, mainly keratan
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sulphate (KS) and chondroitin sulphate (CS) are found to attach in two adjacent regions of the 
aggrecan core protein between G2 and G3 (Paulsson et al., 1987).
Gl domain is 56kDa in weight and is located at the N-terminal of the aggrecan core 
protein where HA binds. It has an immunoglobulin (Ig) fold that contains similar sequences to 
those in the IgG superfamily of proteins. There are two PG tandem repeats (PTRs), which are 
also found in this domain that possess a similar sequence to that of the lymphocyte homing 
receptor, CD44, which is a glycoprotein that can bind to hyaluronan (Dudhia 2004).
G2 Domain has a molecular weight of 45kDa, which also has a tandem repeat region 
which closely resembles those in the Gl. However, the G2 domain lacks HA binding activity 
(Watanabe et al., 1997).
G3 Domain is composed of two epidermal growth factor-like domain (EGF1 and EGF2), 
a carbohydrate recognition domain (CRD) similar to the mammalian type C lectins and a 
complement regulatory protein B (short complement repeat, SCR). It is readily cleaved from 
secreted aggrecan. The G3 domain appears to provide the core protein with correctly folded C- 
terminal cap that is important for intracellular trafficking of aggrecan and preventing core protein 
degradation (Kiani 2002; Domowicz et al., 2000).
In addition to collagens and proteoglycans, other ECM components found in lesser amounts 
includes, fibronectin, tenascins, cartilage intermediate layer protein (CILP), cartilage oligomeric 
matrix protein (COMP) and matrilins have been identified previously (Deak et al., 1999). SLRPs 
such as decorin, biglycan and fibromodulin are also found in cartilage (see Table 1.2). The 
distribution, arrangements and expression levels of different collagens and PGs vary within 
different zones of the articular cartilage. In order to produce a tissue using MSCs that resembles 
articular cartilage, it is important to understand the zonal organisation of the native tissue. This 
will be discussed in the following sections.
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1.7.2 Zonal organisation o f Articular Cartilage
Mature articular cartilage is organised into histologically and biochemically distinct overlapping 
zones: i) superficial or tangential zone, ii) intermediate/middle or transitional zone, iii) deep or 
radial zone and, iv) calcified zone (see Figure 1.17). Each of the zones varies in terms of their 
cell morphology, collagen arrangement and which ECM molecules they contain giving unique 
properties to each zone (see Figure 1.18). In addition to these variations, chondrocytes located in 
different zones may respond differently to mechanical loading and to certain factors (Aydelotte 
et al, 1992; Hauselmann et al., 1996), suggesting that the development and maintenance of 
normal articular cartilage is dependent upon the unique phenotypic population of chondrocytes. 
Evidence has shown that the cartilaginous tissue composition, and possibly the mechanical 
properties may be modulated using cells from different zones of cartilage from native tissue and 
cultured in vitro within a three dimensional construct (Waldman et al, 2003 a and b). Hayes and 
colleagues have illustrated that it is possible to reconstruct articular cartilage zonal organisation 
in Transwell cultures (Hayes et al, 2007).
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Figure 1.17: Diagram of different zonal organisation within an articular cartilage.
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Chondrocyte
Morphology
Collagen
O rganisation
Matrix
Com position
Matrix Constituents:
Type I Collagen Fibril 
Superficial Zone Protein (SZP)
Aggrecan, Link Protein & HA
Cartilage Oligomeric Matrix 
Protein (COMP)
Cartilage Intermediate Zone 
Matrix Protein (CILP)
Type ll/XI Collagen Fibril 
Type IX Collagen 
\  Fibromodulin
^  Biglycan
Decorin
Type X Collagen
Figure 1.18: Schematic diagram to show the macromolecular organization of mature articular 
cartilage. It is organised into histologically and biochemically distinct overlapping zones: i) 
superficial or tangential zone (SZ), ii) intermediate/middle or transitional zone (MZ), iii) deep or 
radial zone (DZ) and, iv) calcified zone (CZ), below which is the subchondral bone (SB). Each 
zone varies in terms of their cell morphology (left panel), collagen arrangement (middle panel) 
and ECM compositions (right panel). Matrix constituents are presented as molecular schematics 
(adapted from Hayes et al., 2007).
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1.7.2.1 Superficial Zone
The superficial zone is typically 200-500pm thick and contributes 10-20% of the cartilage cell 
number. The superficial zone chondrocytes are flattened and synthesize a matrix rich in collagen, 
but with a low concentration of proteoglycans. Surface zone protein (SZP, or lubricin) is 
synthesized by cells found at the articular surface as well as synovial cells (Schumacher et al, 
1999; Klein et al., 2003). Recent studies have shown that SZP is also able to reduce cartilage- 
cartilage integration in vivo (Schaefer et al., 2002). The superficial zone contains flattened 
chondrocytes that are surrounded by a polarised organisation of thin collagen fibrils, mainly 
collagen type I, that run parallel to each other and to the articular surface. Collagen fibres found 
in this region are arranged tangentially and are covered by a dense, separate layer of small fibrils 
(Clark 1990; Clark JM 1990). For this reason, this region of the articular cartilage is also referred 
to as the tangential zone. This zone has the lowest aggrecan content, however, other 
proteoglycans have been found in this region such as decorin and biglycan (Poole et al., 2001). It 
is interesting to note that this region of cartilage is more suspectible to interleukin-1 (IL-1) 
induced damage than the deeper layers (Hauselmann et al., 1996). Archer and colleagues have 
recently implied the existence of progenitor cell populations on the surface of articular cartilage, 
which play a role in cartilage growth (Dowthwaite et al., 2004).
1.7.2.2 Middle Zone
This is the intermediate region (or transitional zone) between the superficial and deep zones and 
contributes 40-60% of the articular cartilage cell number. The cells in this zone have a rounded, 
spherical morphology. It has the lowest cell density of all the zones, but the cells found in this 
region have a higher concentration of synthetic organelles than superficial zone cells 
(Buckwalter 1999; Hunziker 1999). Chondrocytes in the middle/deeper layers of the tissue have 
been found to express cartilage intermediate layer protein (CILP), which is then deposited in the 
interterritorial matrix (Lorenzo et al., 1998). An abundant amount of collagen type II and 
aggrecan are found in this zone and collagen fibrils are larger and are arranged in a more random
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pattern than the surface zone. In the pericellular region surrounding the chondrocytes in this 
zone, decorin and type VI collagens are also found (Poole et al., 2001).
1.7.2.3 Deep Zone
The deep zone contributes 30% of the articular cartilage cell number and contains a low cell 
density but the aggrecan content and fibril diameter are higher than in any of the other zones. In 
contrast to the superficial and middle zones, the collagen content is very low. Within this region 
of the articular cartilage, the main ECM molecules are aggrecan, collagen type II and collagen 
type X.
1.7.2.4 Calcified Zone
The calcified zone provides a buffer, with intermediate mechanical properties, between 
uncalcified cartilage and subchondral bone. Chondrocytes in this zone are thought to have 
reached terminal differentiation and have a hypertrophic phenotype. The calcified matrix is not 
fully resorbed in development and resists vascular invasion. These properties provide an 
excellent structural integration with the subchondral bone (Buckwalter & Mankin 1998; Poole et 
al., 2001).
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1.8 Aim of this study
Current research has shown that it is possible to attach b-MSCs to an artifical matrix that can be 
implanted into full thickness osteochondral defects to later drive the formation of cartilage and 
bone, thereby generating and repairing the appropriate tissue (Qintavalla et al., 2002). Previous 
studies by Dr Anthony Hayes and Amanda Hall within our laboratory have demonstrated the 
successful production of cartilage grafts using Millipore filter inserts (Kandel et al., 1995). The 
grafts were initially produced from chondrocytes obtained from young bovine articular cartilage 
and seeded at high density onto filter inserts pre-coated with a selected ECM protein that helps 
cell attachment. After 4 weeks culture, a stratified hyaline-like tissue graft was generated, which 
closely resembles the in vivo features of young native articular cartilage, identified through 
histology and immunofluorescent labelling techniques. Thus, the focus and aims of my studies 
were:-
Aim 1: Characterisation of primary bovine MSCs by assessing the gene expression of cartilage- 
specific genes (SOX-9, Aggrecan and Collagen type II) and non-specific genes (Collagen type I 
and type X)
Aim 2: Investigate the effects of culture medium supplemented with FGF-2 or with the addition 
of an extra growth factor, TGF-p2, on bovine MSCs in a two dimensional culture system 
Aim 3: Characterise the phenotypes of MSCs tissue grafts produced using MSCs pre-cultured in 
culture medium supplemented with FGF-2 or with the addition of TGF- p2 in a three dimension 
culture system (Transwell) seeded at high (6xl06 cells) and low (0.5xl06 cells) cell density
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CHAPTER 2: General Materials and Methods
2.1 Materials
Histology: All commercial stains, histology slide holder, disposable blades and mounting 
medium were obtained from RA Lamb, Eastbourne, East Square, England. Xylene and powdered 
Alcian Blue were purchased from Fisher Scientific, Loughborough, Leicestershire, UK and 
Sigma-Aldrich, Poole Dorset, UK, respectively.
Immunohistochemistry: Immunomountant and HistoBond slides were purchased from RA 
Lamb, Eastbourne, East Square, England. All serum, negative controls, FITC-conjugated 
secondary antibodies and Dakocytomation pen were from Dako, Ely, Cambridgeshire, England. 
Chondroitinase ABC was obtained from Sigma-Aldrich, Poole, Dorset, UK. Keratanase and 
Vectashield Mountant with DAP I were obtained from Seikagaku, Tokyo, Japan and Vector, 
Orton Southgate, Peterborough, England, respectively.
DMMB: DMMB was obtained from SERVA and chondroitin sulphate C was purchased from 
Sigma-Aldrich, Poole, Dorset, UK. Multiwell plates were bought from Elkay.
SDS-PAGE/WB: 4-12% gradient gels were obtained from Invitrogen. Nitrocellulose membrane 
and filter papers were obtained from Whatman. NBT, BCIP and anti-mouse alkaline phosphatase 
were purchased from Promega.
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2.2 Methods
2.2.2 Histological Techniques
2.2.2.1 Histology
Specimens were preserved in 4% (w/v) Paraformaldehyde (PFA) in Phosphate Buffered Saline 
(1 PBS tabet was dissolved in 100ml of water; each PBS tablet is composed of 8 M Sodium 
Chloride pH 7.4, 0.2 M Potassium Chloride, 1.5 M Di-sodium hydrogen phosphate, 0.2 M 
Potassium dihydrogen phosphate) overnight at 4°C. The specimens underwent an ascending 
alcohol series of 70% (v/v) ethanol (EtOH), 95% (v/v) EtOH and three times in 100% (v/v) 
EtOH, followed by xylene, a clearing fluid that is miscible with the dehydrating alcohol and wax 
embedding agent. This was followed by the impregnation of the specimen in molten wax for the 
final embedding stage.
Paraffin blocks containing the specimen were sectioned at 10pm using a Leitz microtome and 
processed for dewaxing, rehydration and staining using Alcian Blue at pH 2.5, which stains 
glycosaminoglycans (GAG) blue. Later counterstained with haematoxylin and eosin, as outlined 
in Table 2.1.
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Chemicals Time
Xylene 2 x 2  minutes
100% (v/v) EtOH 2 x 1  minutes
95% (v/v) EtOH 1 minute
70% (v/v) EtOH 1 minute
Wash in running tap water 1 minute
Stain with Alcian Blue, pH 2.5 20 minutes
Wash in running tap water 1 minute
Stain with Commercial Mayer’s Haematoxylin 1 minute
Wash in running tap water 3 minutes
Stain in 1% (v/v) Commercial Eosin 2 minutes
Wash in running tap water 20 seconds
70% (v/v) EtOH 20 seconds
95% (v/v) EtOH 45 seconds
100% (v/v) EtOH 1 minute
100% (v/v) EtOH 2 minutes
Xylene 2 x 2  minutes
Mount in DPX mountant
Leave in fumehood to dry overnight
View under a brightfield microscope
Table 2.1: Summary of the procedure for staining specimens using Alcian Blue, Haematoxylin 
and Eosin, which recognise sulphated glycosaminoglycans (GAG), cell nuclei and cytoplasm, 
respectively.
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2.2.2.2 Immunohistochemistry
Harvested tissue was preserved in 0.5 -  1.0 ml of 95% (v/v) EtOH overnight, tissue was then 
transferred to ice-cold 5% (w/v) sucrose in PBS and incubated at 4°C for 1 -  3 hrs. Specimens 
were embedded and cryosectioned using a cryostat (Bright OTF 5000) at 10 pm and the 
sectioned specimen was collected onto HistoBond slides. The collected specimen was allowed to 
sit at room temperature for 1 -  2hrs before processing for immunostaining .
For immunohistochemical labelling, the sections were circumscribed with a water repellent ring 
using an ImmEdge pen to prevent cross contamination of immunoreagents. All incubations were 
at room temperature in a light-proof humidified chamber unless otherwise stated. The sections 
were soaked in PBS (pH 7.4) containing 0.1% (v/v) Tween 20® (PBS / Tween) for 10 mins prior 
to digestion with the appropriate enzymatic treatment(s) (refer to Table 2.2) for 1 hr at 37°C. The 
sections were washed in PBS / Tween20® three times for 5 mins. They were then blocked in the 
appropriate blocking serum (either goat or swine) at 1 in 20 dilutions in PBS / Tween20® for 30 
mins. The serum was discarded and the selected primary antibody was applied using the dilution 
shown in Table 2.2, and incubated at 4°C overnight. The sections were washed in PBS / 
Tween20® 3 x 5  mins, then the appropriate FITC -  conjugated secondary antibody, either Goat 
anti-mouse or Swine anti-rabbit, was applied at 1 in 50 dilution in PBS / Tween20® and 
incubated for 1 hr. Following the incubation, the sections were washed in PBS / Tween20® and 
mounted using Vectorshield Mountant containing 4’, 6-Diamidino-2-phenylindole (DAPI), 
which stains cell nuclei blue. The edges of the coverslip were sealed with clear nail varnish, and 
the sections viewed under a fluorescent microscope (Olympus BX61).
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Antibody Dilutions Ig Species Pre-treatment_________. Epitope_________________ Reference
#70-XR90 1:200 Ascite Rabbit
(P)
C-ABC/K
t  r  r
Type I collagen Fitzgerald Industries Int.
CIICI 1:5 IgG2a,x Mouse
(M)
C-ABC/K Type II collagen DSHB/ Holmadhl et al., 
1986
aType X 1:100 “ Mouse
(M)
C-ABC/K Type X collagen Gibson et al. ,  1996
6B4 1:20 IgGl Mouse
(M)
C-ABC/K Aggrecan (IGD domain) Caterson et al. ,  2000 
Little et al. ,  2002
12C5 1:5 IgGl Mouse
(M)
C-ABC/K Versican (HA binding 
region)
DSHB/ Asher et al., 1991
28.4 1:20 IgGl Mouse
(M)
C-ABC/K Decorin (core protein) Bidanset et al. ,  1992
PR8A4 1:20 IgG Mouse
(M)
C-ABC/K Biglycan (core protein) Roughley et al., 1993; 1994
1B5 1:500 IgGlK Mouse
(M)
C-ABC/K Unsulphated chondroitin (C- 
0-S) stub
2B6 1:20 IgGl Mouse C-ABC/K Chondroitin-4-sulphate (C-4- Couchman et al., 1984(M)
C-ACII
C-B
S) stub
Chondroitin-4-sulphate (C-4- 
S) stub in Dermatan sulphate
Caterson et al., 1985
3B3 1:20 IgM Mouse
(M)
C-ABC/K
None
Chondroitin-6-sulphate (C-6- 
S)
Native Chondroitin sulphate 
chains
Caterson et al., 1985
5D4 1:20 IgGl Mouse
(M)
None Native keratan sulphate 
chains
Caterson et al., 1983
BKS-1 1:10 Mouse
(M)
K Keratan sulphate neoepitope Dr B. Kerr
Negative
Controls
Mouse Ig 1:10 Mouse
Rabbit Ig 1:200 Rabbit
Table 2.2: Antibodies used for immunohistochemistry to identify extracellular matrix components within a specimen. P = Polyclonal 
antibody; M = Monoclonal antibody; C-ABC = Chondroitinase ABC; K = Keratanase
2.2.2 Biochemical Techniques
2.2.2.1 Extraction o f Matrix Components from cartilage and tissue grafts
For extraction of PGs, samples were finely diced prior to extraction in 4 M guanidine- 
hydrochloric acid (pH 6.0) containing 0.05 M sodium acetate, 0.01 M sodium 
ethylenediaminetetraacetic acid (EDTA), 0.1 M 6-amino-hexanoic (caproic) acid, 0.005 M 
Benzamidine HC1, 0.5mM phenyl methyl sulfonyl fluoride (PMSF). 1 ml of extraction buffer 
was used per 100 mg of tissue and incubated at 4 °C for 24 -  48 hrs with continuous rolling. 
Following extraction, samples were centrifuged at 14000 rpm for 5 mins and the supernatant 
exhaustively dialysed against Milli-Q™ water. The dialysed supernatant was stored at -20°C for 
later analysis of matrix molecules using dimethylmethylene blue (DMMB) and hydroxyproline 
assays.
The remaining residue was treated with pepsin prepared in 0.5 M acetic acid (24.1 enzyme 
unit/mg tissue wet weight) overnight at 4°C with rolling. Then, the remaining residue was 
removed by centrifugation at 12,000 x g for 15 mins and the collagen content of the supernatant 
was determined using a hydroxyproline assay (see Section 2.2.3.4). The residue remaining 
following guanidine extraction and pepsin digestion was buffered in 0.005M sodium acetate pH 
5.6 containing 0.025 M Na2EDTA, 5 mM cysteine-HCl, and digested with papain (1 enzyme unit 
per ml of buffer) at 65°C for 18hrs with occasional mixing. Following digestion, the sGAG 
concentration of the supernatant was determined using the DMMB assay (refer to Section 
2.2.3.2).
2.2.2.2 Dimethylmethylene Blue (DMMB) Assay
Proteoglycan (PG) concentration was measured as sGAG using the DMMB assay. This assay 
uses the principle of the metachromatic dye Dimethylmethylene Blue binding to the negatively 
charged sulphate groups on sGAG forming a dye-GAG complex. Formation of this complex 
produces a colour change from blue to pink, which can be read at 525 nm (Famdale et al., 1986).
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Standard solutions were prepared using chondroitin sulphate C sodium salt from shark cartilage. 
Five standards of 0, 10, 20, 30 and 40 pg/ml were prepared in Milli-Q water. 40 pi of each 
standard or test sample were pipetted in triplicate into the appropriate wells of a 96 well plate 
(Elkay). 200 pi of DMMB solution (32 mg 1,9-DMMB, 20 ml absolute ethanol, 59 ml 1M 
sodium hydroxide at 4 g /100 ml, 7 ml of 98 % (v/v) formic acid and made up to 2 L with Milli- 
Q™ water) was added to the samples and standards, the plate was then read at 525 nm 
immediately on a Labsystem Multiscan MS spectrophotometer. The concentration of sGAG in 
the unknown sample was calculated from the linear regression standard curve using the software 
package Microsoft Excel and the statistical analyses were carried out using the computer 
software MiniTab.
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CHAPTER 3: 
Development of Quantitative Polymerase Chain Reaction for the 
quantification of cartilage-specific and cartilage non-specific genes 
involved in Mesenchymal Stem Cells (MSCs) differentiation
3.1 Introduction
The objectives of this chapter were to develop quantitative polymerase chain reaction (qPCR) for 
markers of MSCs differentiation in order to assess the gene expression of hyaline cartilage- 
specific (SOX-9, Aggrecan and Collagen type II) and cartilage non-specific genes (Collagens 
type I and X) for primary bovine MSCs (Chapter Four) cultured in different growth factors 
(Chapter Five) and for tissue grafts produced using passaged bovine MSCs (Chapter Six).
3.2 Materials
Primer pairs and plasmid DNA for aggrecan and collagen type II for qPCR were kindly provided 
by Dr Emma Blain. Collagen type I primers and plasmid DNA were kindly provided by Dr 
Siyuan Li at CTBL, Cardiff Tri-reagent and Sybr Green mastermix were purchased from Sigma- 
Aldrich, Poole, Dorset, UK. All PCR buffers and reagents were obtained from Applied 
Biosystems Roche Molecular System Inc. Agarose and molecular markers were obtained from 
MP Biomedicals Inc., UK and BioVentures Inc., respectively.
3.3 Methods
3.3.1 Extraction of RNA
3.3.1.1 Extraction o f RNA from old and young bovine articular cartilage
Total RNA was isolated from old and young bovine articular cartilage tissue harvested from the 
metacarpo-phalangeal (MCP) and metatarso-phalangeal (MTP) joint as positive controls for
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SOX-9, aggrecan and collagen type II expressions (n=l). Approximately 100 mg of cartilage 
cuttings were initially weighed, snap-frozen in liquid nitrogen and homogenized for 1 minute at 
2000 rpm in a liquid nitrogen chilled Braun Mikro-Dismembrator Vessel (Braun Biotech 
International GmbH). 1ml of Tri reagent per 100 mg tissue was added to the powdered cartilage 
and transferred to a sterile 1.5 ml Eppendorf tube. The vessel was washed in 5M sodium 
hydroxide and rinsed three times in Milli-Q™ water.
3.3.1.2 Extraction o f RNA from Bone Marrow harvested from young bovine metacarpal and 
metatarsal bones
Total RNA was isolated from bone marrow harvested from young bovine metacarpal and 
metatarsal bone. Approximately 5 g of bone marrow harvested from 3 - 6  separate carpo/tarsal 
bones was dispersed using 20 ml of sterile serum-free DMEM containing 0.05 mg/ml 
gentamicin, repeat this dispersal step twice. The cell suspension was transferred to a sterile 50 ml 
centrifuge tube and inverted gently to mix. The tube was allowed to stand until all the fatty 
deposits had separated. The fatty deposits and any debris were filtered through a 40 pm cell 
strainer (Falcon, VMR). The filtrate, containing a mixed population of red blood cells and stem 
cells, was centrifuged at 200 x g for 5 mins in order to obtain a cell pellet. The supernatant was 
discarded and the cell pellet, containing an unknown cell number of a heterogenous population 
of cells was resuspended in 1 ml of Tri reagent. The cell suspension was transferred to a sterile
1.5 ml Eppendorf tube.
3.3.2 RNA Isolation
RNA was phase separated by the addition of 200 pi of chloroform and the mixture was left to sit 
at room temperature for 15 mins. Samples were phase separated by centrifuging at 10,000 x g for 
15 mins. The upper aqueous phase containing the RNA was removed and mixed with 375 pi of 
70% (v/v) ethanol by gentle inversion. Qiagen RNeasy miniprep kit and reagents were used
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according to the manufacturer’s protocol to isolate total RNA from the sample. The mini­
columns in the miniprep kit work by binding RNA to the silica-gel-based membrane allowing 
contaminants to be washed away by microspin technology. To remove DNA contaminants, the 
membranes were incubated with DNase I (80 pi, Qiagen) during the wash steps. Purified RNA 
was subsequently eluted in 30 pi of sterile RNase-free water (Qiagen) and quantified as shown in 
Section 3.3.6. The sample was then stored at -80 °C.
3.3.3 Quantification of RNA
RNA concentration and purity in each sample were measured using the Nanodrop (LabWare) at 
260 nm and 280 nm. The concentration of RNA in a sample can also be calculated using the 
following formula:
(A260-A320) x *40 x Dilution factor x Final sample volume = RNA yield (ng)
A260 -  A320 (OD readings)
40 (RNA extinction coefficient)
* The amount of DNA can be calculated by changing the coefficient to 50
3.3.4 Reverse Transcription of RNA (RT-PCR)
cDNA required for primer specific polymerase chain reaction amplification of a required target 
sequence was produced during the initial reverse transcription polymerase chain reaction (RT- 
PCR) procedure. For RT-PCR, 250 ng of RNA was used for cDNA amplification with a final 
reaction volume of 20 pi (See Table 3.2). The RT reaction mixture was gently mixed and 
incubated at room temperature for 10 mins. It was then subjected to the following cycle: 42°C for 
30 mins, 99°C for 5 mins and incubated at 4°C for a short period of time in a Technegene 
thermal cycler. Once the RT was completed, the samples were stored at -20°C for later analysis.
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RT mix Volume
Magnesium-free 1 OxPCR Buffer 
(Final concentration: IX)
2 pi
25 mM Magnesium Chloride 
(Final concentration: 2 mM)
1.6 pi
2.5 mM dNTPs
(Final concentration: 0.2 mM)
1.6 pi
20 U/pl RNase inhibitor 
(Final concentration: 1 U/pl)
lp l
50 U/jj.1 Reverse transcriptase 
(Final concentration: 2.5 U/pl)
lp l
50 pM Oligo d(T)’s 
(Final concentration:! pM)
lp l
Milli-QlM water 11.8 pi -  RNA volume
RNA sample * Volume = 250 ng
Calculations:
250 ng / RNA cone (ng/jil) = Volume for 250 ng
RNA
Table 3.2: RT-PCR reaction mixture.
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3.3.5 Primer design for Quantitative Polymerase Chain Reaction (qPCR)
For amplification of SOX-9, aggrecan and collagens type I, type II and type X genes, primers 
were designed using sequences for each target gene obtained from Genbank 
(www.ncbi.nlm.nih.gov). Typically, they were designed using DNasis computer software for 
Macintosh. Primers were designed where sequences matched bovine SOX-9, aggrecan and 
collagens type I, type II and type X. Primer sequences used in this study for SOX-9, aggrecan 
and collagens type I, type II and type X are listed in Table 3.3 and were previously published 
(refer to Table 3.3).
A number of criteria had to be considered when designing the primers for qPCR (using Sybr 
Green assay), these included:
1. primers should be between 15-30 nucleotide in length
2. annealing temperature of the two primers should be within 2°C of each other, between 50 -  
65°C
3. GC content of the primers should be between 40 -  60% and avoid G/C clumps at the 3’ends 
of the primers
4. self complementary sequences should be avoided to minimize primer dimer formation
5. the location of the primer (i.e. intron / exon boundaries) should also be considered
6. product size should range between 100 -  300 bp
Bovine glyceraldehydes-3-phosphate dehydrogenase (GAPDH, see Table 3.3) specific primers 
were also designed to be used as a endogenous control in RT-PCR analysis.
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Proteins Primers names Primer Sequences Product Size (bp) Tm (°C) Reference
Bovine
SOX-9
7700  SOX9.F 
7700  SOX9.R
5'-ACG CCG AGC TCA GCA AGA 
5'-CAC GAA CGG CCG CTT CT
71 bp 58 S h in tan i e t al., 2007
Bovine
Aggrecan
77 0 0  ag g reca n .F  
77 0 0  ag g recan .R
5'-GCT ACC CTG ACC CTT CAT C 
5' AAG CTT TCT GGG ATG TCC AC
76 bp 60 Darling & A thansiou , 2005
Bovine 
Collagen 
Type I
7 7 0 0  Col I.F 
77 0 0  Col.R
5'-TGC TGG CCA ACT ATG CCT CT 
5'-TTG CAC AAT GCT CTG ATC
8 6 b p 60 Mr S iyuan  Li's P rim ers
Bovine 
Collagen 
type II
7 7 0 0  col II.F  
7 7 0 0  col II.R
5'-AAC GGT GGC TTC CAC TTC 
5 '-GCA GGA AGG TCA TCT GGA
69 bp 60 Darling & A thansiou , 20 0 5
Bovine
GAPDH
7 7 0 0  GAPDH.F 
77 0 0  GAPDH.R
5'-GGC ATC GTG GAG GGA CTT ATG A 
5'-GGG CCA TCC ACA GTC TTC TG
68 bp 60 Blain e t  al., 2 0 0 6
Bovine 
Collagen 
type X
7700  ColX.F 
7 7 0 0  ColX.R
5'-ACT TCT CTT ACC ACA TAC ACG TGA 
AAG
5'-CCA GGT AGC CCT TGA TGT ACT CA
108 bp 60 Sh in tan i e t al., 20 0 7
Table 3.3: Oligonucleotide primers used in qPCR amplification of bovine SOX-9, aggrecan, collagens type I and type II. Bovine
GAPDH was used as a positive control.
The primer pairs designed were assessed using a standard curve measurement generated from a 
serial dilution of plasmid DNA (pGEM-T vector containing primer product sequence for either 
bovine SOX-9, aggrecan, collagens type I and type II, and also GAPDH as a positive control) at 
1 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, and water. In this study, pGEM-T vectors 
containing GAPDH, aggrecan and collagen type II were already produced and kindly provided 
by Dr Emma Blain (Cardiff University, CTBL). pGEM-T vector containing collagen type I was 
kindly provided by Mr Siyuan Li (Cardiff University, CTBL).
3.3.6 Construction of pGEM-T vector containing the appropriate product sequence
pGEM-T vectors containing PCR products for SOX-9 and collagen type X were generated 
through a process of six steps:
* 1. RT-PCR to generate the PCR product and agarose gel electrophoresis to verify the product 
size
2. Purification to remove unwanted PCR products
3. Ligation of PCR product into a pGEM-T vector (Promega)
4. Transformation of the ligated PCR-product / vector into competent cells
5. Purification of plasmid DNA using Miniprep kit (Qiagen)
6. Restriction digest and agarose gel electrophoresis were used to confirm the size of the 
incorporated PCR product.
The following sections will outline the procedures carried out for each step. Figure 3.5 
summarizes the steps involved to produce plasmid DNA.
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Figure 3.5: A summary diagram to methods used for gene cloning.
3.3.6.1 RT-PCR for SOX-9 and Collagen type X  gel electrophoresis
RT-PCR (Section 3.3.4) was set up as described in Section 3.3.7 using RNA isolated from young 
bovine articular cartilage (for SOX-9) and young bovine subchondral bone (Collagen type X) as 
described in Section 3.3.4.1. The PCR products were run on 2% (w/v) agarose gel (see Section 
3.3.7) to verify the product size.
3.3.6.2 QIAquick Nucleotide Removal Kit
This kit was used for the removal of oligonucleotides from enzymatic reactions. PN buffer (10 
volumes) was added to one volume of the reaction sample. The mixture was transferred to a spin 
column and centrifuged at 13,000 xg for 1 min and the flow through discarded. The column was 
washed using 750 pi of PE buffer (with ethanol added), centrifuged at 13,000 xg, the flow­
through discarded, and then re-centrifuged at 13,000 xg for a further 1 min. The column was 
transferred to a fresh, sterile 1.5 ml tube and the plasmid DNA (pDNA) eluted using 100 pi of 
distilled water by centrifugation at 13,000 xg for 1 min. The eluate was processed for ligation 
(see Section 3.3.9.3).
3.3.6.3 Ligation o f PCR product into pGEM-T vector
A  ligation reaction of 5 pi was set up as described in Table 3.3, gently mixed and incubated 
overnight at 4°C. This ligation reaction enables the PCR product to be inserted into the multiple 
cloning site of the pGEM-T vector.
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Reagents Volume for one reaction
2 X rapid ligation buffer, T4 DNA ligase
* v o r t e x  b r ie f l y  b e f o r e  u s e 2.5 pi
pGEM-T vector (50 ng, Promega) 0.5 pi
PCR product 1.5 pi
T4 DNA ligase (3 weiss units / pi) 0.5 pi (1.5 weiss unit)
Table 3.3 Ligation reaction of PCR product
3.3.6.4 Transformation using pGEM-T vector ligation
The ligation reaction mix was centrifuged briefly and 2 pi of the mixture was transferred to a 
sterile bug tube containing 25 pi of JM109 competent cells (Promega), mixed and incubated on 
ice for 20 mins. The cell mix was heat shocked at 42°C in a waterbath for 45-50 secs, and 
immediately returned to ice for 2 mins. 475 pi of SOC medium was added to the cell mixture 
and incubated for 90 mins at 37°C with shaking at 150 rpm. When the incubation was completed, 
100 pi of each transformation culture was streaked onto an LB agar plate containing 100 mg/ml 
of ampicillin, 500 pM of Isopropyl beta-D-l-thiogalatopyranoside (IPTG) and 50 pg/ml of X- 
gal. The plates were dried for 15-20 mins at room temperature, incubated overnight at 37°C. 
White colonies containing the ligated PCR product were selected and grown in 10 ml of LB 
medium overnight at 37°C with shaking at 220 rpm.
3.3.6.5 Miniprep DNA Purification
The bacterial culture was centrifuged at 10,000 x g for 5 mins and the supernatant discarded. The 
pellet was resuspended in 250 pi of cell resuspension solution and transferred to a sterile 1.5 ml 
tube. A further 250 pi of cell lysis solution was added and mixed by inversion. 10 pi of alkaline 
protease solution was added to the cell suspension, mixed by inversion and incubated at room
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temperature for 5 mins. 350 pi of neutralisation solution was added and mixed by inversion. The 
mixture was centrifuged at 14,000 x g for 10 mins and the clear lysate transferred to a miniprep 
spin column and centrifuged at 14,000 x g for 1 min. The flow-through was discarded and the 
column washed in 750 pi of column wash solution (with ethanol) by centrifugation at 14,000 x g 
for 1 min. The flow-through was discarded and a further 250 pi column wash solution was added 
and centrifuged at 14,000 x g for 2 mins. The column was transferred to a clean 1.5 ml tube and 
the plasmid DNA was eluted using 100 pi of nuclease free water, by centrifugation at 14,000 x g 
for 1 min. The eluate containing pDNA was stored at -20°C. Concentration of the plasmid 
product was determined using the Nanodrop (Labware).
3.3.6.6 Restriction digest
'* The restriction enzymes Sal I and Nco I were used to cleave the multiple cloning site (which 
contains the cDNA sequence of interest) from the pGEM-T vector. The restriction digest was set 
up as described in Table 3.4. The mixture was incubated at 37°C for 2 hours and was either kept 
at 4°C overnight or run on a 2% agarose gel to verify the product size. Sequence analysis was 
also carried out using the core facilities at Cardiff University.
Reagents Volume required per reaction
10 x Digest Buffer 2 pi
Sail 1 pi
Nco I 1 pi
BSA 0.5 pi
Distilled water 10.5 pi
cDNA template 5 pi
Table 3.4 Restriction digest reaction contents.
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3.3.7 Agarose Gel Electrophoresis
PCR reaction products were run for visualization on 2% (w/v) agarose gels made up in 30 ml of 
Tris Borate EDTA buffer (TBE; Sigma T-3913). The solution was microwaved to dissolve 
agarose and allowed to cool from boiling to warm. 2 pi of a 10 mg/ml ethidium bromide solution 
was added to the gel. The gel was poured into a PCR cassette and allowed to sit at room 
temperature for 10 mins and at 4°C for 10 mins. A DNA ladder of molecular weight standards 
was prepared by mixing 1 pi of dye solution (6 x tracking dye Cambio BV-BT-10) with 2 pi of 
lx PCR buffer and 3 pi of DNA ladder (LMV 50 -  1000 bp Cambio BV-1159-01). 5 pi of all 
PCR reaction products were mixed with 1 pi of tracking dye. 5 pi of the DNA ladder and 5 pi of 
all samples were loaded into wells in the gel and run at 100 volts in 0.5x TBE until the dye front 
reached the bottom of the gel cassette. Bands were visualized on a UV light box and 
photographed.
3.3.8 Quantitative Polymerase Chain Reactions (qPCR)
PCR technology is a widely used method for quantifying DNA by amplifying the sequence of 
interest. In qPCR, the amount of amplified product is linked to fluorescence intensity using a 
fluorescent reporter molecule. In this study, the fluorescent signal was measured while the 
amplification was still progressing in order to calculate the initial template number. This 
measures the fluorescence at each cycle. This allows quantification of the template to be based 
on the fluorescence signal during the exponential phase of amplification.
In qPCR, a fluorescent DNA chelator is used to monitor the progress of the amplification 
reaction. With each amplification cycle, the fluorescence intensity increases proportionally with 
the increase in amplicon concentration, with the qPCR instrument system collecting data for 
each sample during each PCR cycle. Threshold cycle (Ct value) indicates the amount of initial 
DNA template in the sample, the earlier the Ct values for that sample, the greater the amount of 
initial DNA template.
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Sybr green was used to measure the level of fluorescence of bound double-stranded DNA. As the 
amount of double stranded DNA increases, the binding sites for dye will also be increased 
therefore fluorescence increase is proportional to the concentration of DNA. As the target is 
amplified, the increasing concentration of double-stranded DNA in the solution can be directly 
measured by the increase in fluorescence signal. A limitation with using Sybr green is that it is 
based on the binding of any double-stranded molecule including primer dimers, therefore 
introducing errors into the analysis by inclusion of non-specific products. So primers should be 
designed to avoid non-specific binding. Such non-specificity can be detected by performing 
melting curve analysis (i.e. amplification curve) on the PCR product from every run. 
qPCR reactions for the standards and the unknown samples were run in parallel with each other. 
qPCR reactions were prepared as shown in Table 3.5. The reaction mixture was mixed gently by 
vortexing, centrifuged and 24 pi of the reaction mix was placed into each of the 0.2 ml non­
skirted wells on a 96 well plate (ABgene). 1 pi of cDNA was added to the mixture, mixed and 
when a row is completed, lids were placed over it. Typically the qPCR was set up as shown in 
Table 3.6.
Reagents Volume
Sybr Green JumpStart1M Taq ReadyMix 12.5 p i
(Sigma)
Forward and Reverse Primers 0.5 pi
(MWG; Final concentration o f 200 nM)
dH20 10.5 pi
(Sigma)
Table 3.5: Reaction mix for quantitative PCR.
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Segments Time Temperature Cycles
One 2 minutes 95 °C x 1
Two
2 minutes 95 °C
x 4040 seconds 60 °C
20 seconds 72 °C
Three 1 minute 95 °C x 1
Four 30 seconds
60 °C
(heats up at every 1°C from 60°C 
until it reaches 95°C)
x 40
Table 3.6: A typical quantitative polymerase chain reaction (qPCR) thermal profile setup.
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3.4 Results
3.4.1 Verification of newly designed primer pairs for SOX-9 and Collagen type X
Primer pairs specific for bovine SOX-9 and Collagen type X with a product size of 71 and 68 
base pair (bp), respectively, were tested using young bovine full depth articular cartilage.Young 
bovine subchondral bone (1 pi cDNA of 500 ng) was used as a positive control for collagen type 
X. Young bovine articular cartilage was used as a postive control for SOX-9. Water was used as 
a negative control. RT-PCR mixture was prepared and carried out using Technegene PCR 
machine (Section 3.3.4) for 35 cycles with an annealing temperature of 60°C, other conditions 
were as described in Chapter 2, Section 2.2.4.5. PCR products were run on a 2% (w/v) agarose 
gel in order to verify the product size and the primers’ function (Figure 3.15).
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*-------108 bp
<«-------71 bp
Figure 3.15: Analyses of RT-PCR products for bovine SOX-9 and Collagen 
type X using young bovine articular cartilage and subchondral bone 
cDNA. Primer pairs for bovine SOX-9 (7700SOX9.F/R), was used in 
lanes 1 and 2. Primer pairs for bovine collagen type X (7700ColX.F/R) was 
used in lanes 3 and 4. The migration positions of bSOX-9 and bovine 
collagen type X cDNAs are indicated by arrows on the right.
Collagen type X SOX-9
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3.4.2 Generation of pGEM-T / SOX-9 vector and pGEM-T / Collagen type X and 
verifications
Once the PCR products were verified, the remaining PCR products were purified and processed 
for ligation into a pGEM-T vector. The ligated products were transformed using JM109 
competent cells (Promega) and were incubated overnight at 37°C. White colonies were selected 
and further cultured in bacteria. DNA was purified from bacterial culture in order to obtain the 
plasmid DNA (pDNA; pGEM-T containing SOX-9 or Collagen type X products). The pDNA as 
cleaved from pGEM-T vector using the restriction enzymes of Sal I and Nco I for 2 hrs at 37°C. 
The product was run on 2% agarose gel for verification as shown in Figure 3.16. The products 
were measured using Nanodrop to obtain the DNA concentration and OD260/280 ratio as shown in 
Table 3.8.
Products DNA concentration (ng/ml) 260/280 ratio
SOX-9 (1) 105.9 1.88
SOX-9 (2) 89.0 1.91
Collagen type X (1) 90.8 1.93
Collagen type X (2) 96.8 1.90
Collagen type X (3) 52.6 1.77
Collagen type X (4) 76.1 1.89
Table 3.8: Quantification of DNA for SOX-9 and Collagen type X pDNA products.
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Figure 3.16: Restriction digestion analysis of bovine SOX-9 and Collagen type X expression 
constructs. Endonucleases Sal I and Nco I were used to insert PCR product into p-GEMT expression 
vector (3kb). Linearised vector can be seen after digestion. Excised pDNA for bovine SOX-9 (71 
bp, lanes 1-2) and collagen type X (108 bp, lanes 3-5)can be seen after digestion with Sal I and Nco 
I, however, the level detected was much weaker than linearised vector. Migration of size standards 
is shown to the left.
Linearised vector
3.4.3 Standard curves (Absolute quantification)
qPCR was used to assess the gene expression level of cartilage-specific and non-cartilage 
specific markers on MSCs cultured using two-dimensional and three-dimensional culture 
systems in vitro. To quantify each gene of interest, a standard curve was prepared from a dilution 
series (see Table 3.9) of template (pDNA containing one of the gene of interest: SOX-9, 
aggrecan, collagens type I, II and X). This allows a measurement at the exact level of template in 
the samples. The concentration and quality of pDNA used are shown in Table 3.10. The standard 
curve was set up the same time as the unknown samples in order to make comparisons.
Labels pDNA concentrations Serial dilution volume
A 1 ng 1 pi pDNA + (Concentration of template -1 pi) water
B 100 pg 10 pi of A + 90 pi water
C 10 pg 10 pi of B + 90 pi water
D 1 pg 10 pi of C + 90 pi water
E 100 fg 10 pi of D + 90 pi water
F 10 fg 10 pi of E + 90 pi water
G Ifg 10 pi of F + 90 pi water
H Water 100 pi water
Table 3.9: Dilution series for the generation of a standard curve.
pDNA used for Standard curve Concentrations 260/280 ratio
SOX-9 105.9 ng/pl 1.88
Aggrecan 1 ng* 1.80
Collagen type I 100 ng/pl 1.90
Collagen type II 110.7 ng/pl 1.95
Collagen type X 96.8 ng/pl 1.90
GAPDH 109.5 ng/pl 1.88
Table 3.10: Concentration and quality of each pDNA sample used for preparing the serial
dilution for standard curve. *used 2 pi of pDNA with 18 pi of water to prepare 1 ng of pDNA
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Standard curves on the gene expression using pDNA for Bovine SOX-9, aggrecan, collagens type 
I, II and X
pDNA for different genes of interest (SOX-9, aggrecan, collagens type I, II and X) were serially 
diluted to generate a standard curve using qPCR technology. Bovine GAPDH was used as a 
endogenous control and at least 2- 3 no template controls (NTC) were included in all the qPCR 
reactions. Amplifications of the standard dilution series of all the pDNA for SOX-9, aggrecan,
collagens type I, II and X all produced a linear regression curve, which is denoted by the R
2 2 squared value (R or Pearson Correlation Coefficient). For all pDNA standards, the R values
were very close to 1 (± 0.007). Formation of primer dimers was only detected from the
dissociation curve generated from pDNA for bovine collagen type II. All of the efficiency values
generated from all the pDNAs were within the range of 90 -  110% with the exception of
collagen type II (121.8%) and collagen type X (71.3%), which may be due to the primer pairs
effect and suboptimal primer pairs, respectively. Table 3.11 summaries the efficiency and the R
values obtained from each standard curve. The R values were all close to 1.0, suggesting that all
standards showed a linear regression with high reaction efficiency of between 71 -  121%.
Amplification plots, dissociation curves and the standard curves were generated for GAPDH
(Figure 3.17), SOX-9 (Figure 3.18), aggrecan (Figure 3.19) and collagens type II (Figure 3.20),
type I (Figure 3.21) and type X (Figure 3.22). The copy number for each gene of interest was
calculated using the qPCR machine and these were plotted against the standards (in fg) as shown
in Figure 3.23.
83
Genes Efficiency (%) 2R values
GAPDH 92 0.999
SOX-9 106.5 0.993
Aggrecan 97.3 0.999
Collagen type II 121.8 0.998
Collagen type I 71.3 0.993
Table 3.11: Summary table to show the R values and PCR efficiencies for each plasmid DNA 
(pDNA) designed to contain different gene if interest, namely, GAPDH, SOX-9, collagens type 
I, II and X and aggrecan.
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Figure 3.17: Quantitative PCR using a serial diliution o f  pDNA for Bovine GAPDH. The amplification plot 
(Panel A) and dissociation curve (Panel B) showed the initial quantity o f  the DNA and the quality o f  the 
product generated, respectively. Panel A and B showed lng (Blue), lOOpg (Dark Red), lOpG (Green), 
lOOfg (Mustard Yellow), lOfg (Light Blue), lfg  (Purple) and water (Orange). The standard curve (Panel C) 
gave an efficiency o f  92% and an R2 value o f  0.999.
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Figure 3.18: Quantitative PCR using a serial diliution of pDNA for Bovine SOX-9. The 
amplification plot (Panel A) and dissociation curve (Panel B) showed the initial quantity of the 
DNA and the quality of the product generated, respectively. Panel A and B showed lng 
(Blue), lOOpg (Dark Red), lOpG (Green), lOOfg (Mustard Yellow), lOfg (Light Blue), lfg 
(Purple) and water (Orange). The standard curve (Panel C) gave an efficiency of 92% and an 
R2 value of 0.999.
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Figure 3.19: Quantitative PCR using a serial diliution of pDNA for Bovine Collagen Type II. 
The amplification plot (Panel A) and dissociation curve (Panel B) showed the initial quantity 
of the DNA and the quality of the product generated, respectively. Panel A and B showed lng 
(Blue), lOOpg (Dark Red), lOpG (Green), lOOfg (Mustard Yellow), lOfg (Light Blue), lfg 
(Purple) and water (Orange). The standard curve (Panel C) gave an efficiency of 121.8% and 
an R2 value of 0.998.
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Figure 3.20: Quantitative PCR using a serial diliution of pDNA for Bovine aggrecan. The 
amplification plot (Panel A) and dissociation curve (Panel B) showed the initial quantity of the 
DNA and the quality of the product generated, respectively. Panel A and B showed lng 
(Blue), lOOpg (Dark Red), lOpG (Green), lOOfg (Mustard Yellow), lOfg (Light Blue), lfg 
(Purple) and water (Orange). The standard curve (Panel C) gave an efficiency of 97.3% and an 
R2 value of 0.999.
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Figure 3.21: Quantitative PCR using a serial diliution of pDNA for Bovine Collagen Type I. 
The amplification plot (Panel A) and dissociation curve (Panel B) showed the initial quantity 
of the DNA and the quality of the product generated, respectively. Panel A and B showed lng 
(Blue), lOOpg (Dark Red), lOpG (Green), lOOfg (Mustard Yellow), lOfg (Light Blue), lfg 
(Purple) and water (Orange). The standard curve (Panel C) gave an efficiency of 71.3% and an 
R2 value of 0.993.
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Figure 3.22: Quantitative PCR using a serial dilution of pDNA for Bovine Collagen Type X. 
The amplification plot (Panel A) and dissociation curve (Panel B) showed the initial quantity 
of the DNA and the quality of the product generated, respectively. Panel A and B showed lng 
(Blue), lOOpg (Dark Red), lOpG (Green), lOOfg (Mustard Yellow), lOfg (Light Blue), lfg 
(Purple) and water (Orange). The standard curve (Panel C) gave an efficiency of 98.2% and an 
R2 value of 0.992.
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Figure 3.23: Standard curves generated using plasmid DNA containing the genes GAPDH, 
SOX-9, Collagen types I and II and aggrecan. The graphs were plotted on a log scale with copy 
numbers against standards ofpDNA from different gene of interest. Expressed in femtogram (fg)
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3.5 Discussion
The aims of this section were to design bovine derived cartilage-specific primer pairs (SOX-9, 
aggrecan and collagen type II) and non-cartilage specific primer pairs (Collagens type I and X) 
for gene expression from MSCs cultured in two-dimensional (Chapter 4 and 5) and in three- 
dimensional (Chapter 6) culture systems. The designed primer pairs were used to amplify 
specific sequence of bovine SOX-9, aggrecan, collagens type I, II and X to generate PCR 
products which were inserted into the multiple cloning site of pGEM-T plasmid. The plasmid 
containing the cloned gene of interest was transformed into competent cells, cultured and the 
pDNAs were purified and verified by restriction digestion using endonucleases Sal I and Nco I.
Agarose electrophoresis and sequence analyses have indicated that the correctly sized cloned 
gene of interest (SOX-9 and Collagen type X) was inserted into the plasmid. At leaset 2- 3 no 
template control was included in all the qPCR reactions. Amplifications of the standard dilution 
series of all the pDNA for SOX-9, aggrecan, collagens type I, II and X all produced a linear 
regression curve. The linearity is denoted by the R squared value (R or Pearson Correlation 
Coefficient). For all pDNA standards, the R values were all very close to 1, which implied that 
the efficiency of amplification was consistent at varying template concentrations. However, 
primer dimers were detected from the dissociation curve generated from pDNA for bovine 
collagen type II. The efficiency of the standard curves produced ideally should be between 90 -  
110%. One hundred percent implies perfect doubling of amplicon number per cycle. Our data 
showed that all of the efficiency values generated from all the pDNAs were within the range of 
90 -  110% with the exception of collagen type II (121.8%) and collagen type X (71.3%). The 
higher efficiency value obtained from collagen type II (121.8%) may be due to the formation of 
primer dimers as observed from the dissociation curve. In contrast, the low efficiency value 
obtained from collagen type X (71.3%) indicated that the reaction may be slowed either due to 
inhibitors present in the master mix or suboptimal primer pairs or reaction conditions.
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3.6 Summary
• Bovine specific primer pairs were designed for GAPDH, SOX-9, aggrecan, collagens 
type I, II and X.
• pGEM-T 7 plasmids containing cloned gene of interest (SOX-9 and Collagen type X) 
were produced and were verified using agarose gel electrophoresis and sequence 
analysis.
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Chapter 4:
Characterisation of primary cultured bovine bone marrow derived 
mesenchymal stem cells for specific markers associated with stem 
cells and chondrocytes
4.1 Introduction
The objectives of this section were to establish primary cultures of young bovine bone marrow 
mesenchymal stem cells (BMSCs) by adherence to tissue culture plastic and to establish methods 
for the identification and quantification of the stem cell markers (Notch-1, Delta and Jagged-2). 
In addition, the molecular expression of chondrogenic markers such as SOX-9, aggrecan, and 
collagen type II were analysed. The expression levels were compared between freshly isolated 
heterogenous population of bovine bone marrow cells and undifferentiated BMSCs in primary 
culture, referred to as PO BMSCs.
In this study, the method used to extract bone marrow from young bovine legs was direct 
extraction from an open carpo bone. The cell suspension obtained from bone marrow consisted 
of a mixture of cell types, including red blood cells, unidentified nucleated cells of the 
hematopoietic lineage, monocytes, macrophages and fibroblast-like cells. The cell mixture was 
plated into culture flasks and BMSCs are isolated by adherence to plastics, non-adherent cells 
were removed by regular changes of culture medium. When cells reached confluency, the 
cultures were trypsinized and further cultured (refer to Chapter 4 and Chapter 5). The following 
analyses were carried out on the trypsinised cells:
• Cell number determination, as compared to original material
• Analysis of protein expression in the isolated stem / progenitor cells for Notch-1, Delta 
and Jagged-2 using FACS
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• Analysis of gene expression in the freshly isolated PO BMSCS stem cells for SOX-9, 
aggrecan, collagens type I and II markers to investigate if these genes are already 
expressed before further culturing.
The outline of the experiment and the analyses carried out for this chapter are summarised in 
Figure 4.1.
ISOLATION & EXPANSION OF b-BMSCs ANALYSIS
Direct Extraction of Young Bovine Bone 
Marrow
• Allowed to adhere for 4 days in 
DMEM with 10% FCS at 37°C, 5 %
co2
• Replenished with fresh media on 
Day 4 and 6
• Trypsinized on Day 8
V
V
Direct extract of young bovine bone 
marrow
• Gene Expression using qPCR 
(GAPDH, SOX-9, Aggrecan, Col II, Col 
If
PO bovine bone marrow mesenchymal stem cells 
(PO BMSCs)
• Trypsinized at confluence by eye [~
• Addition of cytokine(s) at PI
Refer to Chapter Five
PO BMSCs
• Gene Expression using qPCR 
(GAPDH, SOX-9, Aggrecan, Colli, Coll)
• Flow cytometry 
(Notch-1, Delta and Jagged-2)
Figure 4.1: A flow chart to show the isolation of BMSCs from young bovine bone marrow and the 
conditions used to culture the isolated BMSCs. Confluent cells were trypsinised by trypsin-EDTA. 
Analyses carried out on direct extracts of bovine bone marrow and on PO BMSCs are highlighted on 
the right in purple.
4.2 Materials
Polyclonal antibodies for FACs analyses were obtained from Santa Cruz Biotechnology Inc., 
Mile Elm, Cain, Wiltshire, UK. Primer pairs and plasmid DNA for aggrecan and collagen type II 
for quantitative PCR were kindly provided by Dr Emma Blain. Collagen type I primers and 
plasmid DNA were kindly provided by Dr Siyuan Li at CTBL, Cardiff University, Cardiff. Tri­
reagent and TBE were purchased from Signma-Alrich, Poole, Dorset, UK. All PCR buffers and 
reagent were obtained from Applied Biosystems Roche Moelcular System Inc. Agarose and 
molecular weight markers were obtained from MP Biomedicals Inc., UK and Bio Ventures Inc., 
respectively. Cell culture reagents such as Dulbecco Modified Eagle Medium (DMEM), 
gentamicin and Foetal Calf Serum (FCS) were purchased from Invitrogen. Trypsin-EDTA was 
purchased from Paisley, UK. All other reagents were of laboratory grade.
4.3 Methods
4.3.1 Harvest of Bone Marrow and mesenchymal stem cell (MSCs) isolation by adherence 
to tissue culture plastic
Bone marrow derived MSCs (BMSCs) were harvested from the carpo bones of freshly 
slaughtered (<24 hrs) 7 day old calves (F. Drury, Swindon). Typically, three to six separate carpo 
bones were sawed open under sterile conditions. The bone marrow was then removed from the 
two chambers using a surgical spatula and transferred to a pre-weighed Petri-dish (Figure 4.2).
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A2) Saw bone using a band
1) Removal of Bone Marrow
5) Collection of Bone Marrow
Figure 4.2: Extraction of Bone Marrow
97
The marrow removed was dispersed twice in 20 ml of sterile serum-free Dulbecco’s Modified 
Eagles Medium (DMEM) containing 0.05 mg/ml gentamicin. The cell suspension was 
transferred to a sterile 50 ml centrifuge tube and inverted gently to mix. The tube was allowed to 
stand until all the fatty deposits had floated to the top. Fatty deposits and any debris were 
removed by filtration through a 40 pm cell strainer (Falcon, VWR). The filtrate, containing a 
mixed population of red blood cells and mesenchymal stem cells (MSCs), was centrifuged at 200 
x g for 5 mins. The supernatant was removed and the cell pellet resuspended in 40 ml of DMEM 
containing 0.05 mg/ml gentamicin and 10% (v/v) heat -inactivated Foetal Calf Serum (hi-FCS), 
referred to as Basic Medium (BaM). The cell suspension was seeded into T-75cm vented flasks 
(Coming). The cells were incubated at 37°C in a humidified atmosphere of 95% air and 5% (v/v) 
carbon dioxide (CO2) for 4 days to allow the cells to adhere. The cells were washed twice using 
. semm free DMEM to remove any non-adherent cells and replaced with 20 ml of BaM. This 
washing step was repeated after 6 days. On Day 8, the cells were trypsinised and analyses on 
protein expression of stem / progenitor cell markers and gene expression were performed. 
POBMSCs were subcultured up to Passage two (P2) in culture medium with different cell 
replating densities (refer to Chapter 5).
4.3.2 Trypsinisation of P0 plastic adherent sub-population of BMSCs
The cells were maintained in DMEM containing 10% (v/v) FCS and 0.05 mg/ml gentamicin for 
8 days. On day 8, the cells were washed twice using 10 ml of semm free DMEM with gentle 
agitation and subsequently photographed. Cells were trypsinised using 0.05 % (w/v) Trypsin in 
ImM EDTA (Invitrogen), 5 ml per T-75 cm2 flask, and incubated at 37°C for 5 -  10 mins until 
most of the cells had detached from the base of the flask. The trypsinisation process was 
terminated by adding 30 ml of DMEM with 0.05 mg/ml gentamicin containing 10% (v/v) Fetal 
Calf Semm (FCS). The cells were pelleted by centrifugation at 200 x g for 5 mins and the cell 
pellet resuspended in 10 ml of DMEM with 10% (v/v) FCS and 0.05 mg/ml gentamicin. The
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cells were counted using a haemocytometer (Sigma). The number of BMSCs per flask was 
calculated as shown below:
1) Formula for calculating cells / ml:
Average cell number per square x 104 x Dilution factor
2) Formula for calculating the total number of cells
Cells /  ml x original volume o f fluid
4.3.3 Fluorescence-activated cell sorting (FACS) analyses of adhered MSCs using 
antibodies recognising the cell surface marker Notch-1 and its ligands, Delta and Jagged-2
FACs analysis was performed using a FACS Canto (BD Bioscience). Cells were harvested by 
trypsinisation (see Section 3.3.2), 1 xlO6 cells were retained after tryspinisation and were 
pelleted by centrifugation at 2000 rpm for 5 mins. The cells were fixed in 1 ml of 2% (w/v) 
paraformaldehyde (PFA) at room temperature for 2 mins, the cell suspension was divided into 4 
times 0.2 ml, containing approximately 0.2x106 cells for each analysis. The cell suspensions 
were centrifuged at 2000 rpm for 5 mins and the supernatant discarded. Non-specific binding 
sites were blocked using 5% (v/v) rabbit serum in PBS / 1% Tween20® for 15 mins at 4°C, 
followed by incubation in appropriately diluted primary polyclonal antibodies (refer to Table 
4.1) for 30 mins at 4 °C. FACs analysis was carried out using 30,000 events.
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Antibodies Dilutions Isotype Species Epitope References
Goat IgG 1:200 IgG
Goat
Polyclonal
- Invitrogen
Notch-1 
C-20
1:40 IgG
C-terminus 
of Notch-1 of 
human origin
Santa Cruz 
Biotechnologies, 
Inc.
Delta
F-15
1:40 IgG
N-terminus 
of Delta of 
human origin
Jagged-2
NOTCH-19
1:40 IgG
N-terminus 
of Jagged-2 
of human 
origin
Table 4.1: A table to show the Notch-1, Delta and Jagged-2 specific antibodies used for FACs 
analyses.Goat immunoglobulin (goat IgG) was used as a negative control. Note no positive 
controls were used for FACs analyses.
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4.3.4 Immunohistochemistry of BMSCs using Notch-1, Delta and Jagged-2 and, the co­
localization with cell membrane using fluorescently labeled Wheat Germ Agglutinin 
(WGA)
WGA is a carbohydrate - binding protein that selectively recognizes non-reducing terminal sialic 
acids and N-acetylglucosaminyl sugar residues on molecules (e.g. glycoproteins and glycolipids) 
which are predominantly found in the plasma membrane of cells. Hence, WGA is often used as a 
tool for co-localization to identify membrane associated proteins (Wright 1984).
Trypsinized cells from Day 8 (750,000 cells) were allowed to adhere to HistoBond slides in a 
humidified atmosphere of culture media (DMEM containing gentamicin and 10% [v/v] hi-FCS) 
overnight at 37°C 5 % (v/v) CO2. Sterile PBS and wheatgerm agglutinin Alexa -  647 were pre­
chilled on ice. The cells were chilled on ice for 45 mins. The media was removed and 1 ml of 
200 pg/ml of WGA -  Alexa 647 in PBS, was incubated on the cells on ice for 20 mins. 
Following incubation, the WGA was removed and the cells were washed 3 times using pre­
chilled sterile PBS and fixed for 20 mins using 2ml of pre-chilled 2% (w/v) paraformaldehyde 
(PFA). The PFA was removed and the cells were washed 3 times in PBS and blocked in rabbit 
serum (1:20 dilution in PBS) for 15 mins at room temperature. After blocking, the cells were 
transferred to a humid chamber and incubated with appropriately diluted primary antibodies 
(refer to Table 3.1) for 20 mins at room temperature. The cells were washed 3 times in PBS, 
followed by incubation in goat anti-mouse secondary antibodies for 15 mins at room 
temperature. The cells were washed three times in PBS, then mounted in ProlongGold™ 
(Invitrogen) and were viewed under a confocal microscope.
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4.4 Results
4.4.1 Comparison of bone marrow wet weight with cell number obtained at Day 8 of 
culture
Variations in the bone marrow chamber size and the presence of a mid-bone separating the two 
chambers were observed to be visually different for all young bovine legs that were processed. 
The dimension of each chamber and the wet weight of bone marrow harvested were recorded 
from 12 individual legs from different bone marrow harvests, to ascertain whether bone marrow 
wet weight influenced the number of cells obtained after 8 days of culture in DMEM containing 
10% (v/v) FBS and gentamicin. Figure 4.3 illustrates the diversity of chamber dimensions from 
12 legs obtained from different animals, the bone marrow wet weight and cell count following 8 
days of primary culture in serum-containing medium. From the 12 legs obtained from different 
animals, a broad range of cell count per leg ranging between 0.25x106 to 1.74xl06 cells counted 
on Day 8 was obtained (see Figure 4.3, ‘Cell count per leg’). From Figure 4.3, it shows that the 
heaviest bone marrow sample (Leg 10, 3.956g with 0.68 xlO6 cells) did not generate the highest 
cell count (Leg 9, 2.02lg with 1.74 xlO6 cells). In some cases, no BMSCs were harvested from 
the bone marrow sample at all, as observed from Leg 11 (3.177g bone marrow, with no cells). 
These data were further analyzed using a scatter plot of cell number against gram per wet weight 
of bone marrow. Normally, an R value close to 1 indicates a linear relationship between two 
variables. The R value for wet weight and cell number was 0.0115 as shown in Figure 4.4 
suggesting no correlation. Furthermore, scatter graphs were plotted to investigate whether a 
correlation existed between 1) cell number and the area of the bone marrow chamber (Figure 
4.4) and 2) weight of bone marrow harvested and the area of the bone marrow (Figure 4.5). The 
R2 values obtained were 0.0092 (Figure 4.5) and 0.2463 (Figure 4.6) suggesting no correlation 
between these factors.
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1Bone 
Marrow 
Weight (g)
1.288 1.183 0.717 2.607 1.116 3.82
Cell count 
per leg
(x 106 cells)
0.75 1.25 0.74 0.48 0.25 0.97
Bone 
Marrow 
Weight (g)
2.743 0.544 2.021 3.956 3.177 2.665
Cell count 
per leg 
(x 106 cells)
1.4 0.17 1.74 0.68 0 1.03
o Figure 4.3: Photographs to show the variations of exposed bone marrow chambers between different young bovine mid-bone by eye. Thew weight of bone marrow and cell count obtained per bone are shown to the corresponding bone from the images.
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Figure 4.6: Relationship between the area of none marrow chamber with weight
4.4.2 Cell morphology of adherent Mesenchymal stem cells (MSCs) from day 0 to day 8 of 
culture
The method used for isolation of BMSC was a simple selection based upon the adherence of 
BMSC to plastic (Oreffo et al., 1997). The initial plating of the cell inoculum was observed and 
photographed under a phase -  contrast microscope. Typically, within one hour of plating, a rich 
population of hematopoietic cells was observed as shown in Figure 4.7. Following a 4 day 
adhering period, the medium was discarded and the cells were washed and replenished with fresh 
medium.
On day 4, small numbers of heterogenous adherent cells were observed using a phase contrast 
microscope. The adherent cells appeared to have a spindle-shaped fibroblastic morphology as 
shown in Figure 4.7. It is interesting to note that small colonies of cells were beginning to 
appear, as small foci of a few cells (no data shown). Visual observation suggests that the small 
colonies of cells present at day 4 appeared to remain fairly static up to Day 6, followed by rapid 
cell division observed by eye. However, between day 6 and 8, rapid cell division occurred in the 
central area of the cell foci (Figure 4.7, Panel C), whilst the periphery of the foci contained areas 
of uneven cell density as shown in Figure 4.7, Panels D and E.
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Figure 4.6: Cell morphology of freshly isolated young bovine bone marrow-derived mesenchymal stem cells (b-BMSCs) 
at Day 0 (Panel A), after 4 days of adhering period (Panel B) and at Day 8 (Panel C) for before trypsinisation. Panel C, D 
and E highlighted the different population density (dense, semi-dense and sparse areas) observed throughout the base of a 
T-75 flask.
4.4.3 Cell surface expression of Notch-1, Delta and Jagged-2 on stem / progenitor cell 
population at day 8 of primary cultures
Monolayers of cells were trypsinised at day 8 (herein named PO) and analyzed for the expression 
of the cell surface receptor Notch-1, and its ligands Delta and Jagged-2 using FACs analyses. 
Table 4.2 summarised the detection of trypsin-treated cells harvested on Day 8 against young 
bovine articular chondrocytes (n=l), which acted as a positive control. The average detection for 
PO BMSCs for Notch-1 (90.3%), Delta (78.9%) and Jagged-2 (92.8%) were calculated as shown 
in Table 4.2. An n = 1 was used for the cell surface expression of Delta due to cell shortage. The 
graph shown in Figure 4.7 shows a shift in the fluorescence of the cells towards 105 for Notch-1, 
Delta and Jagged-2, away from the control, suggesting a positive expression. Colocalisation 
between WGA (shown in red, Figure 4.8, Panels D, E and F) and surface antibodies shown in 
green in Figure 4.8, Panels A, B and C were carried out to locate the expression of Notch-1, 
Delta and Jagged-2. The individual detection for Notch-1, Delta and Jagged-2 were combined 
with WGA, as shown in Figure 4.8, Panels G, H and I, respectively. These confocal images 
demonstrated the detection of these receptor and ligands on the surface of PO BMSCs cultured in 
serum-containing medium for 8 days.
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Percentage of positive cells (%)
Goat Immunoglobulin 
(Gig) Notch-1 Delta Jagged-2
Young Bovine Articular Cartilage 0.9 98.4 84.7 44.1
Trypsin-treated PO-bovine BMSCs 
(from Experiment 1)
0.5 90.9 No data due to lack of cells 98
Trypsin-treated PO-bovine BMSCs 
(from Experiment 2)
0.5 89.7 78.9 87.5
Average between Experiment 1 & 2 
data 0.5
90.3
(n=2)
78.9
(n=l)
92.75
(n=2)
Standard errors 0 0.6
n/a since 
n =1
5.25
Table 4.2: FACs analyses on trypsin-treated cells harvested on Day 8 (Passage 0, PO). Young bovine full depth articular cartilage was 
used as a positive control for the receptor protein Notch-1 and its ligands Delta and Jagged-2. Protein expression for Gig, Notch -1 and 
Jagged-2 on PO cells from Day 8 was repeated twice, whereas the ligand, Delta only has an n-number of 1 due to shortage of cells.
o
»Del
Jagged
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Figure 4.7: FACs data on the expression of Notch-1, Delta and Jagged-2 on the surface of trypsin-treated young bovine BMSCs on Day 
8. Negative control used is goat immunoglobulin (Goat IgG), no positive control was used.
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Figure 4.8: Detection of the presence of Notch -  1 (A), Delta (B) and Jagged -  2 (C) using FACs analyses on selected population of BMSCs cultured for 8 days 
in DMEM with 10% (v/v) FBS and 0.05 mg/ml gentamicin. Cells were labelled with FITC-conjugated antibodies (counterstained with wheat germ agglutinin, 
D-F) and visualised using scanning confocal microscopy. Panels G, H and I are co-localisation of the two fluorophores.
4.4.4 Quantitative Polymerase Chain Reaction for SOX-9, aggrecan, collagens type I and II 
of trypsin-treated BMSCs obtained from Day 8
Quantitative PCR was used to assess the gene expression level of PO MSCs after eight days of 
culture in vitro. The common cartilage specific markers of SOX-9, aggrecan, and collagen type 
II were used to investigate if these markers were already expressed by direct extract of young 
bovine bone marrow and from PO BMSCs cultured for 8 days in DMEM containing gentamicin 
and 10% (v/v) FBS. Collagen type I was also used to investigate if PO BMSCs were 
differentiating a fibroblastic/fibrocartilage phenotype.
For each gene of interest, a standard curve was prepared from a dilution series of template of 
pDNAs containing the selected cloned gene of interest, namely SOX-9, aggrecan, collagens type 
I and II (refer to Chapter 3 for details). The qPCR for the dilution series of the template was 
carried out at the same time as the unknown samples. Ct values of the unknown were calculated 
from the standard curve plot, which allowed the determination of the copy number for the 
unknown samples.
4.4.4.1 Comparisons o f the gene expression between direct tissue extracts and passage 0 (PO) 
BMSCs cultured for 8 days in serum containing medium
Direct tissue extracts obtained from young bovine articular cartilage (YBAC), old bovine 
articular cartilage (OBAC) and young bovine bone marrow (YBBM) were used to compare the 
gene expression levels of SOX-9, aggrecan, collagens type I and II with trypsin-treated P0- 
BMSCs cultured in DMEM containing 10% FCS with gentamicin for 8 days. The qualities of 
RNA extracted from direct tissue extracts (n=l) and from the PO-BMSCs (n=3) were in the range 
of 1.97-2.10 (see Table 4.3).
113
Samples 260/280 ratio Amount of RNA (ng/pl)
Old Bovine Articular Cartilage extracts 2.1 141.5
Young Bovine Articular Cartilage extracts 2.08 288.0
Young Bovine Bone Marrow extracts 1.97 262.4
PO BMSCs (1) 2.08 275.7
PO BMSCs (2) 1.99 32.6
PO BMSCs (3) 2.07 295.3
Table 4.3: Summary of the quality of RNA etracted from three separate batches of native tissue 
extracts and PO BMSCs.
SOX-9 COLLAGEN II COLLAGEN I AGGRECAN
Old Bovine AC (n=l) 0.058 600.382 0.030 20.650
Young Bovine AC (n=l) 0.048 521.678 31.678 48.042
Young Bovine BM (n=l) 0.000 0.000 0.078 0.000
POMSCs (n=3) 0.076 0.000 2.785 1.119
Table 4.4: Summary of gene expression levels of GAPDH, SOX-9, collagen type I, collagen type II and 
aggrecan from different native tissues (old bovine articular artilage, young bovine articlar cartilage and 
young bovine bone marrow) and from three sets of POMSCs cells.
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Figure 4.10: Histogram to show the expression pattern of GAPDH, SOX-9, collagen type I, 
collagen type II and aggrecan of different tissue extracts (old bovine articular cartilage [n=l], 
young bovine articular cartilage [n=l] and young bovine bone marrow [n=l]) and compared 
these tissue extracts to POMSCs (n=3). The y-axis represents the number of copies each gene 
was expressing, and the x-axis represents the different genes. Error bars were generated from a 
triplicate of POMSCs.
No expression of SOX-9 was detected from bone marrow extracted from young bovine. POMSCs 
expressed the most of SOX-9 (0.076 copies), followed by old bovine cartilage (0.058 copies) 
then from young bovine cartilage (0.048 copies). The expression of SOX-9 detected from 
POMSCs was 1.340 times (0.076/0.058) higher than old bovine cartilage and 1.583 times higher 
than young bovine cartilage. Highest expression of collagen type II was observed from articular 
cartilage extracted from old bovine (600.382 copies). This is interesting because normally, a 
higher amount of collagen type II would be expressed in articular cartilage extracted from young 
bovine rather than from old bovine. Here, articular cartilage obtained from old bovine was 1.151 
(600.382/521.678) times more expressed than articular cartilage obtained from young bovine. No 
expression of collagen type II was detected from POMSCs and from bone marrow extracted from 
young bovine. Cartilage extracted from young bovine generated the highest expression of
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■  Old Bovine AC
■  Young Bovine AC
■ Young Bovine BM
■ POMSCs
collagen type I of 31.678 copies. Articular cartilage obtained from old bovine was 1055.933 
(31.678/0.03) times less than cartilage obtained from young bovine. Expression of collagen type 
I was detected from young bovine bone marrow and POMSCs, however the expression levels 
were 406.128 times (31.678/0.078) and 11.375 times (31.678/2.785) less in comparison to 
cartilage extracted from young bovine, respectively. No expression of aggrecan was detected 
from bone marrow extracted from young bovine. The highest expression of aggrecan was 
detected from cartilage extracted from young bovine (48.042 copies). However, a lower 
expression of aggrecan was detected from cartilage extracted from old bovine (2.327 times 
(48.042/20.650)) than young bovine cartilage. A low expression of aggrecan was detected from 
POMSCs. The level detected was 42.933 times (48.042/1.119) less than the detected generated 
from young bovine cartilage.
From this study, it suggested that bone marrow extracted from young bovine did not express 
SOX-9, Collagen type II and aggrecan. A sound expression of collagen type I was detected in 
this study, however, this result needs to be further verified since this data is based on an n- 
number of one. Despite the fact that collagen type I and aggrecan were detected from triplicates 
sample of POMSCs, in comparison to the detection obtained from cartilage extracted from young 
and old bovine, these genes were expressed at a much lower level. These suggested that POMSCs 
do not possess a chondrogenic phenotype at such an early cell culture stage.
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4.5 Discussion
The aim of this chapter was to isolate primary BMSCs by adherence to tissue culture plastic 
through aspiration of bone marrow from the metacarpal bone of young bovine. This was 
followed by the characterisation of these adhered primary BMSCs, PO BMSCs in serum- 
containing medium for 8 days by observation using a phase contrast microscope, protein and 
molecular expression analyses.
Methods that have commonly been used to extract bone marrow include i) aspiration of the iliac 
crest from live animals (Johnstone et al, 1998) and ii) direct removal of bone marrow from its 
chamber using sterile culture medium (Zangi et al, 2006). In the later method, bone marrow is 
aspirated into a syringe containing heparin which prevents blood coagulation. This method has 
been used in different animal models including rabbit (Johnstone et al, 1998) human (Lennon et 
al, 1996) and bovine (Bosnakovski et al, 2004). Once the bone marrow is obtained, the BMSCs 
are isolated based on their; i) adherence to plastics (Friedenstein et a l 1976; Prockop 1997; 
Murdoch et al, 2007;) and ii) differential adhesion to fibronectin (Archer et al, 2007). It is 
widely agreed that MSCs can adhere to plastic and HSCs cannot (Castro-Malaspina et al, 1980). 
Furthermore, attachment of cells to negatively charged culture dishes is in fact considered a 
selector for fibroblastoid cells (Phinney 2002). Usually, bone marrow in culture medium is 
plated into culture flasks and incubated at 37°C with 5% (v/v) carbon dioxide for 1 - 5 days 
(Murdoch et al, 2007; Zangi et al, 2006; Mauck et al, 2006). After the adhering period, the 
medium is changed and the cells are grown to confluence.
An alternative approach to the selection of BMSCs from an enriched bone marrow exudate is 
based on their adhesion to fibronectin. Differential adhesion to fibronectin utilises the high 
affinity of stem or progenitor cells for fibronectin, a glycoprotein which binds to integrins on the 
cell surface. The cells are subjected to serial incubations in order to select for colony-forming 
cells. The colony -  forming unit fibroblast (CFU - F) assay can be used to quantify the adherent
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cell population by scoring colonies presumed to be derived from a single precursor (Friedenstein 
et al., 1976; Deans et al., 2000; Perkins & Fleischman 1990).
In addition to the above purification methods, separation between nucleated MSCs and non­
nucleated HSCs can be achieved using a Lymphoprep™ kit from Nycomed Pharma (Oreffo et 
al., 1997) or by density gradient centrifugation to obtain mononucleated cells (Majumdar et al., 
1998). The initial method for the extraction of bone marrow utilised in this study was adapted 
from Dr Richard Oreffo’s laboratory in Southampton University (Oreffo et al., 1997).
This study has demonstrated that differences in bone marrow chamber size and bone thickness 
influence the amount of bone marrow and subsequently the number of cells harvested. The 
variations in chamber size could be due to many factors including arrival age, front and back leg 
(carpo versus tarso), arrival breed, sex of the animal, and time after slaughter which may 
influence cell viability. Previous study has shown that the isolation of BMSCs from crude BM, 
by adherence to plastic, enabled a separation of hematopoietic and non-hematopoietic cells as 
described by other research groups (Oreffo et al., 1997). The morphology of the cells at Day 4 
and Day 8 showed the typical spindle-shaped fibroblastic features of undifferentiated MSCs and 
colony-forming MSCs that were previously observed by Friedenstein and Caplan.
FACs analyses indicated that undifferentiated MSCs (harvested at Day 8) expressed the stem / 
progenitor markers of Notch-1, Delta and Jagged-2 (Dowthwaite et al., 2004). This suggested 
that the cells isolated initially exhibit stem cell like features. Hardingham and co-workers 
recently demonstrated that Notch signalling through Jagged-1 is necessary to initiate 
chondrogenesis of MSCs using a human model. However, the expression of Jagged-1 must be 
switched off in order to enable MSCs to complete chondrogenesis (Oldershaw et al., 2008).
From this study, it suggested that bone marrow extracted from young bovine did not express SOX-9, 
Collagen type II and aggrecan. A sound expression of collagen type I was detected in this study, 
however, this result needs to be further verified since this data is based on an n-number of one. Despite 
the fact that collagen type I and aggrecan were detected from triplicates sample of POMSCs, in 
comparison to the detection obtained from cartilage extracted from young and old bovine, these genes
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were expressed at a much lower level. These suggested that POMSCs do not possess a chondrogenic 
phenotype at such an early cell culture stage.
4.6 Summary
• MSCs isolated possessed a spindle-shaped fibroblastic morphology as observed in 
previous published work on similar systems.
• Protein expression of Notch-1, Delta and Jagged-2 by primary MSCs suggests they 
possess some stem/progenitor cell features.
• No expression of SOX-9, aggrecan, type I and type II collagens were detected from 
POMSCs.
4.7 Future work
> Use Lymphoprep to separate hematopoietic and non-hematopoietic cells, enabling a clear 
number of the mononucleated cells to be obtained.
> Carry out cell viability testing to assess the viability of the cells after the first 
trysinisation on Day 8.
> Jagged-1, as well as Notch-1, Delta and Jagged-2, should be used as markers for the 
differentiation of MSCs towards a chondrogenic lineage.
> Perform qPCR analyses using primer pairs designed for Notch-1, Delta and Jagged-2 in 
order to quantify the amount of these markers being expressed by undifferentiated MSCs.
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Chapter 5: 
Investigate the effects of Fibroblast Growth Factor alone and in the 
presence of Transforming Growth Factor Beta-2 on the 
differentiation of BMSCs to a chondrogenic phenotype
5.1 Introduction
In this chapter, a selected sub-population of BMSCs (described in Chapter 4) were cultured in 
serum-containing medium described in Chapter 4 in the presence of 5ng/ml of fibroblast growth 
factor 2 (FGF-2) and in the presence of both FGF-2 and transforming growth factor beta-2 (TGF- 
p2) to ascertain proliferation properties of these cytokines on primary BMSCs and their abilities 
to initiate differentiation of the BMSCs to a chondrogenic lineage.
Many factors such as cytokines and growth factors contribute to the cellular events of 
proliferation, differentiation and maturation of cell types through binding to target cell surface 
receptors and initiating intracellular events (as described in Chapter 1 Section 1.4.1).
Many reports have shown that FGF-2 contributes to the selection of MSCs that are more likely to 
differentiate chondrogenically Bianchi et al., 2003. Previous studies have suggested that addition 
of FGF-2 during the subculture phase enhances the chondrogenic potential of human derived 
MSCs (Solchaga et al., 2005). As well as FGF-2, TGF-P has been found to be one of the most 
potent inducers of chondrogenic differentiation of BMSCs isolated from bone marrow in many 
different species and other tissue sources (Bosnakovski et al., 2004). Alterations in the 
concentration of TGF-P have been shown to affect the expression levels of certain extracellular 
matrix compounds in a bovine model (Bosnakovski et al., 2004). Stevens et al., have 
demonstrated that the combined use of TGF- p and FGF-2 influenced perichondrium to 
differentiate towards a chondrogenic lineage (Stevens et al., 2004).
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In this study, the initial BMSCs cell isolates were plated and maintained in serum-containing 
medium for 8 days (see Chapter 3). On day 8, the cells were trypsinized and subcultured at 
different cell densities in serum-containing medium with 5 ng/ml of FGF-2 and in the presence 
of 5ng/ml FGF-2 and 5ng/ml TGF-p2. The cells were cultured until they were confluent on plate 
under a phase contrast microscope, passaged, and the BMSCs were taken for the following 
analyses:-
• Cell number and cell morphology
• At each passage the protein expression of the stem/progenitor cell markers Notch-1, 
Delta and Jagged-2 were assessed by FACS analysis to determine whether the cells 
remained in an undifferentiated state.
• At each passage molecular expression of SOX-9, aggrecan, collagens type I and type II 
were determined in order to ascertain whether the potential stem cells had undergone 
chondrogenic differentiation
The outline of the experiment and the analyses carried out for this chapter are summarised in 
Figure 5.1.
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PO bovine bone marrow mesenchymal stem cells( b-BMSCs)
Trypsinized at confluence
V
PI bovine bone marrow mesenchymal stem 
cells (b-BMSCs)
V
+  5 ng/ml Fibroblast Growth Factor 2 
(FGF-2)
Trypsinized at 
confluence
P2 bovine bone marrow mesenchymal stem cells 
(b-BMSCs)
V
+ 5 ng/ml Fibroblast Growth Factor 2 
(FGF-2)
Trypsinized at 
confluence
End of Cell Expansion
Figure 5.1: A flow chart to illustrate the processing of Passage One (PI) and Passage Two (P2) bovine 
bone marrow mesenchymal stem cells (b-BMSCs). Analyses carried at different passages were 
summarized as above.
1 2 2
5.2 Materials
All reagents and equipment used are previously described in Chapters 2 and 3
5.3 Methods
5.3.1 Sub-culture of trypsinised BMSCs in T-75 flasks in the presence of FGF-2
Briefly, trypsinized BMSCs were replated at different cell density for each harvest and at each 
passage (as shown in Table 5.1) and were maintained in DMEM in the presence of 0.05 mg/ml 
gentamicin containing 10% (v/v) FCS with 5 ng/ml of basic fibroblastic-growth factor (FGF-2, 
Sigma). The medium was changed every 4 days and the cells were subcultured until confluent by 
eye. When confluent, cells were trypsinized as described in Chapter 4Section 4.3.2)
Replating cell density per flask
Harvests PI BMSCs P2 BMSCs
1 0.7 xlO" 
(33% confluency)
1.92 xlO* 
(33% confluency)
2 0.4 xlO6 
(50% confluency)
1.11 xlO6 
(33% confluency)
3 0.2 xlO” 0.2 xlO6
4 0.4 xlO6 0.4 xlO6
Table 5.1: A table to summarise the replating cell densities for PI and P2 BMSCs cultured in the 
presence of 5ng/ml of FGF-2.
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5.3.2 Sub-culture of trypsinised BMSCs in T-75 flasks in the presence of TGF-p2 and FGF- 
2
Trypsinized BMSCs were plated at different cell density for each harvest and at each passage as 
shown in Table 5.2 and were maintained in DMEM with 0.05 mg/ml gentamicin containing 10% 
(v/v) FCS with 5 ng/ml of basic fibroblastic-growth factor (FGF-2, Sigma) and 5 ng/ml 
transforming growth factor beta-2 (TGF-02, PeproTech). The medium was changed every 4 days 
and the cells were subcultured until confluent by eye. When confluent, cells were trypsinized as 
outlined in Chapter 4 Section 4.3.2)
Replating cell density per flask
Harvests PI BMSCs P2 BMSCs
1 0.7 xlO" 3.3 xlO"
2 0.4 xlO" 4.31 xlO"
3 0.2 xlO" 0.2 xlO"
4 0.4x10" 0.4x10"
Table 5.2: A table to summarise the replating cell densities for PI and P2 BMSCs cultured in the 
presence of 5ng/ml of FGF-2 and 5ng/ml TGF-p2.
At each passage, a total of 2 xlO6 cells were retained for analyses of protein expression of Notch 
-  1, Delta and Jagged -  2 using FACs analyses (see Chapter 4 Section 4.3.3) and for quantitative 
PCR for the expression of chondrogenic markers, namely, SOX-9, aggrecan, collagens type I and 
II (see Chapter 3 Section 3.3.11).
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5.4 Results
5.4.1 Cell morphology and cell numbers of Passage One (PI) and Two (P2) BMSCs 
cultured in Basal Medium supplemented with 5 ng/ml of Fibroblast Growth Factor - 2 
(FGF-2)
BMSCs from four harvests were cultured in serum containing medium for 8 days on tissue 
culture plastic. The selected population of BMSCs were trypinised on Day 8 and replated at 
different cell density for each of the harvest as shown in Table 5.3 and the cells are referred to as 
Passage One (PI). The cells were fed every 2 days with 20 ml of fresh medium.
The cell morphology was recorded by photographing under a phase contrast microscope. Unlike 
PO BMSCs, PI BMSCs cultured in the presence of 5 ng/ml of FGF-2 had no distinct cell foci or 
colonies and were distributed evenly throughout the base of the tissue culture flask. The 
morphology of PI BMSCs were fibroblastic with long and thin cell shape, and appeared to be 
more granular and more fibroblastic than P2 BMSCs as can be seen on Figure 5.2. Even though 
harvests 2 and 4 were replated at the same replating cell density of 0.4 xlO6 cells / flask (Table 
5.3), the number of days for the cells to become confluent differed (Table 5.3). Harvest 2 took 10 
days to become confluent, whilst harvest 4 required half the time to reach confluency. Individual 
cell count from each flask from the four experiments were recorded as shown in Table 5.4. The 
replating cell density and cell count from each flask of Passage two (P2) BMSCs cultured in 
serum-containing medium with the addition of 5 ng/ml FGF-2 were recorded in Table 5.5 and 
5.6, respectively. The data (Table 5.5) showed that the cell count per flask at confluence from P2 
BMSCs was lower than PI BMSCs (Table 5.3). The lowest difference was 0.5-fold from harvest 
3 and the highest difference observed was 4-fold from harvest 1. The number of days the cells 
used to reach confluence was similar between P1 and P2 BMSCs, with the exception of harvest 
4, where there were 6 days difference between PI and P2 BMSCs (see Table 5.3 and 5.5).
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Figure 5.2: Cell morphology of bovine derived mesenchymal stem cells expanded in 
monolayer in the presence of 5 ng/ml FGF-2 at passage 1 (PI) and passage 2 (P2). The scale 
shown represents 5 pm.
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Harvests
Replating Cell 
density per flask
Cells per flask at 
confluent
Number of days 
until ceUs reached 
confluency
1 0.7 xlO6 
(33% confluency)
5.65 xlO6 4
2 0.4 xlO6 
(50% confluency)
3.38 xlO6 10
3 0.2 xlO6 1.77 xlO6 11
4 0.4 xlO6 2.01 xlO" 4
Table 5.3: Replating cell density of Passage One (PI) BMSCs cultured in serum-containing 
medium with the addition of 5ng/ml FGF-2.
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Experiment 1 Experiment 2 Experiments Experiment 4
P I trysinisation cell count (xlO 6)
Experiment 1 
n=6
Experiment 2 
n=8
Experiment 3 
n=6
Experiment 4 
n=3
4.600 4.540 1.620 2.300
5.560 2.220 1.890 1.540
6.480 3.220 1.510 2.200
5.400 3.700 1.620
5.640 2.980 1.890
6.160 3.380
4.100
2.920
2.100
Total cell 33 .840 27 .060 10.630 6.040
Av. cells/flask 5.640 3.383 1.772 2.013
Std dev. 0.651 0.728 0.224 0.413
Error 0.266 0.257 0.091 0.238
Table 5.4: Cell count per flask of PI BMSCs cultured in the presence of 5 ng/ml of FGF-2 from 
four harvests. Top panel shows the average cell count per flask obtained from different harvests 
in a histogram format. Bottom panel is a tabulated format of the cell count data.
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Harvests
Replating Cell 
density per flask
Cells per flask at 
confluent
Number of days 
until cells reached 
confluency
1 1.92 xlO6 
(33% confluency)
1.20x10*’ 5
2 1.11 xlO6 
(33% confluency)
2.71 xlO6 8
3 0.2 xlO6 3.41 xlO6 8
4 0.4 xlO6 0.55 xlO6 10
Table 5.5 Replating cell density of Passage Two (P2) BMSCs cultured in serum-containing
medium with the addition of 5ng/ml FGF-2.
P2 trypsinisation cell count (xlO6)
Experiment 1 Experiment 2 Expperiment 3 Experiment 4
n=14 n=3 n=10 n=7
1.140 2.780 3.600 0.760
2.480 2.520 3.340 0.440
2.300 2.840 2.340 0.600
1.440 3.320 0.500
0.820 3.720 0.440
1.110 5.500 0.500
1.110 3.400 0.620
1.110 2.820
1.110 3.280
0.836 2.760
0.836
0.836
0.836
0.836
Total cell 16.800 8.140 34.080 3.860
Av. cells/flask 1.200 2.713 3.408 0.551
Std Dev. 0.537 0.170 0.846 0.116
Error 0.144 0.098 0.268 0.044
Table 5.6: Cell count per flask of P2 BMSCs cultured in the presence of 5 ng/ml of FGF-2 from 
four harvests. Top panel shows the average cell count per flask obtained from different harvests 
in a histogram format. Bottom panel is a tabulated format of the cell count data.
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Figure 5.3: Comparison between the average cell count from PI and P2 BMSCs trypsinisation 
after culturing in serum containing medium with the addition of 5 ng/ml FGF-2.
Table 5.5 summarised the number of cells obtained per flask and the number of days for cells to 
reach confluence for P2 BMSCs. At this point, the trypsinised cells were seeded at different cell 
density into Transwell inserts (refer to Chapter 6). Figure 5.3 compares the average cell numbers 
obtained from the average cell density per flask for each harvest at different passage number (PI, 
blue and P2, purple) with different replating cell density, cultured in serum containing medium 
with the addition of 5 ng/ml FGF-2. PI BMSCs have a higher overall cell count than P2 BMSCs 
with the exception of harvest 3, the greatest difference was observed between harvests 1 and 4 
for PI BMSCs with a difference of 6- and 5- fold, respectively (see Figure 5.3).
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5.4.2 Cell morphology and cell numbers of Passage One (PI) and Two (P2) BMSCs 
cultured in 5 ng/ml of FGF-2 and 5ng/ml TGF 0-2
BMSCs from four harvests were cultured in serum containing medium for 8 days on tissue 
culture plastic. The selected population of BMSCs were trypinised on Day 8 and replated at 
different cell density for each of the harvests shown in Table 5.7 and the cells are referred to as 
Passage One (PI). The cells were replenished with fresh medium every 2 days. The cell 
morphology was recorded by photographing under a phase contrast microscope as shown in 
Figure 5.8. PI and P2 BMSCs with the addition of 5ng/ml FGF-2 and 5ng/ml TGF-02 did not 
appear to have any obvious difference in terms of cell morphology (Figure 5.2 and 5.8, 
respectively). The appearance of the cells was less fibroblastic than those cultured in 5ng/ml 
FGF-2 (see Figure 5.8). BMSCs at PI and P2 were more hexagonal-shaped (see Figure 5.8).
Harvests
Replating Cell 
density per flask
Cells per flask at 
confluence
Number of days 
until cells reached 
confluency
1 0.7 xlO6 
(33% confluency)
9.64 xlO6 4
2 0.4 xlO" 
(50% confluency)
13.57 xlO6 10
3 0.2 xlO6 6.0 xlO6 7
4 0.4 xlO6 5.26 xlO6 3
Table 5.7: Replating cell density of Passage One (PI) BMSCs cultured in serum-containing 
medium with the addition of 5ng/ml FGF-2 and 5ng/ml TGF-02.
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Figure 5.8: Cell morphology of bovine derived mesenchymal stem cells expanded in 
monolayer in the presence of 5 ng/ml FGF-2 with the addition of 5 ng/ml of TGF-beta 2 at 
passage 1 (PI) and passage 2 (P2).
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When PI BMSCs had reached confluence, the cells were trypsinised as before. The average cell 
number in each flask and the number of days the cells took to reach confluence were recorded 
and the results were summarised in Table 5.8 and 5.9.
Harvests
Replating cell 
density per flask
Number of cells per 
flask at confluence
Days for cells to 
reach confluence
1 3.3 xlO” 5.088 xlO6 5
2 4.31 xlO” 12.73 xlO6 3
3 0.2 xlO6 0.62 xlO6 6
4 0.4 xlO6 6.04 xlO6 4
Table 5.8: Cell count from each flask at Passage One (P2) BMSCs cultured in serum-containing 
medium with the addition of 5ng/ml FGF-2 and 5ng/ml TGF-P2.
The P2 trypsinised BMSCs cells were counted from each flask and all results were recorded as 
shown in Table 5.10. At this stage, the trypsinised cells were seeded at different cell density into 
Transwell inserts (refer to Chapter 6). The cell count data obtained from PI and P2 trypsinisation 
were plotted on a histogram to compare the results as shown in Figure 5.9. Out of the four 
harvests, the average cell count obtained from PI stage exceeded P2 BMSCs, with the exception 
of harvest 4. A difference of 50% and 80% can be seen from Harvests 1 and 3, respectively, 
whilst harvest 2 only had a minute difference of about 10%.
Our data shown that cells cultured in FGF-2 and with the addition of TGF-p2, cells were evenly 
distributed and no formation of cell foci was formed. In FGF-2, PI BMSCs appeared to be more 
fibroblastic than P2 BMSCs. Cell count obtained was higher from PI than P2 BMSCs cultured in 
either FGF-2 or with the addition of TGF-p2. The cell number obtained was generally higher 
from BMSCs cultured in FGF-2/TGF-p2 than in FGF-2 alone. From these data, it has suggested 
that culturing BMSCs in the presence of two growth factors gave an increased number of cells 
per flask, i.e. increased cell proliferation.
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P1 trypsinisation cell count +FGF-2/TGF-beta 2 (x106)
Experiment 1 Experiment 2 Experiment 3 Experiment 4
10.26 18.60 6.46 4.58
10.16 11.00 5.82 6.02
10.20 13.00 6.80 5.44
8.40 13.40 5.70 5.00
8.40 11.40 5.70
10.40 14.00 5.50
14.20
9.00
Average 9.64 13.57 6.00 5.26
Std Deviation 0.96 2.73 0.51 0.62
Std error 0.40 1.11 0.21 0.25
Table 5.8: Cell count per flask of PI BMSCs cultured in the presence of 5ng/ml of FGF-2 and 
5ng/ml TGF-p2 from four harvests. Top panel shows the average cell count per flask obtained 
from different harvests in a histogram format. Bottom panel is a tabulated format of the cell count 
data.
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P2 trypsinisation cell count +FGF-2/TGF-beta 2 (xlO6)
Experiment 1 Experiment 2 Experiment 3 Experiment 4
3.94 12.20 0.52 5.98
3.74 14.80 0.70 5.74
4.34 11.20 0.35 6.34
6.64 0.42 5.26
6.22 0.64 5.60
5.20 1.09 5.78
5.20 6.48
5.20 6.18
5.20 6.90
5.20 6.14
Average 5.09 12.73 0.62 6.04
Std Deviation 0.91 1.86 0.26 0.47
Std error 0.29 0.59 0.08 0.15
Table 5.9: Cell count per flask of P2 BMSCs cultured in the presence of 5ng/ml of FGF-2 and 
5ng/ml TGF-p2 from four harvests. Top panel shows the average cell count per flask obtained 
from different harvests in a histogram format. Bottom panel is a tabulated format of the cell count 
data.
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Figure 5.9: Comparison between the average cell count from PI and P2 BMSCs 
trypsinisation after culturing in serum containing medoium with the addition of 5 ng/ml 
FGF-2 and TGF-(32.
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5.4.3 Protein expression of Notch-1 receptor and its ligands Delta and Jagged-2 by PI and 
P2 BMSCs cultured in the presence of 5 ng/ml FGF-2
Following trypsinisation of BMSCs at PI and P2 cultured in serum-containing medium with 5 
ng/ml of FGF-2, lx l06 cells of BMSCs were retained for protein expression analyses using 
FACs on Notch receptor, Notch-1 (NOTCH-1) and its ligands, Delta (A) and Jagged-2 (J-2). 
0.2x106 cells were used for the analyses for each protein of interest. FACs analyses were carried 
out using 30,000 events. Different replating cell densities were used for each harvest. 
Chondrocytes obtained from young bovine metacarpal joints were also stained with the above 
antibodies.
The FACs data were tabulated as shown in Figure 5.10 Panel A and a histogram was plotted to 
compare the results, shown in Figure 5.10, Panel B compares the expression of NOTCH-1, A and 
J-2. Goat immunoglobulin (Gig) was used as a negative control and all samples (7 days 
chondrocytes, PI and P2 BMSCs) gave a negative detection for Gig, suggesting no non-specific 
binding of primary antibodies took place. The percentages of positive cells were measured using 
FACs. Almost equal detection of NOTCH-1 (~98% of cells) was detected from 7 day old 
chondrocytes and PI BMSCs. In contrast, the expression achieved by P2 BMSCs on NOTCH-1 
was 50% less than chondrocytes and PI BMSCs. The expression pattern for Delta was similar to 
that of NOTCH-1. These data suggested that the expression of NOTCH-1 and Delta were 
reduced with increased passage number of BMSCs in a bovine model. The expression pattern for 
Jagged-2 was different to NOTCH-1 and Delta. PI BMSCs expressed the highest amount of 
Jagged-2 (97%), whilst the expression by P2 BMSCs (55%) exceeds chondrocytes (44%) by 
approximately 10%.
When FACs analyses were completed, PI and P2 BMSCs were counter-stained with DAPI and 
were photographed as shown in Figures 5.11 and 5.12 for PI and P2 BMSCs, respectively. Gig
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was used as a negative control. NOTCH-1, delta and Jagged-2 appeared to be distributed 
uniformly throughout the surface of PI and P2 BMSCs.
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Comparisons between the expression of Notch-1, 
Delta and Jagged-2 against chondrocytes obtained 
from young bovine articular cartilage
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■ S _bLiSCs +5ng/ml FGF-2
□ P2 BMSCs +5ng/ml FGF-2
Gig Notch-1 Delta Jagged-2
B _ _ _ _
Percentaqe of Positive cells (%)
Glq Notch-1 Delta Jaqqed-2
Younq Bovine Chondrocytes 0.90 98.40 84.70 44.10
P1 BMSCs (1) 0.40 90.10 71.30 96.00
P1 BMSCs (2) 0.50 98.50 97.30 98.20
Average 0.45 94.30 84.30 97.10
Std Dev 0.07 5.94 18.38 1.56
Std Error 0.05 4.20 13.00 1.10
P2 BMSCs (1) 0.20 43.80 43.70 48.30
P2 BMSCs (2) 0.50 73.40 67.70 73.00
P2 BMSCs (3) 0.10 56.20 21.00 40.60
P2 BMSCs (4) 0.50 49.40 54.80 59.40
Average 0.33 55.70 46.80 55.33
Std Dev 0.21 12.84 19.80 14.09
Std Error 0.10 6.42 9.90 7.04
Figure 5.10: Protein expression of Notch-1, Delta and Jagged-2 by young bovine articular cartilage 
(YBAC, positive control), PI and P2 BMSCs cultured in serum-containing medium in the presence of 
5ng/ml FGF-2 (Panel A).
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Goat IgG -ve 1:2000 Notch 1 (C-20) 1:40 Delta (F-15) 1:40 Jagged 2 (N-19) 1:40
Figure 5.11: Cell smear images for PI BMSCs cultured in serum containing medium 
with the presence of 5 ng/ml FGF-2. DAPI as a counter stain for staining the nucleus 
(shown in red), FITC staining is shown as green. Scale bar represents 2pm and images 
were taken at x40 magnification
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Goat IgG -ve 1:2000 Notch 1 (C-20) 1:40 Delta (F-15) 1:40 Jagged 2 (N-19)
1:40
Figure 5.12: Cell smear images for P2 BMSCs cultured in serum containing medium 
with the presence of 5 ng/ml FGF-2. DAPI as a counter stain for staining the nucleus 
(shown in red), FITC staining is shown as green. Scale bar represents 2pm and images 
were taken at x40 magnification
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5.4.3 Expression of Notch-1 receptor and its ligands Delta and Jagged-2 by PI and P2 
BMSCs cultured in the presence of 5ng/ml FGF-2 AND 5ng/ml TGF-p2
Following trypsinisation of BMSCs at PI and P2 cultured in serum-containing medium with 
5ng/ml of FGF-2 plus 5ng/ml TGF-p2, lxlO6 cells BMSCs cells were retained for protein 
expression analyses using FACs on Notch receptor, Notch-1 and its ligands, Delta and Jagged-2 , 
before further passaging. 0.2x106 cells were used for the analyses of each protein of interest. 
Chondrocytes obtained from 7 days bovine articular cartilage (n=l) of the same amount of cells 
(0.2x106) for each protein was used. Gig was used as a negative control.
Figure 5.13 Panel B compares the expression of Notch-1, Delta and Jagged -2. All samples had a 
negative detection of Gig suggesting no non-specific binding. Notch-1 was highly expressed by 
7 day old chondrocytes (98%), followed by PI BMSCs (79%) and P2 BMSCs (67%). A similar 
pattern was observed in the expression of Delta but with a lower general expression level of 85% 
(chondrocytes), 70% (PI BMSCs) and 48% P2 BMSCs. These data suggest that an increase in 
passage number for bovine BMSCs may result in a reduction in the expression of Notch-1 and 
Delta. For Jagged-2 expression, PI BMSCs generated the highest expression level of 89%, 
whilst similar detection was obtained from chondrocytes (44%) and P2 BMSCs (49%).
When FACs analyses were completed, the cells were counter-stained with DAPI and for PI and 
P2 BMSCs, cell smears images (Figure 5.14 and 5.15 respectively) were obtained to show the 
visual staining of each protein of interest. All Notch-1, Delta and Jagged-2 appeared to be 
distributed uniformly throughout the surface of PI and P2 BMSCs.
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C om p arison  o f  prote in  e x p r e s s io n  o f  Notch-1, Delta and  
J a g g e d -2  o n  c h o n d r o c y te s  d er iv ed  from yo u n g  b ov in e  
articular ca rt ila g e  a n d  P1 and  P2 BMSCs cultured in serum  
m ed iu m  with the  add ition  o f  FGF-2 and  TGF-beta 2
□  Y oung Bovine Chondrocytes 
(n=1)
■  PI BMSCs +FGF-2/TGF-B2 
D P2 BMSCs +FGF-2/TGF-B2
Gig j a g g e d - 2
B
FGF-2 & TGF-beta 2 Percentage of Positive cells
Gig Notch- Delt Jagged
Younq Bovine Chondrocvtes 0.9 98.40 84.7 44.10
P1 BMSCs (1) 0.3 89.10 69.8 97.50
P1 BMSCs (2) 0.4 99.70 99.0 99.70
P1 BMSCs (3) 0.6 77.30 74.1 76.10
P1 BMSCs (4) 0.5 79.30 39.2 81.70
Average 0.4 86.35 70.5 88.75
Std Dev 0.1 10.29 24.5 11.64
Std Error 0.0 5.14 12.2 5.82
P2 BMSCs (1) 0.6 70.50 2.00 1.10
P2 BMSCs (2) 0.4 97.90 95.8 97.70
P2 BMSCs (3) 0.0 0.00 0.00 0.00
P2 BMSCs (4) 0.5 99.00 94.2 95.50
Average 0.3 66.85 48.0 48.58
Std Dev 0.2 46.48 54.2 55.46
Std Error 0.1 23.24 27.1 27.73
Figure 5.13: Expression of Notch-1, Delta and Jagged-2 are plotted on a histogram (Panel A) and 
Panel B is a table to summarise the data.
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Goat IgG -ve 
1:2000
Notch 1 (C-20) 1:40 Delta (F-15) 1:40 Jagged 2 (N-19) 
1:40
Figure 5.14: Cell smear images on PI BMSCs after trypsinisation cultured in serum 
containing medium with the addition of 5ng/ml FGF-2 and 5ng/ml TGF-/8 2. DAPI was 
used as a counter stain (shown in red) for staining the nucleus, FITC staining is shown as 
green. Scale bar is at 2pm, images taken at x40 magnification
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Goat IgG -ve 1:2000 Notch 1 (C-20) 1:40 Delta (F-15) 1:40 Jagged 2 (N-19)
1:40
Figure 5.15: Cell smear images on P2 BMSCs after trypsinisation cultured in serum 
containing medium with the addition of 5ng/ml FGF-2 and 5ng/ml TGF-/8 2. DAPI 
was used as a counter stain (shown in red) for staining the nucleus, FITC staining is 
shown as green. Scale bar is at 2pm, images taken at x40 magnification
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5.4.5 Gene expression of SOX-9, aggrecan, collagens type I and II by PI and P2 BMSCs 
cultured in the presence of 5ng/ml FGF-2 and in combination with 5ng/ml TGF-02
After trypsinisation of PI and P2 BMSCs, small aliquots containing lxlO6 cells were taken for 
the analysis of the commonly reported chondrogenic marker genes, namely SOX-9, aggrecan 
and collagens type I and II at the mRNA level. As a comparison, RNA was also harvested from 
young (7 days) and old (18 months) bovine articular cartilage and young bovine bone marrow. 
The quality and quantity of RNA harvested from tissues and lxlO6 cells from PI and P2 BMSCs 
cultured in the presence of FGF-2 and in combination with TGF-p2 were measured using a 
Nanodrop. The results are summarised in Table 5.10 and 5.11.
Samples 260/280 ratio RNA (ng/pl)
Young Bovine Articular Cartilage 2.08 288
Old Bovine Articular Cartilage 2.10 141.5
Young Bovine Bone Marrow 1.97 262.4
PI BMSCs (1) 2.10 657.8
PIBMSCs (2) 2.11 257.0
PI BMSCs (3) 2.09 202.7
P2 BMSCs (1) 2.07 385.3
P2 BMSCs (2) 2.11 697.0
P2 BMSCs (3) 2.07 229.6
Table 5.10: Quality and quantity of RNA extracted from tissue samples and BMSCs at PI and 
P2 cultured in the presence of FGF-2.
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Samples 260/280 ratio RNA (ng/pl)
Young Bovine Articular Cartilage 2.08 288
Old Bovine Articular Cartilage 2.10 141.5
Young Bovine Bone Marrow 1.97 262.4
PI BMSCs - Harvest2 2.09 754.7
PI BMSCs -  Harvest3 2.08 115.3
PI BMSCs -  Harvest4 2.07 145.5
P2 BMSCs -  Harvest2 2.07 417
P2 BMSCs-Harvest3 2.10 638.9
P2 BMSCs -  Harvest4 2.09 222.8
Table 5.11: Quality and quantity of RNA extracted from tissue samples and BMSCs at PI and 
P2 cultured in the presence of 5ng/ml FGF-2 and 5ng/ml TGF-(32.
The ratio between the readings at 260 nm and 280 nm (OD260/OD280) provides an estimate of the 
purity of the nucleic acid extracted from all the unknown samples. RNA preparations for tissues 
and PI and P2 BMSCs samples have OD260/OD280 values of ~ 2.0 (± 0.1) as shown in Table 5.10 
and 5.11. The cDNA was used for quantitative PCR (qPCR) in order to assess the molecular 
expression of a series of reported chondrogenic marker genes, namely SOX-9, aggrecan and 
collagens type I and II using primers designed specifically for qPCR (refer to Chapter 3). Bovine 
GAPDH was used as a endogenous control and all genes of interest were normalised against 
GAPDH.
Mesenchymal stem cells (MSCs) at passage 1 (PI) and 2 (P2) were treated with 5ng/pl of FGF-2 
and with the addition of 5ng/pl TGF-P2. The gene expression levels for SOX-9, collagens type I 
and II, and aggrecan were examined using qPCR. GAPDH was used as an endogenous control.
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SOX-9 COL. II COL. I AGGRECAN
PI MSCs +FGF-2 (n=3) 0.000 0.000 3.096 0.010
P2 MSCs +FGF-2 (n=3) 0.000 0.000 1.436 0.001
PI MSCs +FGF-2/TGF-B2 (n=3) 0.000 0.000 0.093 0.009
P2 MSCs +FGF-2/TGF-B2 (n=3) 0.000 0.000 0.445 0.001
Table 5.12: A summary table showing the average copies of genes generated from two dimensional 
cultures of Passage 1 and 2 MSCs maintained in culture medium with 5ng/pl of FGF-2 and with the 
combined supplementation of 5ng/pl TGF-beta 2.
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Figure 5.17: Histogram showing the different expression levels of SOX-9 collagen type I, collagen type 
II and aggrecan from Passage 1 and 2 MSCs cultured in 5ng/pl of FGF-2 and 5ng/pl TGF-beta 
supplemented medium.
No expression of SOX-9 and collagen type II was detected from all the different cultures. Collagen type I 
was detected from all the cultures, the highest expression was detected from PI MSCs cultured in 
medium with the addition of 5ng/pl FGF-2 (3.096 copies). P2MSCs cultured in FGF-2 supplemented 
medium was 2.156 (3.096/1.436) times less than PI MSCs cultured in the same medium. Such decrease in 
collagen type I may be due to the effect of an increase in passage number (?). In contrast, PI MSCs 
cultured in two growth factors, FGF-2 and TGF-B2 expressed 4.785 times less than P2 MSCs cultured in 
the same medium. Equal detection of aggrecan was generated from P2 MSCs cultured in FGF-2 
supplemented and with the addition of TGF-P2 (0.001 copies). PI MSCs cultured in FGF-2 and with the 
addition of TGF-P 2 generated similar expression of aggrecan of 0.01 and 0.009 copies, respectively.
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This study suggested that culturing MSCs in one or two growth factors do not elevate or influence the 
expression of SOX-9, collagens type I and II, and aggrecan. Early passage number and one passage 
difference did not have much influence on varying the expression levels of the genes of interest. The 
purity and the size of the qPCR products were verified by the dissociation curve summerised in Figure 
5.19.
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SOX;
Collagen Type
Collagen Type I
Figure 5.19: Dissociation curves on GAPDH (housekeeping gene), SOX-9, aggrecan, 
collagens type II and I. Young Bovine Bone Marrow (Grey), Old Bovine Articular Cartilage 
(Blue), Young Bovine Articular Cartilage (Maroon Red), PI BMSCs +FGF-2 (Pale 
Turquoise), PI BMSCs +FGF-2 TGF-B2 (Green), P2 BMSCs +FGF-2 (Mustard Yellow), P2 
BMSCs +FGF-2 TGF-B2 (Purple), Water NTC (Orange).
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5.5 DISCUSSION
The aim of the work described in this chapter was to understand the effect of the addition of 5 
ng/ml FGF-2 in serum-containing medium on the differentiation of sub-cultured BMSCs towards 
a chondrogenic phenotype.
Subculturing BMSCs from PI to P2 in the presence of FGF-2 appeared to reduce the growth rate 
of both PI and P2 BMSCs. Our data shown that cells cultured in FGF-2 and with the addition of 
TGF-p2, cells were evenly distributed and no formation of cell foci was formed. In FGF-2, PI 
BMSCs appeared to be more fibroblastic than P2 BMSCs. Cell count obtained was higher from 
PI than P2 BMSCs cultured in either FGF-2 or with the addition of TGF-p2. The cell number 
obtained was generally higher from BMSCs cultured in FGF-2/TGF-p2 than in FGF-2 alone. 
From these data, it has suggested that culturing BMSCs in the presence of two growth factors 
gave an increased number of cells per flask, i.e. increased cell proliferation.
Previous studies by Walsh et al, have used FGF-2 for cell expansion, and shown it to enhance 
the osteogenic potential of adult human-derived BMSCs (Walsh et al, 2000). In contrast, 
Mastrogiacomo’s and Hardingham’s groups proposed that FGF-2 helps to select for a cell 
population with chondrogenic potential from the total stem cell population (Bianchi et al., 2003; 
Hardingham et al., 2006). Furthermore, Stewart et al., illustrated that culturing of equine BMSCs 
with FGF-2 enhances subsequent chondrogenesis in a three dimensional culture system, as well 
as significantly increasing DNA and GAG content, indicating increased cell proliferation 
(Stewart et al., 2007). Stewart et al., showed that seeding PI MSCs at a low cell density (10,000 
cells / cm2) enhances chondrogenesis in a three dimensional culture system (Stewart et al, 
2007). Both Mastrogiacomo and Stewart’s group agreed that FGF-2 had no effect on colony 
formation, however, FGF-2 markedly increased the cell proliferative potential. Worster et al, 
demonstrated that treatment of cells with FGF-2 increased the expression of the developmental 
marker STRO-1 and alkaline phosphatase (AP), a major marker for osteoblast lineage (Worster 
et al, 2001). Interestingly, supplementation with ascorbate, or the combined use of FGF-2 with
dexamethasone, modulates the effect of FGF-2 on AP expression and consequently the lineage 
which the stem cells will differentiate into. This suggests that since in this study FGF-2 was not 
used in conjunction with another ‘FGF-2 effector’, such as ascorbate or dexamethasone, no 
effects on protein expression were observed. Cell morphology observed in the current study 
replicated previous published data (Murdoch et al., 2007). Solchaga et al., has previously shown 
that in the absence of FGF-2, MSCs appeared to be flatter, polygonal and more spread out than 
MSCs cultured in the presence of FGF-2, which gave a smaller, spindle-like fibroblastic 
morphology (Solchaga et al., 2005). It is interesting to note that as well as FGF-2, recently, FGF- 
18 has also been shown the ability to promote chondrogenesis of MSCs (Davidson et al., 2005). 
Grayson et al., illustrated that sub-culturing human-derived MSCs in the absence of any growth 
factors is sufficient to maintain the viability of MSCs. But oxygen tension, as well as growth 
factors, contributes to the behaviour of MSCs influencing their final differentiation lineage 
(Grayson et al., 2006).
FACs analyses showed positive staining of Notch-1, Delta and Jagged-2 from PI and P2 BMSCs 
cultured in FGF-2 or with the addition of TGF-p2. PI BMSCs cultured in FGF-2 or with the 
addition of TGF-p2 have similar pattern on the percentage of positive cells for the three proteins 
of interest. The pattern was, Jagged-2 > Notch -1 > Delta. In contrast, P2 BMSCs cultured in 
FGF-2 have a pattern of: Jagged-2 > Notch -1 > Delta. P2 BMSCs cultured in FGF-2 and TGF- 
P2 have a pattern of Notch -1 > Delta > Jagged-2. These imply that PI and P2 BMSCs both 
express these three proteins, but the different pattern observed from P2 BMSCs in comparison to 
PI BMSCs suggested that the passage number may have an influence on the expression of these 
proteins. On the other hand, the culturing conditions (i.e. FGF-2 or with the addition of TGF-P2) 
did not appear to contribute to the expression of these proteins.
Collagen type I was highly expressed by PI and P2 MSCs cultured in FGF-2 alone or with the 
addition of TGF-p2. The order of expression was PI MSCs +FGF-2>P2MSCs+FGF- 
2/TGFp2>P2MSCs+FGF-2/TGFp2>P 1 MSCs+FGF-2/ TGF02. SOX-9, collagen types II and
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aggrecan were not highly expressed. These data suggested that the culturing conditions used to 
maintain MSCs at PI and P2 did not contribute to the expression of these genes.
5.6 SUMMARY
o Cell morphology was similar to primary isolated cells but no colonies or cell foci were 
formed.
o The use of two growth factors showed an increase in the number of cells per flask, which 
implies that two growth factors enhanced cell proliferation of BMSCs in a bovine model.
o The different protein expression pattern observed from P2 BMSCs suggested that this 
change may be influenced by passage number rather than by the addition of one or two 
growth factors.
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CHAPTER 6:
INVESTIGATING THE CHARACTERISTICS OF TISSUE 
GRAFTS PRODUCED FROM PASSAGED BOVINE BONE 
MARROW DERIVED STEM CELLS USING A TRANSWELL 
CULTURE SYSTEM
6.1 Introduction
The objective of this chapter was to determine if passaged BMSCs harvested at P2 and P3 are 
capable of forming a tissue graft when cultured in defined chondrogenic medium using the 
Transwell culture system (Kandel et al.,., 1995). The purpose of exposing BMSCs to 
chondrogenic medium was to determine if this would further differentiate the passaged BMSCs 
towards a chondrogenic lineage, by causing the cells to produce an extracellular matrix 
resembling hyaline cartilage, thus allowing them to be used as a cell-based strategy for cartilage 
repair.
Adult mesenchymal stem cells (b-MSCs) are basic cells that have the unique ability to self- 
renew and under certain conditions, differentiate multi-potentially into specialized cells such as 
cartilage, muscle and bone (Ashton et al., 1980; Ferrari et al., 1998; Jiang et al, 2002). Their 
unique ability to repair and regenerate tissues, plus their ready availability from a variety of 
tissue sources make them an attractive candidate for tissue engineering of connective tissues 
such as articular cartilage. Damaged articular cartilage has a limited capacity for self repair and 
often the repaired tissue has a fibrocartilaginous phenotype, which does not possess the 
properties of native normal healthy articular cartilage (Hunziker 2000; Hunziker 2001). 
Currently, limited treatments are available for cartilage repair due to increase prosthesis failure. 
This limits the treatment that can be carried out for individuals under the age of 50 therefore, a
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desirable treatment for repairing and regenerating cartilage lesions is the use of cell-based 
strategies, rather than the usual methods of debridement, abrasion, perichondral grafting and 
mosaicplasty (Hunziker 2001). Tissue engineering of cartilage using a cell-based strategy, such 
as autologous chondrocyte transplantation (ACT; Kim et al., 2003) is a recent novel approach to 
cartilage repair. Commonly, an autologous cell source, normally primary chondrocytes, are used 
however, MSCs have now become a viable alternative. The cells are usually expanded in culture 
until sufficient cells are obtained. The cells are then delivered into the defected area and 
localised by a suitable method.
Typically, MSCs are harvested from bone marrow, followed by cell expansion in high glucose 
DMEM medium containing foetal bovine serum (FBS) or in high glucose DMEM medium 
supplemented with growth factors, such as FGF-2, which has been shown to select for a cell 
population of b-MSCs that has an increased chondrogenic potential (Bianchi et al.,. 2003). 
Usually, MSCs are passaged, until the required cell number or passage number is achieved 
before being seeded into a chosen culture system where they are maintained in a medium 
containing all the necessary factors for MSCs to differentiate towards a chondrogenic lineage. 
However, prolonged passaging may result in cell senescing and losing their differentiation 
potential (Digirolamo et al., 1999).
Many previous studies (refer to Chapter 1 Section 1.4.1) have indicated that a range of 
cytokines, growth factors and different culture methods contribute to the chondrogenic 
differentiation of b-MSCs. However, most of these data are based on studies using pellet or 
micromass culture systems, which do not show the in vivo organization evident in native bovine 
articular cartilage. Recent studies have demonstrated the use of a Trans well culture system to 
generate a cartilage-like tissue graft using young bovine articular chondrocytes in DMEM 
supplemented with 20% FBS, 5pg/ml TGF-beta 2 and 100 jug/pl ascorbic acid over a 4 week
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culture period (Kandel et al, 1995; Hayes et al., 2007). Such cartilage grafts have been shown to 
produce varying zonal morphology, resembling those observed in native cartilage (Hayes et al, 
2007). Recently, Hardingham and colleagues have illustrated the use of the Transwell system to 
form a cartilage-like tissue graft using human MSCs (hMSCs) in vitro (Murdoch et al, 2007).
This chapter describes the culture of young bovine bone marrow MSCs (Bb-MSCs) using the 
Transwell system. Briefly, Bb-MSCs were expanded in culture, seeded into inserts at passages 2 
and 3 (P2 and P3, respectively), and maintained for 4 weeks in chondrogenic medium (CM), 
(containing TGF-P3 and dexamethasone [refer to Methods Section for details]). The tissue grafts 
produced were characterized using a range of analytical methods as follows:-
• Determined the wet mass of the tissue grafts produced
• Compared the phenotype of successful versus unsuccessful grafts and related this to the 
initial phenotypic state of the cells before seeding into the Transwell system
• Histological analyses were also carried out to assess the PG and collagen type II and type 
X contents within the matrix of the grafts produced.
• The GAG content of the outer and insert media were analyzed to assess the GAG release 
profile of the tissue grafts produced
• Analyzed the molecular expression of GAPDH as the endogenous control, investigate the 
expression of cartilage-related genes, SOX-9, aggrecan and collagen type II, and used 
collagen type X as a marker for osteogenesis.
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6.2 Materials
Dulbecco’s Modified Eagle Medium (DMEM), foetal Bovine Serum (FBS), gentamicin and lOx 
Trypsin / EDTA were purchased from Gibco, Paisley, UK. Basic fibroblast growth factor 
(bFGF), type II collagen from chick sternum, and ascorbate were purchased from Sigma-Aldrich, 
Poole, Dorset, UK. Pronase from Streptomyces griseus was obtained from Roche Applied 
Science, Lewes, East Sussex, UK. Collagenase type II from Clostridium histolyticum was 
obtained from Worthington, Reading, Berkshire, UK. Millipore filter inserts was purchased from 
Millipore (U.K.) Limited, Watford, England, UK. Transforming growth factor beta 2 (TGF-p2) 
was obtained from Peprotech EC. Ltd., London, UK. All plastic wares were obtained from 
Greiner Bio-one, Stonehouse, Gloucestershire, UK and Coming Ltd., Artington, Surrey, UK.
6.3 Methods
6.3.1 Extraction of Bone Marrow and Isolation of Bb-MSCs
Bone marrow was extracted from 7 day old bovine, metatarsel bone several hours after slaughter. 
One end of the bone was sawed open under sterile condition and a small amount of exposed bone 
marrow was removed. The unexposed marrow was scooped out using a surgical spatula and 
transferred to a pre-weighed Petri dish.
The extracted bone marrow was dispersed using 50 ml of sterile semm free DMEM containing 
0.05 mg/ml gentamicin and transferred to a sterile 50 ml centrifuge tube and inverted gently. The 
tube was allowed to stand until all the fatty deposits had floated to the top, the fatty deposits 
were filtered through a 0.4 jam cell strainer placed over a sterile 50 ml centrifuge tube and 
discarded. A filtrate was obtained and was centrifuged at 200 x g for 5 minutes and the 
supernatant was removed gently, leaving behind a red cell pellet. The cell pellet was resuspended 
in 40 ml of Basic Medium (DMEM containing 0.05 mg/ml gentamicin and 10% (v/v) heat-
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inactivated FBS). The 40 ml of cell suspension was seeded at equal volume into two T-75 cm2 
vented flask and incubated at 37°C with 5% carbon dioxide (CO2) for 4 days to allow the cells to 
adhere. The media was changed on the fourth day and the cells were washed in serum free media 
to remove any non-adherent cells. The cells were fed every 2 days with 20ml of Basic Medium 
until day 8 . When the cells reached confluence they were trypsinized and passaged until the 
target cell number was reached. On day 8 , the Basic medium was supplemented with 5ng/ml of 
FGF-2.
6.3.1.1 Passaging Bb-MSCs
When the Bb-MSCs reached confluency, they were washed three times using 10 ml serum free 
DMEM containing 0.05 mg/ml gentamicin with gentle agitation. The Bb-MSCs were 
photographed and then trypsinised by adding 2ml of lx (v/v) Trypsin / EDTA to each T-75 cm2 
vented flask. They were then incubated at 37°C until the cells started to detach from the bottom 
of the flask. 10ml of cell suspension was transferred to a sterile 50 ml centrifuge tube containing 
30ml of Basic medium and centrifuged at 200 x g for 5 minutes. The cell pellet was resuspended 
in 10 ml of basic medium and the cells were counted using a haemocytometer. Cells were plated 
into T-75 cm2 vented flask at 6  x 106 cells per flask (33% confluent) for further expansion.
6.3.2 Dissection of cartilage and isolation of chondrocytes
Cartilage was dissected from seven day old bovine metacarpophalangeal (MCP) joints obtained 
from a local abattoir. After washing, the feet were skinned, and the joint was opened under 
sterile conditions in a laminar flow hood. Full depth articular cartilage was removed from the 
joint using a sharp scalpel blade and was transferred to a tube containing 30 ml of DMEM 
containing 0.05 mg/ml gentamicin and 10% (v/v) FBS (Basic Medium).
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Cartilage pieces harvested from MCP joint were digested in 0.1 % (w/v) pronase (at 7.5 ml per 
given weight of tissue) for 3 hours at 37°C with gentle mixing followed by overnight digestion in 
300U / mg (120,000 U / 100ml) collagenase type II. The digested cell suspension was filtered 
through a cell strainer (4 pm pore size) to remove any undigested debris. Cell suspensions were 
pelleted by centrifugation at 200 x g for 5 minutes and resuspended in 10 ml of basic medium 
and the cell number counted using a haemocytometer. Cells were plated into T-75 cm2 vented 
flask.
6.3.2.1 Passaging o f chondrocytes
When chondrocytes reached confluency, they were washed three times using 10 ml of serum free 
DMEM containing 0.05 mg/ml gentamicin with gentle agitation, and subsequently 
photographed. Cells that were left for 4 days or more were treated with 300 U / mg of 
collagenase type II for 5 minutes at 37°C followed by three washes in serum free medium. 
Chondrocytes were trypsinised using 2 ml of lx (v/v) Trypsin/EDTA per T-75 cm2 vented flask, 
and incubated at 37°C until they were detached from the bottom of the flask. 10 ml of cell 
suspension was transferred to a sterile 50 ml centrifuge tube containing 30 ml basic medium, and 
centrifuged at 200 x g for 5 minutes. The cell pellet was resuspended in 10 ml of basic medium 
and the cells were counted using a haemocytometer. Cells were plated at low cell density ( 6  x 
106 cells per flask, 33% confluent) for further expansion.
6.3.3 Seeding Bb-MSCs and chondrocytes in Transwell inserts
Briefly, the filter insert are placed into individual wells of a 24 well plate, coated with chick type
II collagen (in 0.1 N acetic acid), dried overnight under sterile conditions, UV irradiated for 10
minutes and washed extensively with serum free DMEM before cell seeding. When the
appropriate passage number was obtained from the monolayer expansion, the Bb-MSCs and
chondrocytes were detached using methods described in Sections 3.3.1.1 and 3.3.2.1
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respectively, pelleted, resuspended in fresh media and counted. Cells were then resuspended in 
an appropriate volume of DMEM plus 0.05 mg/ml gentamicin and 20% (v/v) heat inactivated 
FBS. The cells were seeded at 12 x 106 cells per 500 pi into filter inserts pre-coated with 0.5 
mg/ml chick type II collagen. After seeding, the cells were incubated at 37°C for 5 minutes 
before adding 600pi of DMEM containing 0.05 mg/ml gentamicin and 20% (v/v) FBS to the 
outer chamber (see Figure 3.1).
These high cell density cultures were maintained for 4 weeks in two different media: i) 
maintaining medium (MM), composed of DMEM (with 4.5 g/L glucose, L-glutamine, no sodium 
pyruvate) containing 0.05 mg/ml gentamicin, 20% (v/v) FBS, 5 pg/ml TGF-p2 and 100 pg/ml 
ascorbate (sodium salt), and ii) chondrogenic medium (CM) that has DMEM (with 4.5 g/L 
glucose, L-glutamine, no sodium pyruvate) containing 0.05 mg/ml gentamicin, 50 pg/ml 
ascorbic acid 2-phosphate (magnesium salt), 40 pg/ml L-proline, lOOnM dexamethasone, 10 
ng/ml TGF-P3 and 1% (v/v) ITS+1. The outer and inner media was replaced three times a week 
(600 pi in the outer and 400 pi in the inner wells (refer to figure 6.1).
At the end of the culture period, the grafts produced were harvested, weighed and subdivided for 
histological (refer to Chapter Two, Section 2.2.1.1), immuno-histochemical (refer to Chapter 2, 
Section 2.2.1.2), biochemical (refer to Chapter Two, Section 2.2.2) and molecular (refer to 
Chapter Two, Section 2.2.3) analyses, summaries in Figure 3.1b.
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Pre-coated Filter membrane with chick 
type II collagen
- 0.6 cm 2 growth area; 0.4 |iim pore size
Filter insert (inner)
-containing 6 x 106 cells
Culture well (outer)
-containing 600pl of media
Figure 6.1 Diagram showing the layout of a typical Transwell culture system
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6.4 Results:
6.4.1 Analysis of chondrogenic differentiation of passaged bovine BMSCs in Transwell 
cultures
Passaged bBMSCs obtained from P2 and P3 (refer to Chapter 4 and 5) were seeded into 
Transwell cultures at high (6x106 cells per filter) and low (0.5x106 cells per filter) density. Lower 
seeding density appeared to have a higher overall successful graft production rate using P2 and 
P3 BMSCs pre-cultured in the presence of FGF-2 with and without the addition of TGF-p2 
during monolayer expansion, as shown in Table 6.1. In contrast, when P2 and P3 BMSCs were 
seeded using a higher cell density of 6 x l 0 6 cells, a lower successful graft production was 
observed. Typical successful and unsuccessful grafts are shown in Figure 6.2, Panels E and F, 
respectively. The morphology of P2 and P3 BMSCs cultured in FGF-2 and in the presence of 
TGF-beta 2 are shown in Figure 6.2, Panels A-D, which allow us to distinguish any obvious 
difference in cell morphology that may contribute to successful graft production.
The wet weight of the grafts derived from high and low seeding cell density were recorded and 
are shown in Figure 6.3 and 6.4, respectively. The wet weight of the grafts produced was 
compared to grafts produced by young and old bovine chondrocytes with the same cell seeding 
densities. MSCs pre-cultured in FGF-2 with the addition of TGF-p2 were able to produce tissue 
grafts than MSCs pre-cultured in FGF-2. The passage number of BMSCs (either P2 or P3) did 
not affect the generation of a tissue graft. However, the seeding cell density appeared to affect 
the weight of tissue grafts produced. At 6xl06 cells/well, grafts produced using cells pre-cultured 
in FGF-2 were lighter than grafts produced by cells pre-cultured in FGF-2 with the addition of 
TGF-P2. A similar pattern was observed from tissue grafts generated using 0.5x106 cells/well. 
From Harvest3 (replating density of 0.2 xlO6 cells), grafts produced using P3 BMSCs pre- 
cultured in FGF-2 was approximately 4 times heavier than those produced using P2 BMSCs. No 
grafts were produced using P3 BMSCs passaged in FGF-2/TGF-P2, 12 times heavier grafts were 
produced by P2 BMSCs passaged in FGF-2/TGF-P2. In contrast, from Harvest 4 (with a
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Fraction olF successful graft
P2 +FGF-2 P3 +FGF-2 P2 +FGF-2/TGF-B2 P3 +FGF-2/TGF-B2
6 x l0 6 (0 .2 x 10 6) 0 /1 0/4 0/4 not enough cells
6xl06 (0.4x106) not enough cells not enough cells 0 /2 0/4
6x106 (50%) 3/3* not enough cells 0 /6 not enough cells
0.5x106 (0.2x106) 1/1 0/4* 4/4 2 /2
0.5xl06 (0.4x106) 2 /2 2 /2 2 /2 4/4
0.5xl06 (50%)
* hard cell lump
* characterised by staining
Table 6.1: Overall successful grafts produced using different initial seeding cell density. * represents the presence of a hard 
cell lump after 4 weeks of culture.
* indicates that the graft has been characterised by staining.
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Figure 6.2: Cell morphology for P2 and P3 BMSCs cultured in the presence of 5 ng/ml FGF-2 alone (Panels A and B) and with the 
addition of 5 ng/ml TGF- p2 (Panels C and D). The grafts produced using the Transwell culture system were photographed as shown 
in Panel E, indicating a successful graft production and Panel F shows the morphology of an unsuccessful grafts with a transparent 
filter membrane attached to it for support.
Lump of cell
mbrane
replating density of 0.4 xlO6 cells), no grafts were obtained using P2 and P3 BMSCs pre-cultured 
in FGF-2. BMSCs passaged in the presence of both FGF-2/ TGF-p2 is able to produce tissue 
grafts. P2 BMSCs generated grafts weighed twice as much than P3 BMSCs generated grafts. In 
conclusion, the use of a lower seeding cell density per Transwell insert (0.5x106 cells/well) and 
BMSCs pre-cultured in the presence of FGF-2 and TGF-P2 generated a more successful tissue 
graft than using 6xl06 cells/well and BMSCs pre-cultured in FGF-2.
Similar patterns were observed from young and old bovine chondrocyte grafts seeded at 0.5 xlO6 
cells/well, however, their weights were 16 and 3 times less (respectively) than those produced 
using 6xl06 cells. P2 and P3 BMSCs pre-cultured in FGF-2/ TGF-p2 from Harvests 3 and 4 all 
produced grafts with similar weights as shown in Figure 6.3 Panel A. However, BMSCs that 
were pre-cultured in FGF-2 also produced graft except harvest 4, P2 BMSCs, and Figure 6.3 
Panel B. From harvest3, P2 BMSCs grafts were 5 times heavier in mass than those produced 
using P3 BMSCs, and the opposite was observed from harvest 4 graft production can only be 
seen using P3 BMSCs, but not with P2 BMSCs.
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A 6 x l0 6 cells/insert (+FGF-2)
Average Std Error
6 x l0 6cells/insert ( + FGF-2/TGF-B2)
Average Std Error
Young Bovine chondro graft  in CM 16.8 0.46 Young Bovine chondro graft in CM 16.8 0.46
Old Bovine chondro graft  in CM 6.25 0.35 Old Bovine chondro graft in CM 6.25 0.35
Harvest 3 P2BMSCs 0.8 0 Harvest 3 P2BMSCs 12.83 0.98
Harvest 4 P2BMSCs 0 0 Harvest 4 P2BMSCs 3.9 0.5
Harvest 3 P3BMSCs 4.43 1.4 Harvest 3 P3BMSCs 0 0
Harvest 4 P3BMSCs 0 0 Harvest 4 P3BMSCs 1.55 0.13
B Cells seeded at 6x10 cells / insert
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Figure 6.3: Graft weight obtained from plating 6 xlO6 cells into each of the Transwell system. The average weights and standard errors for 
grafts cultured using chondrocytes derived from young bovine articular cartilage (n= 6), old bovine articular cartilage (n= 6) and from P2 
and P3 BMSCs were tabulated (Panel A) and the overall results were plotted on a histogram (Panel B). Note that these results are based on
Os
harvests 3 and 4 (refer to Chapter 4 and 5 for details).
A
0.5x10® cells/insert ( + FGF-2)
Average Std Error
0.5xl0® cells/insert (+FGF-2/TGF-B2)
Average Std Error
Young Bovine chondro graft in CM 1.3 0.1 
Old Bovine chondro graft  in CM 2.7 0 
Harvest 3 P2BMSCs 6.6 0 
Harvest 4 P2BMSCs 0 0 
Harvest 3 P3BMSCs 1.4 0 .12 
Harvest 4 P3BMSCs 3 0.4
Young Bovine chondro graft  in CM 1.3 0.1 
Old Bovine chondro graft in CM 2.7 0 
Harvest 3 P2BMSCs 5 0 .62  
Harvest 4 P2BMSCs 6 .2  0 
Harvest 3 P3BMSCS 5.1 0.6 
Harvest 4 P3BMSCS 5.7 0 .18
B Cells seeded at 0.5x10 cells/insert
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Figure 6.4: Graft weight obtained from plating 0.5 xlO6 cells into each of the Transwell system. The average weights and standard errors for 
grafts cultured using chondrocytes derived from young bovine articular cartilage (n= 6), old bovine articular cartilage (n= 6) and from P2 
and P3 BMSCs were tabulated (Panel A) and the overall results were plotted on a histogram (Panel B). Note that these results are based on 
harvests 3 and 4 (refer to Chapter 4 and 5 for details).
6.4.2 Analysis of sulphated GAG release from media obtained from passaged BMSCs in 
Transwell culture system
The amount of sulphated GAG released to the medium collected at weekly intervals from 
passaged BMSCs transwell cultures was determined using the Dimethyl Methylene Blue 
(DMMB) assay. The GAG concentration was measured in the media, but not in the matrix of the 
transwell cultures due to a shortage of successful grafts formed.
The GAG content of both outer and insert media was plotted on stacked column histograms for 
P2 and P3 BMSCs expanded in the presence of FGF-2 with and without the addition of TGF-p2 
(refer to Chapter 4 and 5, respectively). No differences were observed in the GAG release pattern 
between P2 BMSCs expanded in FGF-2 with or without TGF-P2 (Figure 6 .8 , the high density 
data shown in Panels A and B). The GAG release from low cell density transwell culture 
(0.5x106 cells/insert) is about 3 - 8  fold higher from high density cultures (6xl06 cells/insert) 
(Panels C and D of Figure 6 .8 ). The difference in GAG content between low and high density 
grafts is probably due to the difference in cell number. No difference was observed between P2 
BMSCs expanded in FGF-2 with or without TGF-p2. Higher GAG concentration was detected in 
the insert media than in the outer media (Figure 6 .8 ). Throughout the four weeks of culture the 
GAG release from high density cultures was similar. In contrast, in low density grafts the 
concentration of GAG release decreased with increased time in culture (Figure 6.9). No 
difference was observed in GAG release between P3 BMSCs pre-expanded in FGF-2 (Panel A, 
Figure 6.9) or FGF-2 and TGF-p2 (Panel B, Figure 6.9). In contrast, cultures generated at low 
density released higher concentrations of GAG than at high cell density grafts. However, no 
obvious trend was observed from both densities with different expansion treatments (Figure 6.9, 
Panels C and D). Due to the low number of grafts produced, no statistical analyses could be 
carried out to further investigate the difference between different passage numbers of BMSCs, 
different plating density and different expansion treatment and their effects on GAG release. Our
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GAG analyses showed that a higher GAG level was detected from low density tissue graft than 
high density tissue graft.
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Figure 6.12: GAG contents obtained from high and low density Transwell cultures produced from Passage 2 (P2) BMSCs. 
Comparisons were made between P2 BMSCs pre-expanded in the presence of FGF-2 alone and with the addition of TGF- 
beta 2 to investigate their possible effects on graft formation using the Transwell system.
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Figure 6.13: GAG contents obtained from high and low density Transwell cultures produced from Passage 3 (P3) BMSCs. 
Comparisons were made between P2 BMSCs pre-expanded in the presence of FGF-2 alone and with the addition of TGF- 
beta 2 to investigate their possible effects on graft formation using the Transwell system.
6.4.3 Expression of cartilage-specific genes from BMSCs tissue grafts produced using 
Transwell culture system
Quantitative PCR was used to assess the molecular expression of transwell culture graft after 28 
days. Levels of cartilage-specific gene expression were determined for SOX-9, aggrecan and 
collagen type II, whilst collagen type X was used as a marker for hypertrophic chondrocytes and 
subsequent mineralisation. For each gene, a standard curve was prepared from a dilution series 
of pDNA containing one of the genes of interest (refer to Chapter 3). The standard curves 
produced were set up the same time as the unknown samples for comparison (refer to Chapter 3, 
Table 3.9 and 3.10). Bovine GAPDH was used as the endogenous control. Table 6.1 summarizes 
the efficiency and R values obtained from each standard curve.
Genes Efficiency (%) R2 values
GAPDH 88.4 0.995
SOX-9 99.7 1.000
Aggrecan 66.5 0.801
Collagen type II 92.9 0.996
Collagen type X 92.9 0.996
Table 6.1: Summary of the efficiency and R2 values generated from qPCR reaction for each 
gene
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H igh density Low density
G APDH
SOX-9
Aggrecan
Collagen type II
Collagen type X
-
Figure 6.10 summaries the dissociation curves of the qPCR data obtained from high 
(6xl06 cells) and low (0.5x106 cells) density tissue grafts using primer pairs designed for 
different genes of interest (left).
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6.4.2.1 High density grafts produced using P2 and P3 BMSCs pre-cultured in FGF-2
SOX-9 COL. I I COL. I COLX AGGRECAN
P2 MSCs +FGF-2 (n=2) 0.003 9.176 32.068 0.071 24.525
P3 MSCs +FGF-2 (n=2) 0.002 0.070 3.230 0.003 2.121
P2 MSCs +FGF-2/TGF-B2 (n=2) 0.016 3.392 3.924 0.015 8.300
P3 MSCs +FGF-2/TGF-B2 (n=7) 0.090 129.853 44.831 0.005 257.411
Table 6.3: A table showing the average copies of expression of SOX-9, Collagen type II, 
Collagen type I, Collagen type X and aggrecan from P2 and P3 MSCs-derived grafts. Each graft 
was produced using 6xl06 cells per Transwell. The number of replicates is indicated in the first 
column of the table.
3 0 0 .0 0 0
■ P2 MSCs +FGF-2
■  P3 MSCs +FGF-2
■  P2 MSCs +FGF-2/TGF-B2
■ P3 MSCs +FGF-2/TGF-B2
Figure 6.5: A graphical summary of the gene expression levels for SOX-9, Collagen type I, II and X and 
aggrecan from P2 and P3 MSCs pre-cultured in the either 5ng/pl of FGF-2 alone or in combination with 
5ng/pl ofTGF-(32. Each graft was produced using 6xl06 cells per Transwell.
The highest detection of SOX-9 was generated from P3 MSCs pre-cultured in FGF-2/TGF-p2 medium 
with 0.090 copies. P2 MSCs pre-cultured in the same culture medium was 5.625 times (0.090/0.016) less 
than P3 MSCs. In contrast, the levels of SOX-9 expression detected from P2 and P3 MSCs pre-cultured in
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FGF-2 alone was 30 times (0.090/0.003) and 45 times (0.090/0.002) less than that of P3 MSCs pre- 
cultured in FGF-2/TGF-p. This suggested that pre-culturing MSCs in two growth factors gave a higher 
expression of SOX-9 than those cultured in only one growth factor. P3 MSCs pre-cultured in FGF- 
2/TGF-p2 generated the highest detection of Collagen type II, of 129.853 copies. P2 MSCs pre-cultured 
in the same culture medium was 38.282 times (129.853/3.392) less than the expression generated from P3 
MSCs. However, when MSCs were pre-cultured in FGF-2 alone, a higher expression of Collagen type II 
was detected from P2 MSCs than P3 MSCs. The difference of collagen type II expression between P2 
MSCs and P3 MSCs pre-cultured in FGF-2 alone was 131.086 times higher (9.176/0.070). This indicates 
that pre-culturing MSCs in two growth factors gave a higher expression of Collagen type II than those 
cultured in just one growth factor. The highest detection of collagen type I was generated from P3 MSCs 
pre-cultured in FGF-2/TGF-(32 of 44.831 copies. P2 MSCs cultured in the same culture medium 
expressed 11.425 times (44.831/3.924) less than P3 MSCs. When MSCs were pre-cultured in FGF-2 
alone, a higher expression of Collagen type I was detected from P2 MSCs (32.068 copies) than P3 MSCs 
(3.230 copies). The difference between these two passage numbers of MSCs was 9.928 times 
(32.068/3.230). This suggested that P3 MSCs pre-cultured in two growth factors generated a higher 
expression of Collagen type I than MSCs pre-cultured in one growth factor alone. Overall, the expression 
of collagen type X from all the grafts produced using either P2 or P3 MSCs pre-cultured in FGF-2 alone 
or in FGF-2/TGF-p2 medium was low. Collagen type X was expressed the most from P2 MSCs pre- 
cultured in FGF-2 alone (0.071 copies). P3 MSCs pre-cultured in FGF-2 alone was 23.667 times 
(0.071/0.003) less than that expressed by P2 MSCs pre-cultured in the same culture medium. A three-fold 
expression difference was observed between P2 MSCs and P3 MSCs pre-cultured in FGF-2/TGF-|32 
medium. These suggested that there is a low expression of collagen type X from all the cultures. A 
decrease in collagen type X was observed with increase passage number (one passage number difference). 
No obvious differences were observed between MSCs cultured in FGF-2 alone or in FGF-2/TGF-02. 
Aggrecan was highly expressed by P3 MSCs pre-cultured in FGF-2/TGF-p2 medium with 257.411 
copies. P2 MSCs pre-cultured in the same culture medium was 31.013 times (257.411/8.3) less than that 
detected from P3 MSCs. A reverse pattern of aggrecan expression was observed from MSCs pre-cultured 
in FGF-2 alone. P2 MSCs pre-cultured in FGF-2 alone was 11.563 times higher than P3 MSCs. These
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suggested that the expression of aggrecan was more favourable in MSCs pre-cultured in the presence of 
two growth factors. An increase in passage number appeared to generate a higher expression of aggrecan.
6.4.2.3 Low density grafts produced using P2 and P3 BMSCs pre-cultured in FGF-2
SOX-9 COL I I COL I COL X AGGRECAN
P2 MSCs +FGF-2 (n=3) 0.012 17.223 1.280 0.016 179.582
P3 MSCs +FGF-2 (n=9) 0.207 1.784 4.085 0.017 19.906
P2 MSCs +FGF2/TGFB2 
(n—5) 0.012 1.320 3.413 3.164 11.990
P3 MSCs +FGF-2/TGF-B2 
(n-6) 0.077 5.113 2.445 1.099 52.873
Table 6.4: A table showing the average copies of expression of SOX-9, Collagen type II, 
Collagen type I, Collagen type X and aggrecan from P2 and P3 MSCs-derived grafts. Each graft 
was produced using 0.5x106 cells per Transwell. The number of replicates is indicated in the first 
column of the table.
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Figure 6.6: A graphical summary of the gene expression levels for SOX-9, Collagen type I, II 
and X and aggrecan from P2 and P3 MSCs pre-cultured in the either 5ng/pl of FGF-2 alone or in 
combination with 5ng/pl of TGF-02. Each graft was produced using 0.5xl06 cells per Transwell.
The overall expression of SOX-9 from all the cultured was low. The highest expression of SOX- 
9 was generated by P3 MSCs pre-cultured in FGF-2 alone, with 0.207 copies. P2 MSCs pre- 
cultured using the same medium was 17.25 times (0.207/0.012) less than P3 MSCs. A similar
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pattern was observed from MSCs pre-cultured in FGF-2/TGF-P2, in which P3 MSCs has a 
higher expression of SOX-9 than P2 MSCs. The difference between P2 and P3 MSCs pre- 
cultured in FGF-2/TGF-P2 was 6.417 times (0.077/0.012). This suggested that for tissue graft 
produced using 0.5x106 cells/Transwell, MSCs pre-cultured in FGF-2 alone with a higher 
passage number, in this case, P3 generated more expression of SOX-9. Collagen type II was 
expressed by all the cultures, however, P2 MSCs pre-cultured in FGF-2 alone generated the 
highest expression of 17.233 copies. P3 MSCs pre-cultured in the same culture medium was 
9.665 times less (17.223/1.782) than P2 MSCs. A reverse pattern was observed from MSCs pre- 
cultured in the presence of FGF-2/TGF-p2, in which P3 MSCs expressed 3.873 times higher than 
P2 MSCs. These suggested that pre-culturing MSCs in the presence of FGF-2 alone is more 
favourable for the expression collagen type II. The highest expression of collagen type I was 
generated by P3 MSCs pre-cultured in FGF-2 alone. P2MSCs pre-cultured using the same 
culture medium was 3.191 times (4.085/1.280) less than P3 MSCs. In contrast, a slightly higher 
expression of collagen type I was observed from P2 MSCs pre-cultured in FGF-2/TGF-p2 than 
P3 MSCs. The difference between P2 MSCs and P3 MSCs pre-cultured in FGF-2/TGF-P2 was 
1.396 times (3.413/2.445). This suggested that pre-culturing MSCs in FGF-2 alone influence the 
expression of collagen type I. The highest expression of collagen type X was generated by P2 
MSCs pre-cultured in FGF-2/TGF-p2 of 3.164 copies. P3 MSCs pre-cultured using the same 
culture medium was 2.879 times (3.164/1.099) less than P2 MSCs. A similar expression of 
collagen type X was detected from P2 and P3 MSCs pre-cultured in FGF-2 alone of 0.016 and 
0.017 copies, respectively. This indicated that the expression of collagen type X was more 
favourable when MSCs were pre-cultured in the presence of two growth factors than one. P2 
MSCs pre-cultured in FGF-2 alone generated the highest expression in comparison to other 
genes of interest. A detection of 179.582 copies was obtained from P2 MSCs pre-cultured in 
FGF-2 alone. Interestingly, a drastic reduction in the expression of aggrecan was observed from 
P3 MSCs pre-cultured under the same medium. A difference of 159.676 copies (179.582-19.906)
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was obtained, a 9.022 times difference was detected. In contrast, a higher expression of aggrecan 
was generated from P3 MSCs pre-cultured in FGF-2/TGF-P2 than P2 MSCs was observed. A 
4.4- fold difference between P3 and P3 MSCs pre-cultured in the presence of two growth factors 
was detected. This suggested that early passage number was more favourable for the expression 
of aggrecan when MSCs was pre-cultured in FGF-2 alone. However, when MSCs were pre- 
cultured in the presence of two growth factors, in this case, FGF-2 and TGF-p2, one passage 
number difference appeared to have an influence on the expression of aggrecan. These together 
indicate that the passage number and the presence of different growth factors have a combined 
influence on the expression of various chondrogenic-associated genes.
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6.5 DISCUSSION
The objective of this study was to determine if passaged BMSCs harvested at P2 and P3 are 
capable of forming a tissue graft when cultured in defined chondrogenic medium using the 
Transwell culture system (Kandel et al, 1995). The exposure of BMSCs to chondrogenic 
medium was to determine if this would further differentiate the passaged BMSCs towards a 
chondrogenic lineage, allowing the cells to produce an extracellular matrix resembling hyaline 
cartilage that can be used as a cell-based strategy for cartilage repair.
Bovine-derived BMSCs seeded into Transwell system are capable of forming a uniformly 
distributed tissue graft throughout the dried, porous polycarbonate membrane, pre-coated with 
chick collagen type II. Transwell culture filter inserts, established using inserts of 6.5 mm in 
diameter with 0.4 pm pore size polycarbonate membrane, were used by Murdoch et al., to 
produce tissue grafts using 0.5 xlO6 hMSCs per insert and cultured in chondrogenic medium 
(Murdoch et al., 2007). This study demonstrated the feasibility of forming a flexible, shallow 
tissue graft of passage 2 and 3 (P2 and P3) bovine derived BMSCs seeded at 0.5x106 cells/insert. 
However, successful grafts when formed less often when BMSCs were seeded at 6xl06 
cells/insert. Those seeded using a higher cell density appeared to fail to stay as multi cell layers, 
instead they contract to form a lump of cell mass. This may be due to the effects of residual 
serum left with the cells before resuspending in chondrogenic medium as suggested by Tew et 
al., 2008. In addition, uneven sedimentation of the BMSCs during the settling period without the 
use of centrifugation to produce more uniform cell sedimentation may cause a cell mass to form. 
The wet mass recorded from Hardingham’s group indicated an average of 20-25 mg for tissue 
grafts produced over a 4 week culture period, with a matrix composed of mainly aggrecan and 
collagen type II, which are hallmarks of chondrogenesis (Tew et al, 2008; Murdoch et al., 
2007). Our grafts produced using bovine derived BMSCs are 3-4 times lighter than those 
produced by using hMSCs as shown by Hardingham’s group (Murdoch et al., 2007). This 
difference in graft weight may be due to the use of a bovine model instead of a human model.
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Our data demonstrated that the use of a lower seeding cell density per Transwell insert (0.5x106 
cells/well) and BMSCs pre-cultured in the presence of FGF-2 and TGF-p2 generated a more 
successful tissue graft than using 6xl06 cells/well and BMSCs pre-cultured in FGF-2.
Gene expression study at high seeding density (6xl06 cells/well) suggested that pre-culturing 
MSCs in the presence of both FGF-2 and TGF-p2 favoured the expression of chndrogenic- 
associated genes such as collegn type II and aggrecan. An increase in one passage number Iso 
favours the expression of such genes. From low seeding density (0.5x106 cells/well), similar 
results were obtained. This indicated that the passage number and the presence of different 
growth factors have a combined influence on the expression of various chondrogenic-associated 
genes. In the review by Tew et al., 2008, they suggest that the addition of FGF-2 to the 
expansion medium prior to the differentiation of hMSCs in Transwell culture system improved 
the ability of hMSCs to differentiate towards a chondrogenic lineage (Tsutsumi et al., 2001; 
Bianchi et al, 2003; Bianchi et al., 2001; Solchaga et al., 2005). In contrast, our data suggested 
that the presence of FGF-2 and TGF-p2 gave a better expression of SOX-9, aggrecan and 
collagen types I and II. However, our data suggests that the addition of TGF-p2 to the expansion 
medium did not affect the differentiation process. It is interesting to note that in a human model, 
the absence of FGF-2 in the medium appeared to affect the ability of hMSCs to undergo 
chondrogenesis using the Transwell culture system, in comparison to those pre-expanded in 
medium with the addition of FGF-2. It has also been demonstrated by Hardingham’s group that 
in a human model, MSCs can be passaged continuously to at least P7 in FGF-2 supplemented 
medium (Tew et al., 2008; Bianchi et al., 2003).
In conclusion, this chapter illustrated that it is possible to generate a successful tissue graft using 
the Transwell culture system. The ideal seeding cell density is 0.5x106 cells/well, using P2 or P3 
BMSCs pre-cultured in either FGF-2 and TGF-p2. The tissue graft produced has a high 
expression level of aggrecan, collagens type I and II, which suggested that it has a fibro-cartilage 
phenotype.
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6.6 Summary
■ Low seeding cell density (0.5x106 cells/well) is able to generate more successful tissue 
graft than high seeding cell density (6xl06 cells/well).
■ BMSCs pre-cultured in FGF-2 with the addition of TGF-p2 (see Chapter 5) contributed 
to the generation of successful graft.
■ The gene expression levels of aggrecan, collagens type I, II and X and SOX-9 were 
similar between low and high cell density Transwell grafts.
■ One passage number did not influence any changes on the expression levels or the trends 
of expression.
■ Pre-culturing cells in FGF-2 and TGF-P2 did not affect the expression pattern of ggrecan, 
SOX-9 and collagens type I and II.
■ Higher GAG content was detected from tissue grafts produced using a low cell seeding 
density (0.5x106 cells/well).
6.7 Future work
■ Further examine the effect of passage number on the gene expression pattern by 
increasing the passage number to PlOor beyond
■ Use more chondrogenic markers such as Jagged-1, and -2, Notch -1 and Delta in addition 
to aggrecan, SOX-9, collagens type I, II and X, in order to further understand the lineage 
that the tissue grafts is differentiating into.
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CHAPTER 7: General Discussion
Stem cells are unspecialised cells found in the body which possess the ability to self renew and 
can be induced to proliferate and differentiate into more specialised cells. MSCs are adult stem 
cells that are capable of leaving the bone marrow and travelling in the bloodstream to a different 
site, where they may perform repair or regeneration processes of various mesenchymal tissues 
such as cartilage, bone and fat. Due to these properties of MSCs, they prove to be a useful source 
for the repair and regeneration of cartilage. Before the attempt to differentiate MSCs towards a 
particular lineage, it is important to first optimise a method for the harvesting of bone marrow 
and for the isolation of MSCs using a chosen model.
In this study, a bovine model was used. The establishment of primary cultures of BMSCs by 
adherence to tissue culture plastic of bone marrow stem cells through aspiration of bone marrow 
from the metacarpal or metatarsal phalangeal joints of young bovine calves proved to be a viable 
method for the isolation of primary BMSCs. These findings reiterate previously published 
methods by Caplan et al., 1999 and Oreffo et ah, 1997, using human and rat models, 
respectively. During extraction of the bone marrow, we discovered that there was variation in the 
bone chamber size and bone thickness, and that this influenced the amount of bone marrow and 
cells that could be harvested. The variations in chamber size could be due to many factors 
including arrival age (at abattoir), front and back leg (carpo versus tarso), breed, sex of the 
animal, and time after slaughter which may influence cell viability later on. However, these 
differences did not affect the morphology of the cells isolated or their adherence ability. These 
data suggest that freshly harvested stem cells retain their original ‘status’ despite being processed 
and washed several times, with serum free medium, prior to plating and adhering to plastic. The 
isolated BMSCs possessed a spindle-shaped fibroblastic morphology as shown previously in 
publications by Caplan & Bruder 2001, and Owen 1988. The method used to extract bone 
marrow in this study using young bovine legs was direct extraction from an open carpal or tarsal 
bone. The extracted bone marrow underwent a series of washes and was plated into culture
flasks. Primary cultures of young bovine bone marrow mesenchymal stem cells (BMSCs) were 
established by adherence to tissue culture plastic. After the initial 8 days of culture, cells were 
trypsinised and the cell number was determined. The protein expression of Notch-1, Delta and 
Jagged-2 was analysed. In addition, the gene expression of aggrecan, S OX-9, collagens type I 
and II was determined using quantitative PCR. From Chapter 3 data, it has been found that 
different chamber size and bone thickness influenced the amount of bone marrow and cells 
harvested. However, this did not affect the morphology of the cells and their adherence ability. 
The morphology of the BMSCs cultured in serum-containing medium for the initial 8 days of 
culture, possess a spindle-shaped fibroblastic morphology. This feature resembles that of other 
previously published work (Murdoch et al., 2007). Wakitani and co-workers have also recently 
studied the correlation between cell morphology and aggrecan gene expression level during 
differentiation of mesenchymal stem cells to chondrocytes using a human model. They found 
that the cell morphology of MSCs tended to change from fibroblastic-like to polygonal shape 
and such change resulted in an upregulation of aggrecan mRNA expression level during the 
differentiation of MSCs to chondrocytes (Takagi et al., 2008). FACs analyses indicated that 
undifferentiated MSCs (POBMSCs) harvested at Day 8 expressed the stem / progenitor markers 
of Notch-1, Delta and Jagged-2 These markers were previously described to be expressed on the 
surface of progenitor cells of young cartilage in a chick model (Dowthwaite et al., 2004). This 
suggested that the cells isolated initially exhibit stem cell like features. Hardingham and co­
workers recently demonstrated that Notch signalling through Jagged-1 is necessary to initiate 
MSCs to differentiate towards a chondrogenic lineage using a human model. However, the 
expression of Jagged-1 must be switched off in order to enable MSCs to complete 
chondrogenesis (Oldershaw et al, 2008). Gene expression analyses of SOX-9, aggrecan, 
collagens type I and II suggested that the primary MSCs do not contain any chondrogenic 
features.
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When POBMSCs underwent trypsinisation, they were further cultured in serum containing 
medium with the supplementation of one or two growth factors (FGF-2 or with the addition of 
TGF-p2). Many factors such as cytokines and growth factors contribute to the cellular events of 
proliferation, differentiation and maturation of cell types through binding to target cell surface 
receptors and initiating intracellular events. Several reports have shown that FGF-2 contributes 
to the selection of MSCs that are more likely to differentiate chondrogenically Bianchi et al., 
2003. Previous studies have suggested that the addition of FGF-2 during the subculture phase 
enhances the chondrogenic potential of human derived MSCs (Solchaga et al., 2005). However, 
Walsh et al., have used FGF-2 for cell expansion and have shown that FGF-2 enhanced the 
osteogenic potential of adult human-derived BMSCs (Walsh et al., 2000). These studies imply 
that the application of FGF-2 on the chondrogenic differentiation of MSCs is still controversial. 
In addition to FGF-2, TGF-p has also been found to be one of the most potent inducers of 
chondrogenic differentiation of BMSCs isolated from bone marrow in many different species 
and other tissue sources (Bosnakovski et al., 2004). Stevens et al, have demonstrated that the 
combined use of TGF-p and FGF-2 influenced perichondrium to differentiate towards a 
chondrogenic lineage (Stevens et al., 2004). Subculturing BMSCs from PI and P2 in the 
presence of FGF-2 or with the addition of TGF-P2 did not change the cell morphology. Both PI 
and P2 BMSCs possess a fibroblastic phenotype. The use of two growth factors FGF-2 with 
TGF-p2 showed to increase the number of cells per flask, which implies that the use of two 
growth factors enhanced cell proliferation of BMSCs in a bovine model. FACs analyses showed 
positive binding of Notch-1, Delta and Jagged-2 from PI and P2 BMSCs cultured in FGF-2 or 
with the addition of TGF-P2. This implied that PI and P2 BMSCs still have some progenitor 
stem cells features, which suggest that they were not fully committed to a specific lineage. 
Quantitative PCR on PI and P2 BMSCs cultured in FGF-2 showed no expression of SOX-9, 
aggrecan and collagen type II. Collagen type I was detected but at a lower expression level in 
comparison to those observed from articular cartilage extracted from young and old bovine.
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Passaged BMSCs were harvested and re-seeded as P2 and P3 BMSCs into Transwell inserts. The 
Transwell culture system was first described by Kandel et al, (Kandel et al, 1995), where 
chondrocytes were seeded into a Transwell insert, culture for certain period of time (usually a 
few weeks) and upon tissue grafts are generated. The cells in the Transwell insert formed a 
shallow flat disc on the permeable support, enabling cell-cell contact that other studies have 
shown to be necessary for efficient chondrogenesis (Johnstone et al, 1998; Yoo et al, 1998). 
The advantage of using the Transwell culture system is that it allows all the cells to have a close 
contact to the nutrient supply with easy diffusion access from above and below. Murdoch et al, 
have illustrated that using Trans well culture system results in a five times greater surface area 
than the commonly used three dimensional pellet culture systems. Also they have demonstrated 
that the matrix deposited by the stem cells derived from human tissue has a higher retention of 
PG than pellet culture (Murdoch et al, 2007).
Previous work by Hayes and co-workers have demonstrated the ability to generate a tissue graft 
using young bovine articular chondrocytes cultured in DMEM supplemented with FBS, TGF-p2 
and ascorbic acid, over a 4 week culture period (Hayes et al, 2007). Such cartilage grafts have 
shown to produce varying zonal morphology, resembling those observed in native cartilage. 
Recently, Hardingham and colleagues have illustrated the use of Transwell system to form a 
cartilage-like tissue graft using human MSCs in vitro (Murdoch et al, 2007). Our aim was to 
attempt to produce a tissue graft using BMSCs instead of young bovine chondrocytes. The 
passaged BMSCs were seeded into Transwell cultures at two seeding densities, 6xl06 and 
0.5x106 cells/well. These BMSCs were cultured in chondrogenic medium containing TGF-03 
and dexamethasone. Our study demonstrated that bovine-derived BMSCs seeded into Transwell 
system are capable of forming a uniformly distributed tissue graft throughout the dried, porous 
polycarbonate membrane, pre-coated with chick collagen type II. Transwell culture filter inserts, 
established using inserts of 6.5 mm in diameter with 0.4 pm pore size polycarbonate membrane, 
were used by Murdoch et al, to produce tissue grafts using 0.5 xlO6 hMSCs per insert and
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cultured in chondrogenic medium (Murdoch et al., 2007). This study demonstrated the feasibility 
of forming a flexible, shallow tissue graft of passage 2 and 3 (P2 and P3) bovine derived BMSCs 
seeded at 0.5 xlO6 cells/insert. However, successful grafts when formed less often when BMSCs 
were seeded at 6 xlO6 cells/insert. Those seeded using a higher cell density appeared to fail to 
stay as multi-cell layers, instead they contract to form a lump of cell mass. This may be due to 
the effects of residual serum left with the cells before re-suspending in chondrogenic medium as 
suggested by Tew et al., 2008. In addition, uneven sedimentation of the BMSCs during the 
settling period without the use of centrifugation to produce more uniform cell sedimentation may 
cause a cell mass to form. The wet mass recorded from Hardingham’s group indicated an 
average of 20-25 mg for tissue grafts produced over a 4 week culture period, with a matrix 
composed of mainly aggrecan and collagen type II, which are hallmarks of chondrogenesis (Tew 
et al., 2008; Murdoch et al., 2007). Our grafts produced using bovine derived BMSCs are 3-4 
times lighter than those produced by using hMSCs as shown by Hardingham’s group (Murdoch 
et al., 2007). This difference in graft weight may be due to the use of a bovine model instead of a 
human model. Our data demonstrated that the use of a lower seeding cell density per Transwell 
insert (0.5x106 cells/well) and BMSCs pre-cultured in the presence of FGF-2 and TGF-(32 
generated a more successful tissue graft than using 6xl06 cells/well and BMSCs pre-cultured in 
FGF-2.
Gene expression studies also suggested that our bovine tissue grafts are mainly composed of 
aggrecan and collagen type I and type II with a low expression of SOX-9 and collagen type X. 
Similar gene expression patterns were observed from grafts produced using both high (6 xlO6 
cells) and low (0.5 xlO6 cells) seeding densities. These imply that one passage difference did not 
have any influence on the expression levels or their trend. Also pre-culturing BMSCs in FGF-2 
or with the addition of TGF-02 did not affect the expression pattern. In the review by Tew et al., 
2008, they suggest that the addition of FGF-2 to the expansion medium prior to the 
differentiation of hMSCs in Transwell culture system improved the ability of hMSCs to
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differentiate towards a chondrogenic lineage (Tsutsumi et al, 2001; Bianchi et al, 2003; 
Mastrogiacomo et al, 2001; Solchaga et al, 2005), which corresponds to our findings on the 
effects of the addition of growth factors, FGF-2 and in the presence of TGF-P2. However, our 
data suggests that the addition of TGF-p2 to the expansion medium did not affect the 
differentiation process.
In conclusion, our study has shown that it is possible to produce tissue grafts using Transwell 
culture system by using a cell seeding density of 0.5x106 cells/well. It has shown that the use of 
passaged BMSCs pre-cultured in FGF-2 and TGF-P2 favours the ability to generate a tissue 
graft. Further optimisation on the culture conditions is necessary in order to differentiate 
passaged BMSCs towards a chondrogenic lineage, subsequently generating tissue grafts that 
resemble close to hyaline cartilage, which can be used for the repair and regeneration of 
cartilage. For future experimentation, it would be interesting to isolate BMSCs using different 
methods such as Lymphoprep which enables the separation between hematopoietic and non- 
hematopoietic cells, this allows us to obtain a clear number of mononucleated cells. It would be 
beneficial that further characterisation of passaged BSCs (P0, PI and P2) in order to further 
understand the expression pattern of BMSCs at different stages of culture. Therefore more 
primer pairs (such as Notch-1, Delta and Jagged-1 and -2) designed specifically for bovine are 
essential to carry out further gene expression analyses. During each stage of passage, cell 
viability tests should be carry out in order to assess the viability o the cells after each 
trypsinisation in order to monitor the cell viability at different stages. A standardised replating 
cell density would be useful for studying the effect of cell density on the gene and protein 
expression. The proliferation rates of BMSCs at different passage number can also be studied by 
recording the cell doubling time at each passage step. Furthermore, it would be interesting to 
further investigate the effect of passage number on the gene expression pattern by in creasing the 
passage number to P I0 or beyond.
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